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Abstract
Mutations in the transmembrane protein MEGF10 (multiple epidermal
growth factor-like protein 10) cause early-onset myopathy, areflexia,
respiratory distress and dysphagia (EMARDD), an autosomal recessive
congenital myopathy, characterized by reduced muscle fibre size. MEGF10
is reportedly expressed in satellite cells, playing a role in regulating cell
proliferation and differentiation. The pattern of expression and the function of
MEGF10 have not been clearly described.
Cultured myoblasts, isolated single fibres and a muscle hyperplasia model
were used to investigate changes in MEGF10 expression. Western blotting,
immunofluorescence and RNAseq showed that MEGF10 was expressed at
low levels in cultured myoblasts, suggesting that these cells are a poor
model for studying endogenous MEGF10. Overexpression of GFP-tagged
wildtype MEGF10 and MEGF10 containing pathogenic mutations decreased
myoblasts cell motility and fusion. Isolated single fibres showed the
presence of quiescent (Pax7+), committed and activated (MyoD+ or
myogenin+) satellite cells after 2 - 4 days in culture. However, these cells did
not consistently express MEGF10. A muscle hyperplasia model showed no
MEGF10 expression in CD34+/Pax7+ or MyoD+ positive satellite cells, but
MEGF10+/CD34- cells were present on these fibres. Finally, the expressed
and purified extracellular domain (ECD) of MEGF10 was heavily post-
translationally modified and facilitated myoblast attachment to a non-
adherent surface. Pathogenic mutations in the ECD did not have a
significant effect on myoblast fusion, whilst the wildtype ECD inhibited
fusion.
In conclusion, the choice of skeletal muscle model system is important in
obtaining meaningful results. The discovery of MEGF10 expression in, as
yet, unidentified CD34- cells on isolated fibres requires further study.
MEGF10 is likely to respond to differing cues within the complex muscle
environment to regulate myogenesis through cellular changes affecting
differentiation and motility. Whilst EMARDD is a rare condition, insights into
MEGF10 function may give insight into mechanisms of pathogenesis in a
range of skeletal muscle diseases.
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1 Introduction.
1.1 Early-onset Myopathy Areflexia Respiratory Distress and
Dysphagia (EMARDD)
Muscular dystrophies and myopathies are a heterogeneous group of
inherited conditions, which have some common clinical features and
symptoms. Current care for these conditions predominantly involves
monitoring and managing symptoms, and therefore a better understanding
of these diverse conditions may enable an effective therapy rather than
palliative management of these conditions to be developed. Myopathies and
dystrophies differ in their underlying cause, with myopathies primarily being
caused by mutations causing defects in the contractile apparatus of muscle
as seen in muscle biopsies. Conversely, muscular dystrophies tend to be
caused by defective proteins in the muscle membrane or that support the
muscle and dystrophies are typically characterised by pathological muscle
degeneration and regeneration (Cardamone et al., 2008).
Whilst there are more common and well-characterised muscular dystrophies,
such as Duchenne and Becker muscular dystrophy, there are also a number
of rare muscle wasting disorders, which have not been well described. One
of these rare and under-characterized disorders is early onset myopathy,
areflexia, respiratory distress and dysphagia (EMARDD), an autosomal
recessive congenital myopathy (MIM number 614399), caused by compound
heterozygous or homozygous mutations in the gene encoding multiple
epidermal growth factor-like protein 10 (MEGF10) (MIM number 612453) on
chromosome 5q23. A group of patients were identified that presented with
cyanosis indicating early onset respiratory distress caused by reduced
function in the diaphragm muscle, as well as areflexia and dysphagia. The
severe myopathy EMARDD was named after its clinical features: early onset
myopathy, areflexia, respiratory distress and dysphagia (Figure 1. A.). The
absence of neurological reflexes and the difficulty in swallowing
differentiates EMARDD from some other disorders such as spinal muscular
- 2 -
atrophy with respiratory distress (SMARD). SMARD (MIM number 604320)
is also an autosomal recessive disorder but is characterised by neurogenic
PXVFXODUGHJHQHUDWLRQFDXVHGE\ORVVRIĮPRWRUQHXURQVLQWKHVSLQDOFRUG
In contrast, EMARDD patients have normal nerve conduction speeds in both
sensory and motor neurons suggesting that the muscle weakness is not due
to defective transmission of motor nerve impulses. Muscle biopsies from
EMARDD patients have a reduced muscle fibre diameter and fewer nuclei
per myofibre compared to a control healthy individual, suggesting disruption
in the assembly or maintenance of the myofibres (Figure 1. B.) (Logan et al.,
2011).
Like other muscular disorders, EMARDD appears to be within a spectrum of
conditions with some patients only surviving into early infancy (Logan et al.,
2011), whilst other individuals with EMARDD have been reported at age 12,
suggesting a milder phenotype is present (Meilleur et al., 2012). Mutations
in MEGF10 have also been associated with muscle myopathy with a multi-
minicore disease phenotype (Boyden et al., 2012a; Jungbluth, 2007). More
recently, mutations in MEGF10 have been associated with the congenital
myopathy multi-minicore disease (MIM number 255320), in which patients
had the additional features of scoliosis, distal joint hyperlaxity and adult-
onset respiratory insufficiency, as opposed to the infantile-onset described
for EMARDD (Liewluck et al., 2016). This further implies that mutations in
MEGF10 can produce a number of conditions with differing symptoms and
presentations.
- 3 -
Figure 1. Clinical Presentation and muscle pathology of EMARDD.
A. Aspiration in the lung (1) (arrowheads) indicating dysphagia and distal weakness
shown in the hand (2) and by thinning in the thighs (3) in EMARDD patients. B.
Haematoxylin and eosin stained transverse sections of the deltoid muscle from
healthy and EMARDD patients. The cross-sectional diameter of the fibres was
measured in control (green) and EMARDD patients (red), with fibre diameter
significantly reduced in EMARDD patients. Adapted from (Logan et al., 2011).
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1.2 Multiple epidermal growth factor-like domains protein 10
(MEGF10)
1.2.1 Disease mutations.
Mutations in the gene encoding the type-1 transmembrane (TM) protein
MEGF10 were identified in patients with EMARDD (Logan et al., 2011). Five
mutations were initially identified within the MEGF10 gene for this cohort of
EMARDD patients. Most of these mutations led to the introduction of a
premature stop codon into the DNA sequence, including p.P442’HfsX9,
p.W520X, p.C767X, p.Y1048X, of MEGF10 causing predicted nonsense
mediated decay of the transcript and loss of protein expression (Figure 2.
red). By contrast, the p.C774R mutation in the 16th epidermal growth factor
(EGF)-like domain in MEGF10, through conversion of a cysteine to an
arginine, may cause disruption to the cysteine bond in the EGF-like domain
affecting interactions within the extracellular domain (ECD) of MEGF10
(Logan et al., 2011) (Figure 2. pink). Other cysteine mutations subsequently
identified as being associated with minicore myopathy, p.C326R and
p.C611W (Figure 2. green), may also cause disruption to the EGF-like
domains and destabilization to the ECD of MEGF10 (Boyden et al., 2012a).
Mutations C326R and C774R in MEGF10 associated with skeletal muscle
myopathy, were shown to reduce the tyrosine phosphorylation of MEGF10.
The tyrosine phosphorylation may disrupt signaling by MEGF10 that
regulates myoblast proliferation (Mitsuhashi et al., 2013).
Subsequent identification of additional patients with EMARDD led to the
identification, by SNP array analysis and exome sequencing, of a novel
mutation comprising a deletion of exon 7 in MEGF10 (Meilleur et al., 2012;
Pierson et al., 2013) (Figure 2. blue). Mutations in MEGF10 have also been
associated with a recessive congenital myopathy with minicores
characterised by distal muscle weakness, scoliosis and either infantile-
(Boyden et al., 2012a) or adult-onset (Liewluck et al., 2016) respiratory
failure. Mutations are shown in Figure 2. Knockdown of megf10 in zebrafish
demonstrates the pathogenicity of some of these mutations (Boyden et al.,
- 5 -
2012a), however this study did not investigate the effect of these mutations
in a mammalian muscle system.
- 6 -
Figure 2. Pathogenic mutations in MEGF10.
The genomic sequence of MEGF10 with non-coding exons is shown in grey. The protein sequence of MEGF10 showing conserved domains
including EMI and EGF-like domains (blue boxes), a TM domain and two intracellular motifs. Mutations introducing a premature stop codon are
shown in red, and the missense mutation identified in EMARDD patients shown in pink (Logan et al., 2011). The exon 7 deletion associated with
EMARDD is shown in blue (Meilleur et al., 2012). Mutations causing minicore myopathy are shown in green (Boyden et al., 2012a), and those
highlighted with an asterisk indicate mutations causing minicore myopathy with adult-onset respiratory insufficiency (Liewluck et al., 2016).
Mutations highlighted with a box were used in this study.
Figure adapted from Logan et al., 2011.
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1.2.2 The MEGF Family
MEGF10 is part of the 12-member MEGF family of TM proteins (MEGF1-
12), characterized by repeating EGF-like domains in the ECD. Many of these
contain an N-terminal EMI domain and typically these proteins play a role in
development. Members of the MEGF family were identified by motif-trap
screening, including MEGF1 composed of a large ECD and commonly
expressed in cerebellum, MEGF2 and MEGF3 with seven times TM
domains, MEGF4 and 5 homologues of the Drosophila Slit protein and
MEGF7 an uncharacterized low-density lipoprotein (LDL) receptor-like
protein (Nakayama et al., 2002). Novel proteins MEGF6, and MEGF8 - 12
were also identified and were subsequently studied. MEGF6 has an EMI
domain and multiple EGF domains like MEGF10, but the predicted
sequence lacks a TM domain. It may have a role in extracellular matrix
elastic fibre assembly (Penner et al., 2002). MEGF8, contains multiple EGF
domains, lacks an EMI domain, but contains several CUB (Complement
C1r/C1s, Uegf, Bmp1; (Blanc et al., 2007) and PSI (Plexin, Semaphorin and
Integrin; domains (Basile et al., 2007; Love et al., 2003; Xiao et al., 2004).
Both of these domains contain conserved cysteine residues forming
disulphide bonds and may have a role in mediating protein - protein
interactions. Mutations in MEGF8 cause a subtype of Carpenter syndrome,
characterised by defective left – right patterning during development,
possibly through disruption of Hedgehog signalling (Twigg et al., 2012).
The shorter TM protein MEGF9 (Figure 3.) is post-translationally modified
and its expression in the nervous system and has been shown to be
regulated during development (Brandt-Bohne et al., 2007). MEGF11 is very
similar to MEGF10 in terms of size and domain structure, and has been
shown to interact with MEGF10 (Kay et al., 2012). MEGF12, also known as
JEDI or Platelet endothelial aggregation receptor 1 (PEAR1), is primarily
expressed in platelet cells and has a signaling role upon contact between
platelet cells (Nanda et al., 2005). In Drosophila the genes encoding
MEGF10, MEGF11 and MEGF12 in mammals have a single orthologue,
Draper. Silencing of the Draper gene in flies cause a muscle myopathy
similar to that seen in human EMARDD, as well as vacuoles to form in the
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brain (Draper et al., 2014). In summary, the MEGF family of proteins share
similar domain structures and appear to have a broad range of functions in
tissue development and disease. However, MEGF10, 11 and 12 appear to
be most closely related and may have related functions. Sequence
alignment of MEGF10, MEGF11 and MEGF12 proteins showed high
sequence similarity particularly within the ECDs whilst, the intracellular
domains are more divergent there is some similarity in sequence
surrounding conserved tyrosine residues. This led to the conclusion that
these three proteins are part of a family of TM multiple-EGF like domain
proteins, which differ from other EGF-like repeat proteins such as Serrate or
Jagged since the MEGF proteins lack the characteristic cysteine-rich region
before the TM region of Serrate/Jagged proteins (Krivtsov et al., 2007).
Predicted representations of the domain structure for each of the 12 MEGF
family members are depicted in Figure 3.
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Figure 3. The protein domain structure of the MEGF family.
Comparison of the predicted domain arrangement of members of MEGF family. Domains include the EMI, EGF, TM, CUB, PSI, laminin G domain
(LamG), Leucine Rich Repeat (LRR), Follistatin N-terminal domain (FOLN), C-terminal cysteine knot-like domain (CT), Hormone Receptor domain
(Horm R), Protein families (Pfam), G-protein coupled receptor proteolytic site domain (GPS). Domains were predicted using Simple Modular
Architecture Research Tool (SMART) (Letunic et al., 2015; Schultz et al., 1998) and InterPro (Mitchell et al., 2015).
- 10 -
1.3 The Structure of MEGF10
MEGF10 is a type-1 single-pass TM protein, composed of a signal peptide to
mediate transportation to and orientation in the plasma membrane, an EMI
domain and 17 EGF-like domains in the extracellular region of the protein
(Doliana et al., 2000; Kay et al., 2012). The intracellular region contains
both phosphotyrosine binding (PTB) and Src homology-2 (SH2) binding
sites. Both of these domains indicate a role in receptor tyrosine kinase
(RTK) signalling pathways, as discussed below. The full MEGF10 sequence
and each key region are depicted in Figure 4.
1.3.1 EMI domain
The EMI domain is present at the N-terminus of the protein once the signal
peptide has been cleaved and protein correctly inserted into the plasma
membrane. This cysteine-rich domain, composed of seven conserved
cysteine residues, has been associated with cell adhesion (Doliana et al.,
2000). The seven cysteine residues have been proposed to interact in a
similar way to EGF-like domains, forming intramolecular cross-links between
pairs of residues. However, the remaining unpaired cysteine has been
suggested to play a role in disulphide bond formation with other proteins or
multimerisation of the protein. The EMI domain may therefore be crucial for
MEGF10 extracellular interactions (Doliana et al., 2000).
1.3.2 EGF domains
There are two main types of the 17 EGF-like domains in the ECD: EGF-like
and EGF-laminin domains (Figure 5. A.). Typical EGF-like domains have six
conserved cysteine residues, which form intracellular disulphide bonds
between cysteines 1 and 3, 2 and 4, and 5 and 6 (Figure 5. B.). In EGF-
like domains, the disulphide bond between cysteines 2 and 4, in particular,
has been shown to be critical for mediating signalling across the membrane
into the cytoplasm (Benitez and Komives, 2000). The five EGF laminin
domains are larger than the EGF-like domains, with eight conserved
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cysteine residues that form four disulphide bonds (Figure 5. C.). This
increased interaction has been predicted to reduce the flexibility in these
domains. X-ray crystallography has shown that the binding of Ca2+ to EGF
domains, in proteins such as Notch, stabilises them (Chillakuri et al., 2012),
and that Ca2+ bound to EGF-like domains can also direct protein-protein
interactions (Rao et al., 1995).
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Figure 4. MEGF10 protein sequence and corresponding domain structure
Signal peptide in purple, EMI domain in blue, EGF domains in green, trans-
membrane (TM) domain in orange. The intracellular domain NPXY and YXXL
motifs are highlighted in red and purple respectively. Tyrosine Y1030, the main site
of tyrosine phosphorylation in MEGF10, is highlighted in green. A region of multiple
serine residues at the C-terminus is underlined.
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A. EGF-like domains
EGF1 HCADKCVHG-----RCIAPN-TCQCEPGWGGTNCS------------
EGF3 DCHQRCQCQNG--ATCDHVTGECRCPPGYTGAFCE------------
EGF4 QCEQRCPCQNG--GVCHHVTGECSCPSGWMGTVCG------------
EGF6 LCAETCQCVNG--GKCYHVSGACLCEAGFAGERCE------------
EGF8 ACQQICSCQNG--ADCDSVTGKCTCAPGFKGIDCS------------
EGF9 NCSSRCGCKND--AVCSPVDGSCTCKAGWHGVDCS------------
EGF10 GCNLTCQCLNG--GACNTLDGTCTCAPGWRGEKCE------------
EGF12 NCSLPCYCKNG--ASCSPDDGICECAPGFRGTTCQ------------
EGF13 RCSQTCPQCVHSSGPCHHITGLCDCLPGFTGALCN------------
EGF14 NCAGICTCTNN--GTCNPIDRSCQCYPGWIGSDCS------------
EGF15 NCIHTCNCHNG--AFCSAYDGECKCTPGWTGLYCT------------
EGF17 GCRQICDCLNN--STCDHITGTCYCSPGWKGARCD------------
B. EGF-laminin domains
EGF2 -----CQCKNG--ALCNPITGACHCAAGFRGWRCEDRCEQGTYGNDC
EGF5 -----CQCHNG--GTCDAATGQCHCSPGYTGERCQDECPVGTYGVLC
EGF7 -----CPCHLENTHSCHPMSGECACKPGWSGLYCNETCSPGFYGEAC
EGF11 -----CDCSHA--DGCHPTTGHCRCLPGWSGVHCDSVCAEGRWGPNC
EGF16 -----CQCQNG--ADCDHISGQCTCRTGFMGRHCEQKCPSGTYGYGC
C. Cysteine-cysteine interactions
+--------------+
+-|-------+ | +--------+ +--------+
| | | | | | | |
XCXCXXXXXXXCXXXXXXCXCXXXXXGXXCXXXCXXGAAGXXC
Figure 5. EGF domain alignment.
A. The EGF-like and B. EGF-laminin domains in MEGF10 were aligned and the
conserved cysteine residues highlighted in green. Multiple protein sequence
alignment was performed using Clustal W (CLUSTAL 2.1) (Larkin et al., 2007;
Thompson et al., 1994) C. The typical interactions between conserved cysteine
residues in EGF-laminin domains are shown, the underlined portion is similar to
EGF-like domains. Conserved glycine (G) and aromatic (A) residues to identify
EGF-like domains are shown in the sequence.
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1.3.3 Post-translational modification of EGF-like domains
TM proteins expressed at the surface of cells typically have post-
translational modification (PTM) enabling inter-cellular signaling, adhesion
and migration. The most common PTM is glycosylation which involves the
addition of sugar residues to the protein in the endoplasmic reticulum (ER)
and Golgi. Protein glycosylation is regulated by changes in the localization of
glycosylation enzymes and is important for cell signaling (Bard and Chia,
2016).
Membrane proteins, and in particular proteins containing EGF domains, are
commonly post-translationally modified with N-linked glycosylation (Schwarz
and Aebi, 2011) that gives high structural diversity to proteins due to branch
additions and remodeling. N-glycosylation of the EGF receptor, which is
composed of a similar structure as EGF-like domains, has been shown to
play an important role in determining the conformation of proteins within the
membrane (Kaszuba et al., 2015).
Consensus sequences have also been identified for less common O-linked
PTMs. O-glucose modification of EGF-like containing proteins such as
thrombospondin (Shao et al., 2002) and Notch (Matsumoto et al., 2016).
EGF domains in a smaller proportion of EGF-like domain-containing
proteins, such as Notch, are also modified with O-fucose, which is essential
for Notch signaling (Haines and Irvine, 2003; Okajima and Irvine, 2002; Shi
and Stanley, 2003). Less common O-fucose and O-glucose modifications on
EGF-like repeats in Notch play a role in mediating both downstream and
intercellular signaling (Luther and Haltiwanger, 2009a). Typical sites of
PTMs in EGF-like domains are shown in Figure 6. B.
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Figure 6. Notch1 and DLL4 EGF domain interactions and the typical
glycosylation patterns of EGF-like domains.
A. A ribbon representation of the crystal structure of the Notch1 EGF-like domains
11 - 13 – DLL4SLP(NEGF2) complex showing the two proteins localised in their
respective cells membranes (grey discs) with Notch O-glycans (in orange) and
bound calcium ions (in grey). A collinear, antiparallel interaction is formed between
the two proteins along a narrow protein and glycan rich interface (Luca et al., 2015).
B. A schematic of the typical structure of an EGF-like domain and its internal
cysteine-cysteine interactions. Conserved sites for O-glucose and O-fucose
addition are also shown (Harris and Spellman, 1993b).
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The structure of the EGF-like repeats 11 and 12 of Notch bound to the
Delta/Serrate/Lag-2 (DSL) domain of delta-like 4 ligands (DLL4; and related
ligands), depicted in Figure 6.A., demonstrate the importance of PTMs in the
modulation of binding between these two domains (Luca et al., 2015) and
may give insight into interactions with the ECD of MEGF10. Specific
threonine and serine residues on Notch1 are functionalised with O-fucose
and O-glucose that act like amino acids forming interactions with residues on
DLL4. The complex between Notch and DLL4 is formed of a collinear,
antiparallel interaction between protein and glycan. EGF domains 11 – 13
are stabilised by inter-domain disulphide bonds and Ca2+ ions at the
junctions between EGF domains, however these Ca2+ ions do not directly
contribute to protein interaction (Figure 6. A.) (Luca et al., 2015). O-
fucosylation occurs at consensus sequence C-X(4-5)-S/T-C between the
second and third cysteine residues of EGF-like domain 12 in Notch (Shao et
al., 2003), and this consensus sequence is present in EGF-like domains 3,
5, 12, 14, and 17 of MEGF10. O-glucosylation of Notch and other EGF-like
repeats takes place on a serine residue at the consensus sequence (C-X-S-
X-P-C) between the first and second cysteine residues (Fernandez-Valdivia
et al., 2011; Harris and Spellman, 1993a; Hase et al., 1988). None of the
EGF-like domains of MEGF10 have this exact sequence (Figure 5). O-
fucose modification increases the affinity of Notch for its DLL ligand,
whereas O-glucose modifications increase susceptibility to proteolysis after
Notch binds to its ligand. The interaction between Notch and its ligand on
another cell normally leads to proteolysis of Notch1, endocytosis of the
ligand, and downstream signaling. Both mutations that disrupt the cysteine
residues in the EGF domains of Jagged, together with those that interfere
with these PTMs cause Alagille syndrome, characterised by abnormalities in
the bile ducts, (MIM number 118450) (Luca et al., 2015).
Aside from glycosylation other PTMs have been identified in MEGF10,
including mono-ubiquitination and tyrosine phosphorylation. The protein is
mono-ubiquitinated, as identified by tandem mass spectrometry, and this
modification is predicted to signal MEGF10 transport to lysosomes (Suzuki
and Nakayama, 2007b). A tyrosine residue in the intracellular domain
(Y1030) is phosphorylated by c-Src (Kauskot et al., 2012; Mitsuhashi et al.,
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2013; Nanda et al., 2005). This residue is also conserved in MEGF11 and
MEGF12.
1.3.4 Intracellular domain.
The intracellular domain of MEGF10 contains an NPXY and YXXL motifs,
binding sites for phosphotryrosine binding protein (PTB) and src homology 2
(SH-2) protein domain respectively (Suzuki and Nakayama, 2007b; Wu et
al., 2009) (Figure 4.). These two motifs in the cytoplasmic domain of TM
receptor proteins play a role in enabling cytoplasmic adaptor proteins to
interact and facilitate downstream signaling as well as tyrosine
phosphorylation (Pawson and Scott, 1997). The YXXL motif, which binds
SH2 domain containing adaptor proteins (Zhou et al., 1995), through
phosphorylation of a tyrosine residue plays a role in signalling to facilitate the
reorganization of the actin cytoskeleton (Kwiatkowska and Sobota, 1999).
C-Src has been shown to interact with MEGF10 in a tyrosine-
phosphorylation dependent manner (Mitsuhashi et al., 2013). In addition,
Y1030 is phosphorylated in MEGF10, and this is important for neuronal cell
engulfment, although it is unclear what its function is in muscle cells
(Figure 4.). Two MEGF10 myopathy mutations in the EGF domains C326R
and C774R, decrease tyrosine phosphorylation levels, with C774R (in the
16th EGF domain) having a major effect on muscle function (Mitsuhashi et
al., 2013). The reduced levels of phosphorylation were additionally linked to
a reduction in N-glycosylation, but did not change the localisation of a GFP-
tagged protein when expressed in 293T cells. Phosphorylation of Y1030 is
likely to be important in MEGF10 signalling, but it is not known what
signalling molecules are recruited by MEGF10, or what ligand may bind to
MEGF10 in order to initiate downstream signalling in human muscle. In
addition, the pattern of PTMs has not been explored for MEGF10.
In Drosophila, the N-terminal PTB binding domain of the engulfment adaptor
protein Ced-6 (mammalian orthologue of GULP, Engulfment Adaptor PTB
Domain Containing 1), interacts with the NPXY motif in the cytoplasmic
domain of the MEGF10 orthologue Draper (Eroglu and Barres, 2010; Hamon
et al., 2006; Suzuki and Nakayama, 2007a) (Figure 7.) The C.elegans
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orthologue Ced-1 also interacts with the NPXY motif with Ced-7 and Ced-10
also being involved in this engulfment pathway (Figure 8.). The mammalian
orthologue of Ced-7 is a 12-TM ATP-binding cassette transporter protein
(ABCA1) involved in engulfment, and the transport of phospholipids to the
outer leaflet of the plasma membrane. ABCA1 therefore induces local
changes to the phospholipid composition of the membrane (Hamon et al.,
2006; Wang et al., 2001). Ced-10 is a small GTPase which, induces actin
polymerisation enabling the final stages of phagocytosis (Hamon et al.,
2006; Kinchen et al., 2005) (Predicted interactions are shown in Figure 8.).
MEGF10 was also shown to interact with the AP50 subunit of the clathrin
assembly protein complex 2 (AP2) (Chen et al., 2013; Nakayama et al.,
2002; Suzuki and Nakayama, 2007b) (Figure 8). AP50 plays a role in
endocytosis, sorting proteins trafficking in endosomes and is found
associated with clathrin coated pits (Chen et al., 2013; Nakayama et al.,
2002; Suzuki and Nakayama, 2007b). The tyrosine residue in the NPXY
motif is phosphorylated by the tyrosine kinase c-Src, which activates the
Erk1/2 pathway. In muscle cells, this phosphorylation is thought to result in
an increase in satellite cell proliferation (Singh et al., 2010; Suzuki and
Nakayama, 2007a). The NPXY and YXXL motifs may be partially redundant
in function since the intracellular domain of Ced-1 is not necessary for the
recognition of cell corpses however the intracellular domain has been shown
to control downstream signal transduction to activate the cell corpse
internalization process (Zhou et al., 2001).
MEGF10 additionally contains a short, 22 amino acid region, consisting of
multiple serine residues (13 in total) close to its C-terminus (Figure 4.). This
sequence is similar to that found in other 111 other ‘reviewed’ proteins in
Uniprot from a Basic Local Alignment Search Tool (BLAST) search. These
include FAM104A, zinc finger CCHC domain-containing protein 10, Class E
basic helix-loop-helix protein 22, and E3 ubiquitin protein ligase Mdm2, and
even the muscle protein obscurin. The function of this region is unknown, but
it is likely to be involved in regulation mediated by phosphorylation.
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Figure 7. Role of glial cells in mediating engulfment in Drosophila.
A diagram depicting the interactions and pathways involved in mediating
engulfment of apoptotic debris through rearrangement of the cytoskeleton mediated
by the MEGF10 homologue Draper (Eroglu and Barres, 2010).
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Figure 8. Summary of protein interactions with MEGF10 and its orthologues Draper and Ced-1.
MEGF10 and the corresponding proteins in Drosophila and Caenorhabditis have a number of functions as described above. A dashed
line marks some of the potential interactions described in the literature. These interactions suggest that MEGF10 and its orthologues
may play a number of key roles in mediating cellular homeostasis and acting as part of larger signalling pathways.
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1.3.5 The Function of MEGF10
An analysis of the relative expression levels of MEGF10 in mouse tissues by
quantitative PCR showed high levels of expression in the brain and in muscle that is
regenerating, 3 days after injection of the cobra cardiotoxin (ctx), while levels of
MEGF10 in normal muscle are low (Holterman et al., 2007). Ctx is a type of
phospholipase A2, which binds to the muscle plasma membrane and disrupts its
integrity (Gutierrez and Ownby, 2003). This promotes muscle fibre degeneration while
leaving the nerve and blood supply intact (Cooper et al., 1999). Additional papers
investigating the function of MEGF10 have focused on either the protein’s neuronal or
skeletal muscle roles, giving a complex picture of MEGF10 playing different and
seemingly unconnected roles in both skeletal muscle and the brain. While the function
of MEGF10 in engulfment, and how this is important in the brain or neuronal
development, is becoming clearer, it is much less clear how MEGF10 functions in
skeletal muscle.
1.3.6 The function of MEGF10 in engulfment and apoptosis
Engulfment and apoptosis are important processes in development and neuronal
remodeling of the brain in response to injury and MEGF10 has been shown to play a
role in mediating these processes. The role of the C.elegans orthologue of MEGF10,
Ced-1, has been identified as one of a number of proteins that plays a role in
development and apoptosis through engulfment, interactions and signaling by a number
of Ced proteins (Hengartner, 2001; Lettre and Hengartner, 2006; Mangahas and Zhou,
2005). Ced-1 has also been shown to play a role in enabling the unfolded protein
response and its reaction to an innate immune response (Haskins et al., 2008; Lamitina
and Cherry, 2008).
In mammals, apoptotic cells express specific signals marking them for degradation.
These include PS, which translocates from the inner leaflet to the outer leaflet of the
cytoplasmic membrane in apoptotic cells. The MEGF10 orthologue Ced-1 has
previously been shown to bind to phosphatidylserine (PS) and may even be a novel
apoptotic signal mediating phagocytosis of apoptotic cells (Scheib et al., 2012; Wu et
al., 2009). The conserved NPXY and YXXL motifs in the intracellular domain of Ced-1
have been shown to be critical for mediating phagocytosis through cytoskeletal
rearrangement (Park et al., 2014; Zhou et al., 2001). Transthyretin-like protein 52
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(TTR-52) is a soluble protein which has been shown to mediate interaction between
Ced-1 in phagocytic astrocytes and astrocytes undergoing apoptosis that express PS
via the ECD of Ced-1 (Tung et al., 2013). Conversely, the MEGF10 orthologue in
Drosophila, Draper, has been shown to interact with PS directly via the EMI domain to
recognize apoptotic cells and induce apoptotic cell clearance (Tung et al., 2013)
(Interactions are outlined in Figure 8.).
The role of MEGF10 as an engulfment receptor that mediates apoptosis has also been
shown in mammals through the cooperative working of MEGF10 and ABCA1 (Hamon
et al., 2006). In glial cell engulfment, whilst Draper has been shown to interact with PS,
in mammals MEGF10 has recently been shown not to interact directly with PS but
instead binds to the P-binding protein C1q through the EMI domain (Doliana et al.,
2000; Iram et al., 2016). C1q is a component of the C1 complex, which forms part of the
classical complement pathway and the interaction between C1q and MEGF10 has been
suggested to enable astrocyte mediated clearance of apoptotic mammalian cells (Iram
et al., 2016). Mutations in MEGF10, which cause myopathy, were also investigated in
this study, however the mutations were explored in a neuronal context and not a muscle
environment. This makes extrapolation of the results to the muscle phenotype seen in
EMARDD patients difficult, particularly as these patients do not appear to present with
any neurological symptoms (Iram et al., 2016).
Overexpression of MEGF10 in mammalian cells results in an irregular mosaic-like
pattern of MEGF10 in the cytoplasmic membrane and accumulation of protein at the
points of contact between apoptotic Flp-In T-REx 293 cells expressing cytoplasmic
DsRedMonomer and stably expressing MEGF10_eGFP in co-culture experiments
(Suzuki and Nakayama, 2007a). This group also showed that exogenously expressed
MEGF10 in mammalian cells directly interacts with the clathrin assembly protein
complex 2 (AP2) medium chain (AP50), a cytosolic adaptor protein localised at clathrin
coated pits (Kay et al., 2012; Singh et al., 2010; Smith et al., 2006; Suzuki and
Nakayama, 2007a). AP50 has also been shown to be required for the activity of the
specific vacuolar ATPase that promotes the acidification of endosomes and lysosomes
(Suzuki and Nakayama, 2007b). GFP-tagged MEGF10 was also found to bind strongly
to the culture dish, outside of the cells, and could be isolated after lysing the cells and
washing them away from the dish. Several co-purifying components were identified by
Liquid chromatography–mass spectrometry (LC-MS/MS), including beta-actin (Suzuki
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and Nakayama, 2007b). However, this interaction may be indirect and potentially
mediated by binding to Ced-6, whose mammalian orthologue is engulfment adaptor
protein GULP which, may help to reorganise the actin cytoskeleton at sites of
interaction with cells undergoing apoptosis (Suzuki and Nakayama, 2007b). These
interactions further highlight the role of MEGF10 in engulfment and mediating
interactions between cells (Hengartner, 2001; Lettre and Hengartner, 2006; Mangahas
and Zhou, 2005).
MEGF10 has further been associated with apoptotic engulfment through its interaction
with ABCA1, which transports a number of molecules across membranes both within
the cell and at the plasma membrane, such as cholesterol. Co-expression of MEGF10
and ABCA1 has been shown to increase the capacity of cells to mediate engulfment of
apoptotic cells (Hamon et al., 2006). It has been proposed that activation of ABCA1 in
apoptosis may lead to the membrane being remodelled and PS being translocated to
the outer leaflet, potentially increasing the efficacy of MEGF10 in mediating engulfment
(Hamon et al., 2006) (Interactions are summarized in Figure 8.).
1.3.7 The neuronal function of MEGF10.
High expression of MEGF10 in the brain suggests a neurological function (Holterman et
DO0(*)DFWVDVDUHFHSWRUHQDEOLQJWKHXSWDNHRIDP\ORLGȕWKURXJKOLSLG
raft mediated endocytosis via the NPXY and YXXL consensus sequences in the
intracellular domain. This role of MEGF10 in the brain may therefore provide a novel
target for the treatment of Alzheimer’s disease (Singh et al., 2010).
MEGF10 and its family protein MEGF11 have been shown to be necessary for the
mosaic spacing of retinal starburst amacrine cells and horizontal cells through cell – cell
adhesion contacts. Mutations in MEGF10 and MEGF11 cause the retinal neurons to
become disarranged (Kay et al., 2012). The role of MEGF10 in astrocyte mediated
clearance of dead cells following brain injury was shown by the addition of dead cells to
an astrocyte cell population which, caused an increase in the level of MEGF10 protein
expression (Loov et al., 2012).
Whilst in Drosophila Draper was identified as a playing a role in engulfment via
activation by the tyrosine kinase Shark (Ziegenfuss et al., 2008) mammalian homologue
tyrosine kinase Syk has been identified as a signal transducer for both MEGF12 and
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MEGF10 through interactions with the intracellular domains. Expression of MEGF10 in
HeLa cells was shown to promote engulfment and mutations to the tyrosine residue
within the intracellular domain prevented engulfment (Scheib et al., 2012). MEGF10 has
also been shown to be critical in synapse remodeling mediated by astrocytes through
the MEGF10 and c-Mer receptor tyrosine kinase (MERTK) phagocytic pathways
(Chung et al., 2013). The remodeling of synapses is important in the development of
the mammalian nervous system and MEGF10 in conjunction with proteins including
Jedi-1 (MEGF12) and Six-microns-under (SIMU) plays a crucial role in facilitating
downstream signaling in this process as summarized in Figure 7 (Eroglu and Barres,
2010; Wu et al., 2009).
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1.4 The role of MEGF10 in skeletal muscle
Whilst the role of MEGF10 and its related signaling pathways in neuronal
cell engulfment is relatively well described, the role of MEGF10 in skeletal
muscle is less clear. A number of papers linking MEGF10 to skeletal muscle
disease have been published. However, the results so far do not give a
clear picture of the mechanisms by which disease mutations in MEGF10
produced the reported skeletal muscle phenotypes. The leading hypothesis
is that MEGF10 is expressed in satellite cells and plays a key role in
regulating the progression of myogenesis (Holterman et al., 2007). Skeletal
muscle is a highly ordered tissue, composed of myofibres arranged within a
sheath of extracellular matrix and connective tissue (Figure 9 and Figure
10). Skeletal muscle is formed by early embryonic myogenic precursors,
marked by paired-box 3 (Pax3) expression. Pax3/Pax7 cells migrate away
from the paraxial mesoderm / dermomyotome into the limbs to form skeletal
muscle, and Pax3 is essential for this migration (Bober et al., 1994; Borycki
et al., 1999)
In addition, Pax3 is important for embryonic myoblasts, and Pax7 for foetal
myoblasts. Three groups of founder stem cells (FSCs) migrate from the
dermomyotome and play different roles in forming the myotome in somites,
which subsequently become skeletal muscle in the limb bud. This occurs in
two stages; myogenesis begins with the formation of the myotome.
Embryonic myoblasts then fuse to the myotomal cells to form primary
muscle fibres. A second set of foetal myoblasts, expressing Pax7, continue
to proliferate, differentiating later in development and fusing to form
secondary fibres which, surround the primary fibres and establish the
satellite cell pool (Maqbool and Jagla, 2007). A number of transcriptional
regulators control embryonic muscle development from the somitic skeletal
muscle lineage specification to myoblasts forming premuscle masses and
subsequently primary and secondary myofibres (Shi and Garry, 2006)
including Myf5 and MyoD (Berkes and Tapscott, 2005). Once fibres have
begun to form, the basal lamina is laid down giving satellite cells their
defining localization. During pre- and post-natal development satellite cells
proliferate and some of these cells fuse with neighbouring fibres to increase
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fibre size. In juvenile and adult muscle satellite cells enter quiescence
becoming activated in response to signals of damage or injury from the
muscle fibres (Buckingham, 2001; Cossu and Sampaolesi, 2007; Shi and
Garry, 2006). The processes of myofibre formation and maintenance in
embryonic development and adult skeletal muscle fibres rely on different
mechanisms as reviewed by (Tajbakhsh, 2009) (Figure 10 A.).
Adult skeletal muscle is composed of bundles of multinucleated myofibres
with myonuclei spaced at regular intervals along the fibre. In mature muscle
fibres the turnover of cells is typically low, although muscle regeneration can
occur under conditions of injury, disease or exercise (Hawke and Garry,
2001; Shi and Garry, 2006). A wide range of input signals and down-stream
signalling events enables skeletal muscle plasticity in response to differing
conditions (Hoppeler, 2016). The development and maintenance of matured
muscle fibres are a tightly controlled process regulated by a diverse series of
genetic factors and therefore study in simpler systems such as Drosophila
have proven useful in better understanding the genetic regulation of this
process (Maqbool and Jagla, 2007).
In the adult muscle, the processes of growth, regeneration and maintenance
of skeletal muscle are primarily performed by a small and highly dispersed
population of stem cells, called satellite cells (Mauro, 1961). Located
between the basal lamina and the myofibre plasma membrane, it has been
shown that these cells act as progenitor cells capable of repairing skeletal
muscle fibres after damage (Dhawan and Rando, 2005; Kuang and
Rudnicki, 2008; Mauro, 1961). However, aside from these classical satellite
cells, other cells expressing myogenic marker proteins which may have
myogenic potential can be isolated from other sources including the bone
marrow (Ferrari et al., 1998), vasculature (De Angelis et al., 1999), and
endothelial cells (interstitial cells) (Liadaki et al., 2012). Indeed, stem cells
from blood vessels (such as mesangioblasts and pericytes) express similar
genes to those of adult satellite cells (Seale et al., 2004; Dellavalle et al.,
2007), however it has also been suggested that only native satellite cells
fully contribute to myogenic regeneration (Figure 9.) (Sherwood et al., 2004).
The microenvironment, including the myofibres, motor neurons,
inflammatory cells and local vascular networks, which surrounds satellite
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cells, is described as the satellite stem cell niche (Kuang and Rudnicki,
2008; Shi and Garry, 2006). This protects the satellite cells from most
extracellular stimuli, thereby only activating the cells under specific
conditions such as muscle fibre damage due to injury or disease (Siegel et
al., 2009).
Satellite cells become activated in response to a number of physiological
and damage response signals including hepatocyte growth factor
(Holterman et al., 2007; Jennische et al., 1993; Tatsumi et al., 1998) and
nitric oxide (Anderson, 2000; Wozniak and Anderson, 2007). In response to
muscle damage satellite cells become activated and undergo multiple
rounds of cell division before they leave the stem cell niche on the myofibre
and migrate to the site of damage. These activated satellite cells terminally
differentiate to repair pre-existing muscle fibers or to form multinucleate
myofibres de novo (Seale et al., 2000).
Activated satellite cells down regulate Pax7 expression before differentiation
into myotubes, whilst various muscle TFs (TFs) including myogenic factor 5
(Myf5), myoblast determination protein (MyoD), muscle specific regulatory
factor 4 (MRF4/MRF6) and myogenin are upregulated during the process of
activation and differentiation (Summarised in Figure 10). MyoD and Myf5 are
both important for determination of myoblasts. Knockdown of MyoD has only
minor effects on muscle formation, but results in upregulation of Myf5
(Holterman et al., 2007), and when both Myf5 and MyoD are knocked out, no
muscle fibres or myoblasts form (Bentzinger et al., 2012; Rudnicki et al.,
1993). (Rudnicki et al., 1993) Therefore Myf5 and MyoD have been
suggested to play a role in specifying myoblasts for terminal differentiation.
Myogenin is a downstream target of MyoD, and is important in regulating
differentiation into myotubes by triggering the expression of genes
expressed by differentiated myofibres (Bentzinger et al., 2013). Interestingly,
Pax7 may not be essential for embryonic muscle development (Bentzinger
et al., 2013; Seale et al., 2000) as well as in adult satellite cells as shown by
the conditional inactivation of the Pax7 gene at specific points in skeletal
muscle development (Lepper et al., 2009; Tajbakhsh, 2009). These TFs do
not act in a linear manner but as a series of interacting feedback and feed-
forward networks. Beyond these TFs it has been suggested that there are
- 28 -
other mechanisms by which myogenesis is regulated including microRNAs
such as miR206 (Bentzinger et al., 2012). Satellite cell activation,
proliferation and differentiation are summarised in Figure 10. B. and Table 1.
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A.
Cell Type Markers Directlymyogenic
Indirectly
myogenic
Fibroblastic &
non-myogenic
Differentiate
into MHC+ MCs
Differentiate into MHC+
MCs in co-culture
Form MFs
in vivo
Satellite Cell CD45
-/Sca1-/CXCR4+ȕ-
integrin+/CD34+ + - - + + +
BM
CD45-/Sca1+/CD34+ - - + - - -
CD45-/Sca1+/CD34- - - + - + nd
CD133+ cells CD133+ + - - + nd +
Endothelial
cells - + - - - -
FAP - + - - - -
HSC CD45+ - - - - - +
Pericytes
Nestin-/NG2+ - + - - - -
Nestin+/NG2+ + - - nd nd +
PICs (PW1+/Pax7-) + - - - + +
Figure 9. The contribution of non-satellite cells to myogenesis.
A. Skeletal myofibres are part of a complex environment composed of a number of different cell types with differing roles in myogenesis. B. A
table marking the expression profiles and functional plasticity of native satellite cells, bone marrow (BM) derived cells in the circulation and
haematopoietic stem cells (HSC). (No data = nd, myocytes = MCs, myofibres = MFs. Diagram adapted from (Sherwood et al., 2004).
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Whilst all adult quiescent satellite cells express Pax7, the satellite population
is heterogeneous with more than one type of satellite cell, falling into various
subpopulations, that express a mixture of different markers (Sherwood et al.,
2004). Quiescent adult satellite cells are marked by the expression of not
only TFs such as Pax7 but also a number of cell surface markers including
cluster of differentiation 34 (CD34) (Beauchamp et al., 2000), syndecan-4
(Cornelison et al., 2001), CXCR4 (Ratajczak et al., 2003), vascular cell
adhesion molecule-1 (VCAM-1) (Jesse et al., 1998) Another marker found in
both quiescent and activated satellite cells is M-cadherin (Mcad), a calcium-
dependent homophilic cell-to-cell adhesion molecule (Donalies et al., 1991;
Irintchev et al., 1994). and integrin alpha 7 (Blanco-Bose et al., 2001).
Integrin alpha 7 is a muscle specific cell surface antigen, which has been
used for the isolation of primary mouse myoblasts from a mixed cell
population (Blanco-Bose et al., 2001; Holterman et al., 2007). This integrin is
the main laminin receptor in muscle and typically expressed in cells which
also express c-Met, a tyrosine kinase necessary for muscle regeneration in
response to injury (Pawlikowski et al., 2009; Webster and Fan, 2014).
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.
Figure 10. Satellite Cell Myogenic Progression & Marker Expression.
A. The process of muscle formation during embryogenesis. The myotome forms a scaffold for primary fibres to form before a second set of
founder stem cells fuse to form secondary fibres. The formation of the basal lamina gives satellite cells their characteristic location in perinatal
mature fibres. B. The process of satellite cell activation, proliferation and differentiation in response to muscle fibre damage. Quiescent satellite
cells are capable of self-renewal (circular arrow) through symmetric expansion, whilst asymmetric division produces both a Pax7+Myf5- quiescent
satellite cell and a committed Pax7+Myf5+ satellite cell. Once satellite cells are activated MyoD expression rapidly increases, whilst myogenin
expression marks the later stages of myoblast commitment and differentiation. Image adapted from (Zammit et al., 2006).
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Table 1. Satellite Cell Markers.
A table of some of the identified factors, which play roles in satellite cell quiescence, activation, migration, differentiation and fusion for the
maintenance of skeletal muscle fibres.
Marker Type Function Reference
Quiescence Cluster of Differentiation CD-34 Cell surface glycoprotein Cell-cell adhesion Kuang and Rudnicki
(2008)
Muscle cadherin (M-cadherin) Calcium-dependent cell
adhesion molecule
Anchoring (Kuang and Rudnicki,
2008; Fukada et al., 2007)
Myostatin Transforming growth factor-
ȕVXSHUIDPLO\PHPEHU
Inhibition of satellite cell
activation and myogenesis
(McCroskery et al., 2003)
Paired Box 7 (Pax7) Paired Box TF Satellite cell specification,
proliferation, and self-renewal
(Kuang and Rudnicki,
2008)
Calcitonin Receptor (CTR) G-protein coupled receptor Regulation of quiescence through
binding peptide hormone
calcitonin
(Fukada et al., 2007)
Multiple epidermal growth factor-like
domains 10 (MEGF10)
Type 1 TM protein Regulation of quiescence (Holterman et al., 2007)
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Activation MyoD Myogenic regulatory
factor (MRF)
Satellite cell activation and
myogenic differentiation
(Charge and Rudnicki,
2004; Johnston et al.,
2010)
Myf5 MRF (TF) Myogenic commitment and
transient amplification
(Kuang and Rudnicki,
2008)
Jagged-1 Notch ligand Induced during satellite cell
activation
(Gnocchi et al., 2009)
Migration CXC chemokine receptor (CXCR)-4 Cell surface chemokine
receptor
Migration mediated by stromal
derived factor-1 (sdf1)
(Brzoska et al., 2012)
Angiotensin type 1a (AT1a)
receptor
Receptor to the hormone
angiotensin II
Mediate migration by chemotaxis
in an angiotensin II gradient
(Johnston et al., 2010)
Ephrin (Eph) receptors and ephrin
ligands
Receptor Tyrosine Kinase
that binds ephrin.
Mediate migration through
Eph/ephrin signalling
(Stark et al., 2011)
Differentiation Myogenin MRF (TF) Marks onset of myogenic
differentiation
(Zammit et al., 2006)
Necdin Melanoma antigen-encoding
gene family
Promotes differentiation by
increasing myogenin expression
(Deponti et al., 2007)
Fusion Vascular cell adhesion molecule-1
(VCAM-1) / very late antigen-4
(VLA-4)
VLA is an integrin which
binds to its receptor VCAM-
1
Myoblast fusion (Rosen et al., 1992)
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1.4.1 Renewal of the satellite stem cell pool
Satellite cells also replenish the quiescent stem cell pool, enabling skeletal
muscle to undergo repeated rounds of regeneration and repair after
subsequent injuries (Collins et al., 2005; Dhawan and Rando, 2005). As
activated cells return to quiescence, MyoD and M-cadherin expression levels
fall and CD34 levels rise (Dhawan and Rando, 2005). The homeobox gene
Lbx1 was first described as being expressed during embryogenesis and
possibly playing a role in muscle and CNS development (Jagla et al., 1995)
and increased expression is seen in satellite cells on cut damaged skeletal
muscle fibres (Watanabe et al., 2007a). Expression of the TF Ladybird-type
homeobox 1 (Lbx1) in activated satellite cells maintains proliferation of the
cells through the regulation of Pax7 whilst preventing differentiation before
commitment of the cells to terminal differentiation and thereby helping to
increase the stem cell pool. It may also have the capacity to force activated
satellite cells back into quiescence (Kuang and Rudnicki, 2008; Watanabe et
al., 2007b).
The majority of satellite cells express the TFs Myf5 and Pax7. However, a
small subpopulation have been identified as Myf5 negative, and this may
represent embryonic progenitors which have not become committed to the
myogenic lineage (Kuang et al., 2007). These Myf5- cells are predicted to
produce daughter cells for self-renewal by either symmetrical or
asymmetrical division. The renewal of the satellite cell population is
mediated by symmetric and asymmetric cell division, where symmetric
division replenishes the stem cell pool and asymmetric division produces an
activated daughter cell capable of mediating muscle regeneration (Dumont
et al., 2015).
The expression of dystrophin in satellite cells regulates cellular polarity and
asymmetric division and therefore helps to maintain the satellite cell pool.
Muscle wasting in DMD may be due in part to dysfunction in satellite cells
(Almada and Wagers, 2016; Wang and Rudnicki, 2012). This highlights the
heterogeneity within the satellite cell population, and therefore the need to
further investigate the role of specific satellite cell markers in both the repair
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of damaged muscle but also in the replenishment of the stem cell pool
(Kuang et al., 2007).
1.5 Satellite cell populations
The satellite cell population is heterogeneous, with sub-populations of cells
possessing different properties. Satellite cell populations change as an
individual ages and populations vary in different muscle groups enabling an
alternative response during skeletal muscle regeneration in disparate muscle
fibre types (Kuang and Rudnicki, 2008).
Satellite cells have primarily been identified through their expression of the
sialomucin surface receptor CD34 and Myf5 (Beauchamp et al., 2000;
Schultz, 1996), but more recent studies have identified a smaller sub-
population of cells that do not express CD34. The relationship between
these two populations of cells was assessed by fluorescence-activated cell
sorting (FACS), showing that whilst CD34 negative cells are quiescent in
uninjured muscle, this population increased in response to muscle injury.
This CD34 negative pool of stem cells is also capable of reverting from a
state of activation to repopulate the pool of CD34 positive stem cells. The
number of CD34 positive satellite cells does not change in response to acute
injury, suggesting that these populations of cells are tightly regulated to
respond to muscle injury whilst also maintaining the CD34 positive pool of
cells (Ieronimakis et al., 2010). Experiments using CD34-/- mice show no
obvious developmental phenotype, but present with defective muscle
regeneration in response to acute and chronic muscle injury. Satellite cells in
this mouse model have reduced motility on the fibre and delayed myogenic
progression. These results may suggest that CD34 plays a role in the early
stages of satellite cell activation (Alfaro et al., 2011), which is further
supported by the complete transcriptional down regulation of CD34 at the
early stages of activation (Beauchamp et al., 2000).
1.6 MEGF10 and myogenic cells
Given the heterogeneity described in cells associated with myogenesis, it
has been difficult to identify specific markers that are unique to the satellite
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cell lineage. MyoD plays an important role in muscle differentiation, and yet
its loss does not prevent muscle formation, therefore a recent screen was
performed to try to identify novel specific markers for MyoD dependent
muscle differentiation. Myoblasts isolated from wildtype and from MyoD-/-
mice were used in the screen, and differences in RNA expression were
analysed. The discovery of 51 differentially expressed genes were
discovered, and 40 of these were analysed by western blotting in myoblasts
and differentiated cells, for both the wildtype and MyoD knockout. This
screen identified MD p67, the mouse homolog of human MEGF10
(XM_140362), as expressed in proliferating wildtype and MyoD-/- myoblasts,
but not in differentiated cells, and that MyoD knockout myoblasts expressed
slightly higher levels of Megf10 than wildtype cells, although it was not
selected as an example of a gene with significantly higher expression in
knockout cells (Seale et al., 2004).
This work was then followed up by a focused study on MEGF10 in satellite
cells, confirming by qPCR that Megf10 was down regulated at the mRNA
level by ~6.4 fold when primary myoblasts, isolated from wild-type mice (as
described previously (Megeney et al., 1996; Sabourin et al., 1999))
terminally differentiated, and that MEGF10 expression was ~1.4 fold higher
in MyoD-/- myoblasts, isolated from MyoD-/- mice (Ishibashi et al., 2005) ,
compared to wildtype myoblasts, and was down regulated by ~8 fold after
GLIIHUHQWLDWLRQ +ROWHUPDQ HW DO  )$&6 LVRODWLRQ RI ĮLQWHJULQ+,
CD31í/Sca1í/CD45í satellite cells, 94% positive for Pax7, showed ~100 fold
upregulation of MEGF10 in satellite cells isolated from 8 week old mice that
were activated by in vitro culture for three days compared to freshly isolated
satellite cells. In situ hybridisation with an RNA probe also showed Megf10
expression in cells along the edges of muscle fibres in tibialis anterior (TA)
muscle fibres, a similar localization to satellite cells. Finally, using an
antibody raised to the cytoplasmic domain of MEGF10, this study also
showed that MEGF10 was only expressed in Pax7 positive satellite cells
(Holterman et al., 2007).
The authors then went on to express an HA-tagged full length MEGF10
protein construct in C2C12 cells, which was shown by western blotting to
have a molecular weight of ~120 kDa, in which they probed with the anti-HA
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antibody but not directly with an anti-MEGF10 antibody. Based on its
sequence MEGF10 is predicted to have a molecular weight of 122 kDa,
similar to that seen by western blot. However, this would not include any
increase in size due to PTMs, which might be expected given that the
majority of the protein is extracellular and primarily composed of EGF-like
domains, which are typically heavily glycosylated (1.3.3). Moreover, the
antibody raised against the C-terminal 290 aa of MEGF10 was only used in
immunostaining without any independent characterisation of the antibody to
show that it recognised the expressed HA-tagged protein either by western
blotting or by immunofluorescence. Overexpression of HA-tagged MEGF10
in C2C12 cells (but not fibroblasts) slightly increased growth rates, and
markedly decreased the ability of the myoblasts to fuse and differentiate into
myotubes, as well as down regulating MyoD expression potentially returning
the cells to a quiescent state. Using siRNA to knockdown MEGF10
expression in satellite cells on cultured muscle fibres promoted precocious
activation of satellite cells, as evidenced by an increase in myogenin
expression and increased differentiation in cultures of primary satellite cells.
Lastly, knocking down MEGF10 by 0.56 fold in cultured MyoD-/- cells
reduced expression of Notch 1, Notch 2 and Notch 3, and it was suggested
that MEGF10 might be able to activate Notch signalling. Notch, like
MEGF10, is a TM protein that contains several EGF-like repeats in its ECD
and is activated by interaction with the DSL ligands of proteins such as
Jagged. However, MEGF10 does not contain any DSL repeats, and
therefore would have to interact with Notch via a different mechanism
(Holterman et al., 2007).
These experiments led to the hypothesis that MEGF10 has a role in
regulating proliferation in myogenic cells through the Notch signaling
pathway. Notch has been shown to be critical in facilitating the progression
of satellite cells towards myogenesis (Conboy and Rando, 2006), and is
therefore important in development. Blocking of Notch signalling causes
premature differentiation of myogenic progenitors, and formation of very
small muscle groups, a similar phenotype to that found in EMARDD patients
(Schuster-Gossler et al., 2007; Vasyutina et al., 2007). During the perinatal
period in mice, satellite cells continue to proliferate until postnatal day 21,
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when they adopt quiescent characteristics (White et al., 2010). This is
dependent on Notch signalling, as well as target genes, Hey1, HeyI and
Sprouty1, which negatively regulate tyrosine kinase signalling (Bjornson et
al., 2012). Like MEGF10, activated Notch signalling suppresses
differentiation of cultured C2C12 cells, suggesting a critical role for MEGF10
in maintaining the satellite cell compartment through self-renewal, possibly in
a similar manner to Notch. Mutation of the Notch ligand, DLL1, or
knockdown of Rbpj, the DNA binding protein, which regulates Notch
expression, results in early depletion of the myogenic progenitor pool, and
also results in the formation of small muscle groups that do not contain any
satellite cells (Vasyutina et al., 2007; Bjornson et al., 2012). During foetal
development the knockdown of Rbpj is accompanied by rapid MyoD
upregulation, but ablation of MyoD does not properly rescue satellite cell
depletion. Instead these cells do not migrate normally, and Pax3+ cells are
found instead in the interstitial space, and not the basal lamina, suggesting
that Notch is important for regulating the formation of basal lamina around
satellite cells. Therefore, activated, emerging satellite cells show disruption
in expression of basal lamina components and adhesion molecules including
MEGF10 through its interaction with Notch (Brohl et al., 2012).
This study also assessed the changes to MEGF10 expression in coRbpj:
MyoD-/- (RM) and MyoD-/- mice compared to control mice. In contrast to the
earlier report that expression of MEGF10 is increased in MyoD-/- mice,
(Seale 2004), here it was reported that MEGF10 shows a 1.8 fold decrease
in MyoD-/- mice, which though not significant, rose to a significant 3.1 fold
decrease in the RM mice. Furthermore, induction of MEGF10 expression
was shown to be dependent on DLL1, shown by a significant increase in the
levels of MEGF10 in the presence of DLL1. Finally, it was reported that low
levels of MEGF10 were observed in the plasma membrane of Pax3+ cells in
the RM mice, at embryonic days 15.5 and 17.5, using a commercial antibody
(Santa Cruz), raised to the cytoplasmic domain of MEGF10 (Brohl et al.,
2012).
Although these studies identified a possible function of MEGF10 in myogenic
proliferation evidenced by a link between MyoD and MEGF10, myogenin has
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also been identified as a positive regulator of MEGF10 transcription in
skeletal muscle. By analysing the 5’ end of the Megf10 gene, a myogenin
binding motif was identified that was shown to bind to myogenin (Park et al.,
2014). Moreover, levels of MEGF10 and myogenin expression rose in ctx
damaged muscle as measured by qPCR. A luciferase reporter assay that
showed the activity of the MEGF10 promoter, showed an 11 fold increase in
expression resulting from its interaction with myogenin, whilst Myf5 had a
smaller effect increasing MEGF10 promoter activity by only 2.8 fold.
Myogenin was shown to bind directly to this region of DNA and its effect on
MEGF10 promoter activity is dose dependent (Park et al., 2014). However it
is unclear how MEGF10 can promote proliferation, but inhibit differentiation
as reported (Holterman et al., 2007), if it interacts with myogenin, which is
not expressed until the cells begin to terminally differentiated, and would not
be expected to affect proliferation.
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Overall, these studies suggest that MEGF10 has a clear role in neuronal
cells, where it is in involved in the clearance of apoptotic cells (Iram et al.,
2016) as well in synapse elimination (Chung et al., 2013) by astrocytes. Both
observations are consistent with the role of MEGF10 in patterning retinal
neurons (Kay et al., 2012), and the observed effects of knocking out the
ortholog of MEGF10 on the brain and retina in Drosophila (Draper et al.,
2014).
However, EMARDD patients do not have a neurological phenotype, but do
have a muscle deficiency, and it therefore seems likely that MEGF10 is also
important in satellite cells. It has been suggested to be important for
renewing the satellite cell pool, by maintaining proliferation in cells and
inhibiting the progression of the myogenic program in combination with
MyoD and Notch (Holterman et al., 2007; Logan et al., 2011). It has also
been suggested to promote satellite cell differentiation shown by the
relationship between increasing expression levels of MEGF10 and myogenin
(Park et al., 2014), although overexpression of MEGF10 inhibits
differentiation in vitro (Holterman et al., 2007). MEGF10 has also been
suggested to influence the ability of satellite cells to populate the satellite cell
niche through interactions with Notch and by promoting the adhesion of
satellite cells to the basal lamina or muscle fibre (Brohl et al., 2012). It is
difficult to reconcile these disparate ideas and to explain how a mutation in
the MEGF10 gene leads to a disruption of the stem cell pool, reduces the
ability of skeletal muscle to regenerate leading to the reduced myofibre size
seen in EMARDD patients.
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1.7 Hypothesis and Aims
MEGF10 has a role in both neuronal and skeletal muscle development. This
research intends to focus on the role of MEGF10 in the skeletal muscle
environment. It was hypothesised that MEGF10 expression in satellite cells
may act in a similar manner to Notch, which has a similar domain structure,
enabling both inter- and intra-cellular signaling to effect transcriptional
changes which affect muscle regeneration. It was further hypothesized that
the ECD of MEGF10 may enable interaction with exposed phospholipids to
enable fusion of myoblasts to form multi-nucleated myotubes.
The aim of this research was to gain a better understanding of the role of
MEGF10 in skeletal muscle cell biology. In the first instance this needed the
careful selection and validation of appropriate antibodies recognizing
MEGF10 for use in both the immunofluorescence and western blotting
experiments, which were not always performed in earlier studies (Brohl et
al., 2012; Holterman et al., 2007). It then required a careful re-examination
of the expression and staining patterns for MEGF10 to determine exactly
when and where this protein is expressed in both cultured and primary
myocyte cultures. Given the conflicting relationship between MEGF10 and
MyoD or myogenin expression previously described, the re-examination of
the co-expression of MyoD and myogenin was also needed to determine if
there was any correlation between their expression and that of MEGF10.
RNAseq was used as an alternative technique to investigate any changes in
MEGF10 expression, alongside MyoD, myogenin, and other skeletal muscle
markers during different stages of myoblast differentiation.
To further investigate the effects of increasing levels of MEGF10 on muscle
differentiation, I also wanted to test if culturing myoblast cells in the presence
of the expressed and purified ECD of MEGF10 was as effective at affecting
fusion and differentiation as overexpressing MEGF10 as previously
described (Holterman et al., 2007). A similar effect might be expected if the
ECD of MEGF10 is a ligand for Notch 1, and thus able to induce
downstream Notch signalling as effectively as overexpression of the full-
length protein. Concomitant with this, expression of the ECD additionally
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allowed an exploration into the nature of the PTMs present on MEGF10,
which is of interest as these may be important in regulating the activity of
these proteins. Finally, these experiments also allow me to investigate the
effects of mutations in MEGF10, which cause EMARDD, on myoblast
migration and fusion.
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2 Materials and Methods.
2.1 Chemicals and Enzymes
All chemicals, enzymes and reagents were supplied by Sigma, and
restriction enzymes supplied by Promega or New England Biolabs (NEB),
unless otherwise stated.
2.2 Strains and Genotypes
Strain Genotype Supplier
NEB 5-alpha
Competent E. coli
(High Efficiency)
IKX$ǻDUJ)ODF=8SKR$
JOQ9ĭǻODF=0J\U$
recA1 relA1 endA1 thi-1 hsdR17
NEB
2.3 Growing Escherichia coli (E.coli)
E.coli were cultured using Luria-Bertani (LB) broth composed of 10 g
SELECT Peptone 140, 5 g SELECT Yeast Extract, and 5 g NaCl per Litre
(Invitrogen) at 37°C with shaking at 220 rpm. Antibiotic selection for bacteria
containing plasmids with the relevant resistance genes was performed using
DPSLFLOOLQDQGNDQDP\FLQDWILQDOFRQFHQWUDWLRQVRIȝJPODQGȝJPO
respectively. The plasmids used in this study are listed in Table 2.
To select single colonies on agar plates, LB agar was prepared by dissolving
1 tablet in 50 ml dH2O. LB agar was autoclaved and allowed to cool to 50°C
before adding the required antibiotic stock solution to the final concentrations
described above. Plates were poured and allowed to set for 30 min. All
sterile work was done at the bench by a lit Bunsen flame.
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2.4 Plasmids
The plasmids and sequencing primers used in subsequent cloning steps are shown in Table 2. and 3. respectively.
Table 2. Plasmids used to clone and express MEGF10 constructs.
Plasmid Name Source Resistance Genes present in vector Use
pDC315
Microbix
Biosystems.
Ampicillin Adenoviral Construct
pBHGlox
E1,3Cre
Microbix
Biosystems.
Ampicillin Virus rescue plasmid
pEGFP-N1 AddGene Kanamycin EGFP PCR amplification of eGFP
pBluescriptIISK+
Gift from
C.Johnson
Ampicillin Contains MEGF10 cDNA Amplification of MEGF10
pSecTag2A Invitrogen Ampicillin
Signal peptide for secreted expression
and 6His and c-myc tags for purification
Secreted expression of protein in
cultured ma mammalian cells.
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Table 3. Full length MEGF10 sequencing primers.
The sequencing primer notation shows the sequence being read, the starting base pair number within the construct and forward primers marked F
and reverse primers marked R.
Sequencing Primer Name Sequence Tm (°C)
MEGF10_553F gagcagggcacctatggtaa 60.1
MEGF10_1147F atgtctggagagtgtgcctg 58.8
MEGF10_1751F ccctgccctgctactgtaaa 60.3
MEGF10_2352F acggcactgtgagcagaagt 61.1
MEGF10_2958F gaaacatggcggctacctc 60.6
MEGF10_655R tgtatcctggtgggcagc 60.7
pDC315927F ataagaggcgcgaccagc 61.5
eGFP_F1 aacatcgaggacggcagc 62.4
eGFP_F2 catcacaaatttcacaaataaagca 60.3
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2.5 General Procedures
All media, plastic and glassware for bacteriological work were sterilised by
autoclaving at 121°C for 15 min.
2.6 Working with DNA
All DNA was stored in aliquots at -20°C and thawed on wet ice prior to use.
2.6.1 Spectrophotometric quantification of nucleic acids
DNA concentrations were measured using a Nanodrop spectrophotometer
and ND100-v3.7.1 software. The spectrophotometer sensor was washed
WKUHHWLPHVZLWKȝOG+22SULRUWRLQLWLDOLVLQJWKHLQVWUXPHQWZLWKȝOG+2O.
$ EODQNPHDVXUHPHQW ZDV WDNHQ XVLQJ  ȝO RI EXIIHU DQG  ȝO RI VDPSOH
loaded for measurement. The purity of the sample was determined by the
A260/280 ratio, where a pure sample has a value of 1.8.
2.6.2 Precipitation and concentration of nucleic acid
Low concentrations of DNA were concentrated by isopropanol precipitation.
To a volume of DNA, half the volume of 7.5 M ammonium acetate (NH4OAc)
and 2 volumes of isopropanol were added and incubated at room
temperature for 10 min. The solution was centrifuged at 16,200 xg for 10
min. The pellet was washed with 70% ethanol and the sample vortexed for 1
min to break up the pellet. DNA was pelleted by centrifugation at 16,200 xg
for 10 min. Ethanol was removed and the pellet allowed to air dry for 10 min.
The pellet was resuspended in a small volume of RNase- and DNase-free
MilliQ pure water.
2.6.3 ‘Miniprep’ DNA preparations
Small-scale plasmid DNA was purified from E. coli using the QIAprep® Spin
Miniprep Kit (Qiagen) following the manufacturer’s instructions. Briefly, 4ml
of a 5ml overnight transformed NEB 5-alpha culture was transferred to
sterile Eppendorf tubes. The cell suspension was centrifuged at 16,200 xg
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for 3 min at room temperature. (All speeds are 16,200 xg, unless otherwise
stated). The supernatant was discarded and the pellet thoroughly
UHVXVSHQGHG LQȝOEXIIHU3 UHVXVSHQVLRQEXIIHUFRQWDLQLQJ51DVH$
to remove RNA contamination and lyse blue which indicates alkaline cell
lysis in cells by turning a blue colour and turns white upon neutralisation.
ȝORIEXIIHU3O\VLVEXIIHUZDVDGGHGDQGVROXWLRQPL[HGE\LQYHUVLRQ
WLPHVȝOEXIIHU1QHXWUDOLVDWLRQEXIIHUZDVDGGHGDQGPL[HGDV
before. Lysed cells were centrifuged for 10 min to pellet the cell debris. The
supernatant was applied to the Qiagen spin column and centrifuged for
VHF7KHIORZWKURXJKZDVGLVFDUGHGDQGWKHFROXPQZDVKHGZLWKȝO
buffer PB. The flow through was again discarded and the column washed
ZLWK  ȝO RI EXIIHU 3( 7KH FROXPQZDV FHQWULIXJHG IRU  VHF DQG WKH
flow-through discarded. Residual wash buffer was removed by centrifugation
for 60 sec. The column was transferred to a sterile 1.5 ml Eppendorf and the
'1$HOXWHGLQȝORIEXIIHU(%
2.6.4 ‘Maxiprep’ DNA preparations
In order to have sufficient DNA for subsequent cloning steps or mammalian
cell transfections, larger DNA plasmid preparations were performed using
the Qiagen Hi-speed Maxiprep kit, according to the manufacturer’s
instructions. Briefly, a 400 ml overnight bacterial culture was removed from
the shaking incubator, centrifuged at 3000 xg for 15 min at 5°C and the
pellet resuspended in 10 ml buffer P1. 10 ml buffer P2 (lysis buffer) was
added and the tube was mixed by inversion six times and incubated at room
temperature for 5 min. 10 ml buffer P3 (neutralisation buffer) was added and
the solution mixed by inversion 6 times. The lysate was applied to a QIAfilter
Maxi Cartridge, with the cap attached, and solution allowed to settle at room
temperature for 10 min. A Hi Speed Maxi Tip was equilibrated with 10 ml
buffer QBT before the cleared cell lysate was applied. The lysate was
allowed to enter the resin by gravity flow, enabling the DNA to bind. The
QIAGEN Tip was washed with 60 ml buffer QC before the DNA was eluted
with 15 ml buffer QF into a 50 ml falcon tube. The DNA was precipitated by
adding 10.5 ml of room temperature isopropanol, gently mixing and
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incubating at room temperature for 5 min. The DNA/isopropanol mixture was
passed through a QIAprecipitator Maxi module to bind the DNA. The DNA
was washed with 2 ml 70% ethanol and the precipitator membrane dried by
passing air forcefully over the membrane using a syringe. The DNA was
eluted into a 1.5 ml centrifuge tube with 1 ml of TE buffer and the eluate was
passed through the precipitator a second time to ensure full elution of the
DNA.
2.6.5 Restriction endonuclease digestions of plasmid DNA
Restriction endonucleases were used to cut DNA constructs for cloning and
to test the presence of inserts within a vector, according to the
manufacturer’s instructions. For general diagnostic digests, a final volume
ȝOGLJHVWZDVSUHSDUHGZLWKaQJ'1$ȝOPDQXIDFWXUHU¶VEXIIHUDQG
less than 1/10thYYUHVWULFWLRQHQ]\PHa8ȝO'LJHVWLRQVZHUHLQFXEDWHG
at 37°C for between 1 hr and overnight. The volume of the digestion, amount
of enzyme used and time incubated was scaled up proportionally when
larger amounts of DNA needed to be digested. For digestions using multiple
restriction enzymes, a buffer was chosen in which both enzymes had a
greater than 75% activity, as indicated by the manufacturers. When this was
not possible, DNA was digested with the first enzyme before a buffer
exchange was performed and the second digestion performed in the new
buffer.
2.6.6 Separation of DNA fragments by agarose gel electrophoresis
Agarose gel electrophoresis was used to resolve and separate DNA on the
basis of size. Agarose (Melford) was melted in 1x TAE buffer (0.04 M Tris-
acetate, 1 mM EDTA pH8.0). DNA constructs of different size were
separated using a range of agarose concentrations (Table 4.). Agarose
solution was cooled prior to adding ethidium bromide (EtBr) (Thermo Fisher),
DWD ILQDOFRQFHQWUDWLRQRIȝJPO7KHJHOZDVSRXUHG LQWR WKH UHTXLUHG
size of gel casing and combs, and allowed to set for 30 min. DNA samples
were prepared with 6x Blue/Orange Loading Dye (Promega) (0.4% orange
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G, 0.03% bromophenol blue, 0.03% xylene cyanol FF, 15% Ficoll® 400,
10 mM Tris-HCl (pH 7.5) and 50 mM EDTA (pH 8.0).) to produce a final 1x
concentration. The gel was transferred to a gel tank filled with 1xTAE buffer
DQGWKHVDPSOHVZHUH ORDGHGDORQJZLWKȝONE'1$ODGGHURU/RZ0Z
ladder (NEB or Promega). Gels were run at 90V for ~1 hr before being
imaged on the Molecular Imager® Gel Doc XR+ System (BioRad) and
images processed using the Image Lab Software (BioRad).
Table 4. Agarose Gel Concentrations for DNA separation.
The percentage concentration of agarose required to effectively separate different
sizes of DNA product. (Adapted from Molecular Cloning, a Laboratory Manual.)
Gel Concentration (%) DNA Size (Kb)
0.60 1 – 20
0.70 0.8 – 10
0.90 0.5 – 7
1.20 0.4 – 6
1.50 0.2 – 3
2.6.7 Extraction of DNA from an agarose gel
Restriction digested DNA fragments separated by agarose gel
electrophoresis were extracted and purified from the agarose using the
QIAquick® gel extraction kit (Qiagen) following the manufacturer’s protocol.
Briefly, the gel was viewed using a Gel Doc Imager (BioRad, Molecular
Imager Gel Doc XR+) and bands carefully cut out on a transilluminator using
a clean scalpel. The band was transferred to a pre-weighed 2 ml Eppendorf
tube and the mass of the gel band measured. Three gel volumes of buffer
4*ZDVDGGHGWRWKHWXEHZKHUHPJRIJHOLVHTXDOWRȝORIEXIIHU
The bands were incubated in buffer QG for 10 min at 50°C, mixing the tube
by vortexing at 2 - 3 min intervals. One gel volume of isopropanol was added
to the Eppendorf tube and mixed to precipitate the DNA. The DNA was
applied to a QIAquick spin column and centrifuged at 16,200 xg for 60 sec.
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All subsequent centrifugation steps were also performed at this speed. 500
ȝOEXIIHU4*ZDVDGGHGWRWKHFROXPQFHQWULIXJHGIRUVHFDQGWKHIORZ
WKURXJKGLVFDUGHGȝORIEXIIHU3(ZDVDGGHGWRWKHFROXPQFHQWULIXJHG
for 60 sec and the flow through discarded. The column was centrifuged for
60 sec to remove any residual wash buffer. The QIAquick column was
WUDQVIHUUHGWRDVWHULOHPO(SSHQGRUIWXEHDQGWKH'1$HOXWHGXVLQJȝO
buffer EB after 1 min incubation.
2.6.8 Transformation of competent cells with plasmid DNA
Transformation of plasmid DNA into NEB 5-alpha competent E. coli cells
(NEB) for DNA amplification was performed using either a 5 min (low
efficiency) or 30 min (high efficiency) protocol. An aliquot of competent cells
ZDVWKDZHGRQLFHIRUPLQDQGȝORIFHOOVWUDQVIHUUHGWRDIUHVKPO
tube on ice. 1 pg - 100 ng of plasmid DNA was added to the cells, gently
mixed, and the cells incubated on ice for a further 5 min or 30 min for low or
high efficiency transformation respectively. Cells were heat shocked at 42°C
for 30 seconds before returning to ice for 2 min. In the low efficiency protocol
cells were spread onto selection plates and incubated at 37°C. For a higher
HIILFLHQF\RIWUDQVIRUPDWLRQȝORIURRPWHPSHUDWXUH6XSHU2SWLPDOEURWK
with Catabolite repression (SOC) medium (NEB) was added to the cells and
the cells were incubated at 37°C with 220 rpm shaking for 1 hr. The cells
were then spread onto a warmed selection plate and incubated at 37°C
overnight. Positively selected colonies were picked for plasmid preparations.
2.6.9 Amplification of DNA by the polymerase chain reaction
All primers were designed where possible to start or end with a C or G and
to have a %GC content of approximately 50%. Primers were synthesised by
,'7/\RSKLOLVHG'1$SULPHUVZHUHSUHSDUHGDVȝ0VWRFNVLQ7(EXIIHU
and stored at -20°C. PCR reactions were performed using a T100
Thermocycler (BioRad). The PCR reaction parameters were adapted for
different PCR primers and products, based on the length of the required
product and the primer annealing temperature.
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2.6.9.1 Cloning primers
Primers were designed for InFusion cloning following the manufacturer’s
protocol and using the InFusion primer design tool. Briefly, forward and
reverse primers were designed with 15 bp homologous to the vector
backbone and the remaining 18 - 20 bp covering the sequence to be
amplified. Primers were therefore typically 30 - 50 bp long. The Tm was
calculated without including the 15 bp overhang and was approximately
60°C.
2.6.9.2 Sequencing primers
To sequence large PCR products and vectors sequencing primers were
designed at 600 bp intervals through the sequence so that the resulting
approximately 800 bp reads from sequencing would overlap and produce a
complete sequence for the DNA product. Primers were typically 18 - 20 bp
long and had a Tm of approximately 60°C. MEGF10 sequencing primers are
listed in Table 3.
2.6.9.3 Colony PCR
Standard PCR reactions for confirming positive colonies (colony PCR) were
performed using Taq DNA Polymerase with ThermoPol® Buffer (NEB),
following the manufacturer’s recommendations. Colony PCR reactions were
prepared on ice in thin-walled PCR tubes, by mixing together components
for the following final concentrations 1x ThermoPol®%XIIHUȝ0G173
ȝ0IRUZDUGSULPHUȝ0UHYHUVHSULPHUVPDOOSLHFHRIVHOHFWHGFRORQ\
DQG8RI7DT'1$SRO\PHUDVHPDGHXSWRDWRWDOYROXPHRIȝOZLWK
nuclease-free MilliQ water. For colony PCR, the bacterial cells were lysed
and DNA denatured by heating the PCR reaction mix at 95°C for 15 min
prior to adding the Taq polymerase. The initial denaturation of DNA was at
95°C for 30 sec to enable primer annealing at 3 - 5°C below the calculated
Tm for 15 – 60 sec. The DNA polymerisation to extend the annealed primers
was performed at 68°C for 1 min/kb. The reaction was repeated for
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30 cycles prior to a final 5 min extension at 68°C. PCR products were
resolved by agarose gel electrophoresis.
2.6.9.4 Phusion® High-Fidelity PCR
For InFusion cloning Phusion® High-Fidelity DNA Polymerase (NEB) was
used to reduce the error rate in PCR products. Phusion PCR reactions were
prepared on ice in thin-walled PCR tubes, by mixing together components
IRU WKH IROORZLQJ ILQDOFRQFHQWUDWLRQV[3KXVLRQ+)%XIIHUȝ0G173
ȝ0IRUZDUGSULPHUȝ0UHYHUVHSULPHUQJWHPSODWH'1$DQG
8RI7DT'1$SRO\PHUDVHPDGHXSWRDWRWDOYROXPHRIȝOZLWKQXFOHDVH
free MilliQ® water. The initial denaturation of DNA was at 98°C for 30 sec,
before denaturation at 98°C for 5 - 10 sec to enable primer annealing at 3°C
above the Tm of the lower Tm primer for 10 - 30 sec. The DNA
polymerisation to extend the annealed primers was performed at 72°C for
15 – 30 sec per kb. The reaction was repeated for 35 cycles prior to a final
5 - 10 min extension at 72°C. PCR products were resolved by agarose gel
electrophoresis.
2.6.10 InFusion Cloning
The cloning of MEGF10 constructs into a range of vectors was performed
using the In-Fusion® HD EcoDryTM Cloning Kit (Clontech), in which PCR
primers are designed specific for the gene of interest but with an additional
15 bp homologous to the vector ends. The amplified insert can then be
cloned into a digested vector by homologous recombination between the
vector and overlapping portions added to the insert by high fidelity PCR
amplification. The InFusion Molar Ratio Calculator was used to calculate the
required volumes of purified PCR fragment and linearised vector to enable
an efficient InFusion cloning reaction. The calculated volumes of PCR insert
and vector were added to lyophilised InFusion HD EcoDry pellet and the
YROXPHPDGHXSWRȝOZLWKGLVWLOOHGZDWHU7KH,Q)XVLRQFORQLQJUHDFWLRQ
was performed in the T100 thermocycler (BioRad), incubating the reaction to
&IRUPLQWKHQ&IRUPLQ7KHȝOUHDFWLRQZDVGLOXWHGZLWK
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 ȝO 7ULV ('7$ 7( S+ EHIRUH SHUIRUPLQJ D KLJK HIILFLHQF\
transformation into E.coli.
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Figure 11. An overview of the steps for InFusion cloning.
A diagram depicting the steps involved in InFusion cloning. A linearised plasmid
and PCR amplified gene of interest are mixed in the InFusion cloning reaction for
15 min at 37°C and then 15 min at 50°C. Reaction mixtures were transformed into
NEB-5 alpha competent E.coli and positive clones selected. Adapted from InFusion
HD Cloning Kit User Manual (Clontech).
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2.6.11DNA sequencing
Cloned constructs were sequenced by Source Bioscience or GATC Biotech
Ltd. Available universal primers were used for common sites but custom
sequencing primers were designed for DNA constructs larger than 700 bp
(Sequencing primers listed Table 3.). Sequences were aligned and checked
using Serial cloner 2-6.
2.6.12 Site directed mutagenesis
Single point mutations identified in EMARDD patients were made in
MEGF10 constructs creating disease relevant mutant proteins. Mutagenesis
of MEGF10 in pDC315 and pSecTag2a vectors was performed using
QuikChange XL Mutagenesis Kit (Agilent Technologies) following the
manufacturer’s instructions. Briefly, a pair of 30 - 31 bp mutagenic primers
were designed, each containing the desired mutation in the centre and
capable of annealing to the same sequence on opposite strands of the
plasmid. Primers had a melting temperature (Tm) greater than 75°C, a GC
content of 40 - 50% and terminated in one or more C or G bases. Primers
were synthesised by IDT.
The Tm was calculated by: Tm = 81.5 + 0.41(%GC)  N)  PLVPDWFK
Where N denotes the primer length in base pairs and the values for %GC
and %mismatch are whole numbers.
The mutagenesis reaction was prepared for thermal cycling using the
reaction mixtures described below and the components added in the order
listed in Table 5. The thermal cycling conditions used are listed in Table 6.
The reaction was placed on ice for 2 min and a Dpn I digest performed to
GLJHVWWKHSDUHQWDOQRQPXWDWHGGV'1$)RUGLJHVWLRQȝO8RIDpn I
was added to each reaction and incubated at 37°C for 1 hr.
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Table 5. Site directed mutagenesis reaction mixture.
Reaction Component Amount
[5HDFWLRQEXIIHU ȝO
dH2 7RDILQDOYROXPHRIȝO
Template DNA 10 ng
)RUZDUGSULPHUȝ0 ȝO
5HYHUVHSULPHUȝ0 ȝO
G173PL[ ȝO
4XLFN6ROXWLRQ ȝO
3)87XUER'1$SRO\PHUDVH8ȝO ȝO
Table 6. Site directed mutagenesis PCR cycling parameters.
Cycles Step Temperature (°C) Time
1 Initial Denaturation 95 1 min
30
Denaturation 95 50 sec
Annealing 60 50 sec
Extension 68 1 min per kb of plasmid
1 Final Extension 68 7 min
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2.7 Mammalian Cell Culture
All cell culture media and reagents were obtained from Gibco (Thermo
Fisher Scientific). All reagents and materials used were sterile and all work
was performed in a class II biological safety cabinet. All media was heated to
37°C prior to use. The media and growth conditions used for each cell line
are listed in Table 7.
Table 7. Cell Lines and Media.
Cell
Line Media
Growth
Conditions Differentiation Conditions
C2C12 DMEM + 20% FBS
+ 1% P/S + 2% CEE
37°C, 5% CO2 DMEM + 4% H/S, 1% P/S
37°C, 5% CO2C1F 33°C, 10% CO2
HEK-293 DMEM + 10% FBS
+ 1% P/S
37°C, 5% CO2
n.a.
Ad293 n.a.
2.7.1 C1F myoblasts
The C1F cell line was derived from skeletal muscle tissue from the
Immortomouse H-2Kb-tsA58 heterozygotes. To drive C1F cells muscle was
dissected from the hindlimbs of one day old neonatal mice and digested with
0.1% collagenase and 0.6% trypsin. Cells were plated onto 0.01% gelatin
coated 6 well plate wells in DMEM supplemented with 20% FBS, 2% CEE
DQG JDPPDLQWHUIHURQ Ȗ,)1 &HOOV ZHUH LQFXEDWHG DW &  &22
clones of cells with the small, round morphology of myogenic cells were
isolated and grown under permissive conditions. Cells were determined as
myogenic based upon their ability to form multinucleated myotubes, when
cultured at 39°C and were further characterized by staining for key markers
of myogenic cells (Morgan et al., 1994; Peltzer et al., 2008). These cells
possess a mutant T-antigen gene (tsA58), derived from SV40 virus, which is
temperature sensitive and maintains the cells in a proliferative state. This
JHQHLVXQGHUWKHUHJXODWLRQRIWKHȖ,)1LQGXFLEOHH-2Kb promoter. The cells
SUROLIHUDWH LQ WKHSUHVHQFHRIȖ,)18PODW&DQGGLIIHUHQWLDWH LQWR
PXOWLQXFOHDWHG P\RWXEHV RQFH Ȗ,)1 LV ZLWKGUDZQ DQG WKH LQFXEDWLRQ
temperature increased to 37°C. Cells were seeded onto 13mm diameter
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glass coverslips coated with 0.1% gelatin at a density of 1x104 cells and
incubated overnight in culture media (Table 7.).
2.7.2 Differentiation of C1F myoblasts
To induce differentiation in C1F cells the serum content of the media was
UHGXFHGWKHȖ,)1ZDVZLWKGUDZQDQGWKHLQFXEDWLRQWHPSHUDWXUHUDLVHGWR
37°C with 5% CO2. Differentiation media was composed of DMEM +
GlutaMAX (Gibco) supplemented with 4% H/S, 1% chick embryo extract
(E.G.G. Technologies) and 1% (v/v) Penicillin/Streptomycin (Gibco). Cells
were incubated in differentiation media for between 3 and 7 days until the
myoblasts had fused to form multinucleated myotubes (Morgan et al., 1994;
Peltzer et al., 2008).
2.7.3 Growth of Ad293 and HEK-293 Cells
HEK-293 cells were first described by Graham et al. in 1977, and are
derived from human embryonic kidney cells transformed with fragments of
human adenovirus type 5 DNA to maintain growth in culture (Graham et al.,
1977).
Ad293 cells are derived from the HEK-293 cell line but display increased cell
adhesion compared to HEK-293 cells, which makes these cells less
susceptible to disruption when grown as a monolayer in plaque assays.
Ad293 cells express the adenovirus E1 gene in trans, which enables the
production of infectious adenovirus particles when cells are transfected with
E1-deleted adenovirus vectors, such as the pBHGlox vector (Ausubel, 1987;
Graham et al., 1977).
These non-myoblast cells were cultured in DMEM supplemented with 10%
FBS and 1% Pen/Strep at 37°C, 5% CO2. Cells were typically passaged 2 -
3 times per week, once cells were ~70% confluent and media changed as
required. To seed cells onto coverslips cells were prepared at 1x105 cells/ml
and seeded at 104 cells/coverslip.
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2.7.4 Recovery of cells from liquid nitrogen storage
Vials of cells were recovered from liquid nitrogen storage by rapidly thawing
the vial of cells at 37°C. The 1 ml of thawed cells was diluted into 10 ml of
warmed media in a tissue culture flask. The flask was incubated in a
humidified incubator with 4% CO2.
2.7.5 Passaging cells
Once cells had reached a confluence of ~70% they are ready to be
harvested and seeded at a lower density on a fresh tissue culture flask.
Media was removed from the flask and the cells were gently washed with
5ml Dulbecco’s phosphate buffered saline (DPBS) before being detached
from the flask with 2 ml trypsin replacement TrypLE per 75 cm3 flask. Cells
were incubated with TrypLE for no longer than 5 min before recovering the
cells with 8 ml media to give a final volume of 10 ml. Cells were centrifuged
at 1000 x g for 5 min to pellet before resuspending in 10 ml fresh growth
media. Cells were counted using a haemocytometer (Hawksley BS.748)
and the cells seeded onto flasks at the required density in growth media.
2.7.6 Storage of cells
Stocks of cells at a low passage number were stored in liquid nitrogen for
future use. Cells were harvested with TrypLE, pelleted and resuspended at
~1x106 cells/ml in growth media supplemented with 10% DMSO, to act as a
cryo-protectant. 1 ml of cell suspension was transferred to cryovials (Nunc)
and frozen in a polystyrene box at -80°C overnight. For long-term storage
cryovials were transferred to a liquid nitrogen tank.
2.7.7 Preparation of coverslips
To visualise cells by microscopy cells were seeded onto 13 mm diameter
coverslips at a density of 1x104 cells in 0.5 ml culture media. Coverslips
were prepared by performing an acid wash, in which coverslips were
thoroughly washed with a 37% hydrochloric acid solution in water (Acros
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Organics), washed five times with MilliQ pure water, and stored in 70%
ethanol in the tissue culture hood.
2.7.8 Seeding cells onto coverslips
Prior to seeding with cells, individual coverslips were separated, excess
ethanol allowed to evaporate before the coverslips were transferred to 4 or
24 well plates. Coverslips were coated with 0.1% gelatin for 20 min. Gelatin
was aspirated and the harvested cell suspension was prepared at
1x105FHOOVPODQGȝOFHOOVDGGHGSHUFRYHUVOLS&HOOVZHUHLQFXEDWHGDW
required growth temperature for 30 min to enable cells to attach before
adding sufficient growth media to the wells.
2.7.9 Transfection of mammalian cells
To introduce DNA constructs to cell lines different techniques were used to
efficiently transiently transfect or produce stable cell lines.
2.7.10Calcium chloride transfection
For the production of stable cell lines HEK-293 cells were transiently
transfected using calcium chloride. A 75 cm3 flask was seeded with 4x105
HEK-293 cells to give 10 - 20% confluence. Cells were incubated for 1 - 2 hr
at 37°C to allow cells to attach. During the incubation 2 x HBS was warmed
to room temperature and 20 min before transfection the transfection solution
was prepared in a 15 ml tube. 25 µg DNA was prepared with sterile water to
a volume of 439 µl and 61 µl of sterile-filtered 2 M calcium chloride added
and mixed. 500 µl of freshly thawed 2x HBS (274 mM sodium chloride,
0.4 mM Na2HPO4.7H2O, 55 mM HEPES, pH7.0) was added dropwise with
constant mixing to generate a fine calcium phosphate-DNA precipitate. The
transfection solution was added dropwise over the HEK-293 cells and cells
returned to the incubator.
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2.7.11 Lipid-based transfection (FuGene®)
For transient transfections coverslips were seeded with 1x104 cells and
incubated overnight. FuGene6 Transfection Reagent (Promega) was
warmed to room temperature and 6 µl was mixed with 200 µl 4°C serum-free
'0(0PHGLDLQDPO(SSHQGRUIWXEHDQGLQFXEDWHGIRUPLQȝJRI
DNA was added to the FuGene, mixed gently by flicking and incubated at
room temperature for 15 min. The growth media was removed from the
coverslips and 450 µl of fresh media was added. 50 µl of the transfection
mixture was added dropwise to the centre of each well and incubated at
required growth conditions for 24 – 48 hrs.
2.8 Immunocytochemistry
Immunocytochemistry was performed to visualise expression of specific
proteins within cultured cells. Cells were seeded onto coverslips as
previously described (2.7.8).
2.8.1 Fixation of cells
Cells were grown, transfected or manipulated as required and then fixed by
adding a final concentration of warmed 2% paraformaldehyde (PFA) diluted
in media and incubated at room temperature for 20 min. Cells were washed
three times with DPBS and stored at 4°C.
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2.8.2 Antibodies
Table 8. Primary antibodies.
Primary antibodies used in immunofluorescence and western blotting. Listed in
alphabetical order.
Antibody Company Species
Dilution
(IF)
Dilution
(WB)
A4.1025 Hybridoma Mouse 1:10
CD34 (RAM34) BD Pharminogen Mouse 1:50
C-myc (9E10) Sigma Mouse 1:5000
GAPDH Sigma Rabbit 1:5000
GFP (AB10145) Millipore Rabbit 1:1000
GFP CUSABIO Mouse 1:1000
MEGF10 (ABC10) Millipore Rabbit 1:200 1:1000
MEGF10 (S-18) sc-54244 Santa Cruz Goat 1:50 1:250
MEGF10 (HPA026876) Sigma Prestige Rabbit 1:200 1:1000
MyoD (MA1-41017) Thermo Scientific Mouse 1:100 1:500
Myogenin (F5D) DSHB Mouse 1:50 1:1000
Pax7 sup. DSHB Mouse 1:20 1:50
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Table 9. Secondary antibodies.
Secondary antibodies used in immunofluorescence and western blotting.
Antibody Species
Dilution
(IF)
Dilution
(WB)
Alexa 488 anti-mouse
Invitrogen
Goat 1:400 -
Alexa 546 anti-mouse Goat 1:400 -
Alexa 488 anti-rabbit Goat 1:400 -
Alexa 546 anti-rabbit Goat 1:400 -
Alexa 488 anti-rat Donkey 1:400 -
Alexa Fluor 647 anti-rabbit Goat 1:400 -
FITC Phalloidin Sigma 1:100 -
TRITC Phalloidin Sigma 1:100 -
DAPI Sigma 1:500 -
Anti-mouse IgG poly-HRP Sigma Goat - 1:5000
Anti-rabbit IgG poly-HRP Pierce Goat - 1:5000
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2.8.3 Permeabilisation, immunocytochemistry and mounting
coverslips
Coverslips were transferred to the staining board to reduce the volume of
antibodies needed to stain cells. To enable antibodies to recognize proteins
ZLWKLQ WKH FHOO WKH PHPEUDQH ZDV SHUPHDELOLVHG E\ DGGLQJ  ȝO 
Triton X-100 diluted in PBS with 1% (w/v) bovine serum albumin (BSA) to
each coverslip for 5 min prior to staining. Primary antibodies were diluted in
wash buffer (PBS with 1% (w/v) BSA) using dilutions described in Table 8.
7KHSULPDU\DQWLERG\ZDVDGGHGWRHDFKFRYHUVOLSGLOXWHGLQȝO3%6DQG
incubated at room temperature for 1 hr in a moist, dark chamber. Coverslips
were washed five times in wash buffer before adding the secondary antibody
solution diluted in wash buffer at dilutions listed in Table 9. Secondary
DQWLERG\ZDVDGGHGWRHDFKFRYHUVOLSGLOXWHG LQȝO3%6DQG LQFXEDWHG
for 1 hr as before. Coverslips were washed five times in wash buffer, and
once in PBS prior to mounting on microscope slides using ProLong® Gold
anti-fade mountant (Invitrogen), a curing mountant that forms a optical path
with a refractive index (RI) of 1.47 suitable for imaging and allows longer-
term storage of slides. Slides were allowed to dry overnight at room
temperature in the dark and stored at 4°C prior to visualisation.
2.8.4 Visualisation
Cells were imaged by deconvolution microscopy using the Delta Vision
Widefield Deconvolution microscope, (Delta Vision, USA). The system uses
an Olympus IX-70 epifluorescence microscope equipped with
excitation/emission filters for DAPI (ex 360/40 nm, em 457/50 nm), FITC /
GFP (ex 490/20 nm, em 528/38 nm), TRITC / Rhodamine (ex 555/28 nm,
em 617/73 nm) and Cy5 / AlexaFluor647 (ex 640/20 nm, em 685/40 nm).
The camera, shutters and software are controlled by SoftWoRX software
(Applied Precision Inc.).
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2.9 Isolation of single fibres from murine skeletal muscle
Thanks to Sara Cruz Migoni from the Borycki lab (Sheffield) for teaching me
the single fibre isolation technique.
Six week old C57BL/6J wildtype mice were euthanized by cervical
dislocation before being handed out from the animal facility to be dissected.
The extensor digitorum longus (EDL) was dissected from the leg, although
the gastrocnemius was also dissected to enable sufficient fibres to be
isolated for staining. The whole leg was cleaned with 70% ethanol and the
hindlimb shaved using a scalpel. Loose hairs were removed and skin
cleaned with 70% ethanol.
2.9.1 Dissection of muscle
2.9.1.1 Dissection of extensor digitorum longus (EDL)
To isolate the EDL, a small incision was made through the skin from the
knee down to the paw. The skin was pulled back from the underlying muscle
on both sides of the incision. The mouse was pinned onto a dissecting board
and the connective tissue that covers the muscles was carefully removed
using Cohan-Vannas spring scissors and tweezers. The four tendons of the
EDL were exposed in the foot and tweezers were used to help cut the four
tendons at once. The large TA tendon, located near the ankle on the interior
side of the leg, was cut with the Cohan-Vannas scissors. To release the EDL
muscle both the EDL and TA muscle tendons were exposed and cut. The
four long EDL tendons were teased out at the ankle with fine tweezers. The
TA muscle was lifted upwards and the EDL muscle beneath was carefully
teased out by gently pulling the tendon from the knee out (Figure 12.).
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Figure 12. Dissection of murine EDL and gastrocnemius muscle.
Dorsal (A - D) and ventral (E - F) views of skeletal muscle in the leg of a C57BL/6J
mouse. Arrows show EDL and gastrocnemius (Gas) muscle as well as the
neighbouring soleus (Sol) and tibialis anterior (TA) muscles. (Taken from (Shinin et
al., 2009).
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2.9.1.2 Dissection of gastrocnemius
The gastrocnemius was dissected from the hindlimb by removing the fur with
a scalpel. An incision was made and tweezers used to pull back the skin to
expose the underlying muscle. Cohan-Vannas scissors were used to
carefully cut and remove the connective tissue covering the muscles. The
distal tendon of the gastrocnemius was cut and the muscle gently pulled
back using tweezers. Cohan-Vannas scissors were used to gently release
the muscle and cut the proximal tendons (Figure 12.).
2.9.2 Digestion of muscle and separation of muscle fibres
The isolated muscle was handled by the tendons to avoid damaging the
muscle, and transferred to a solution of sterile-filtered 2 mg/ml collagenase
Type I from Clostridium histolyticum (Sigma) diluted in DMEM + 1% P/S
(10,000 U/ml Gibco). Muscle was digested at 37°C for 1 hr 20 min.
During the digestion 60 mm diameter tissue culture dishes (Nunc) were
coated with 10% H/S diluted in PBS. Three dishes were prepared with 5ml
isolation media (DMEM + 1% P/S) for each muscle digested. Sufficient
dishes for subsequent culture were prepared with 5ml culture media (DMEM
supplemented with GlutaMAX, Na Pyruvate [Gibco], 10% H/S, 0.5% CEE
(v/v), 1% P/S).
After digestion the muscle bulk looked swollen and loose fibres were visible
on the stereomicroscope. All subsequent work was performed using a
stereomicroscope to clearly visualise the isolated fibres. The muscle bulk
was transferred to a prepared dish of isolation media using fire-polished
wide bore glass pipette coated with 10% H/S. The muscle was flushed with
media using the wide bore pipette to release fibres, with care being taken
not to touch the muscle bulk, until 10 - 15 fibres had been released. The
muscle bulk was then transferred to a second dish of isolation media and all
the fibres released as before. Single isolated fibres, defined as individual
fibres that were straight, transparent and without debris, were picked and
transferred to the third dish of isolation media using a fire-polished, narrow-
bore glass pipette coated with 10% H/S.
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2.9.3 Culture of muscle fibres
Isolated single fibres were transferred to 60 mm diameter tissue culture
dishes (Corning) coated with 5% BSA in PBS and filled with 5 ml culture
medium (DMEM + GlutaMAX + Na Pyruvate [Gibco] + 10% H/S + 0.5% CEE
+ 1% P/S). Fibres were cultured in suspension in culture medium (DMEM
supplemented with GlutaMAX, Na Pyruvate [Gibco], 10% H/S, 0.5% CEE
(v/v), 1% P/S) at 37°C, 5% CO2 for 24 - 120 hrs.
2.9.4 Fixation and staining of fibres
To fix freshly isolated and cultured single fibres, the fibres were transferred
to a 2 ml Eppendorf tube using a narrow-bore, fire-polished glass pipette
coated with 10% H/S and allowed to settle to the bottom for 3 min. Excess
medium was carefully removed with a pipette without disturbing the fibres,
and the fibres were fixed with 500 µl warmed 4% PFA for 20 min. Fibres
ZHUHZDVKHGWKUHH WLPHVIRUPLQZLWKȝO3%6)LEUHVZHUHVWRUHG LQ
700 µl PBS at 4°C before staining.
Fibres were stained by permeabilising membranes with 0.5% Triton X-
100/PBS (PBST) for 10 min before washing three times for 3 min with PBS.
Non-specific antibody binding was reduced by incubating the fibres with
 ȝO EORFNLQJ VROXWLRQ  +6 IRU PLQ DW URRP WHPSHUDWXUH 7KH
primary antibody solution was prepared in PBS following dilutions described
LQ 7DEOH  DQG ILEUHV ZHUH LQFXEDWHG ZLWK  ȝO RI DQWLERG\ ZLWK JHQWO\
rocking for 2 hrs at room temperature or at 4°C overnight. The primary
antibody was removed and fibres were washed three times for 3 min with
 ȝO RI 3%6 FRQWDLQLQJ  7ZHHQ 6HFRQGDU\ DQWLERGLHV ZHUH
prepared in PBS according to the dilutions described in Table 9. and fibres
were incubated at room temperature for 1 hr 30 min with gentle rocking. The
secondary antibody was removed and fibres washed three times for 3 min
ZLWKȝO RI3%6ZLWK7ZHHQDQGD ILQDO ȝO3%6ZDVKZDV
performed. Fibres were carefully selected with a fire-polished, narrow-bore
glass pipette coated with 10% horse-serum and placed on a clean
microscope slide. Excess PBS was removed and fibres air dried slightly
before two drops of ProLong Gold antifade mounting medium was added. A
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24 x 40 mm coverslip was placed on top and excess mounting medium
removed. Slides were left to cure overnight in the dark, before storage at
4°C.
The method for the isolation and staining of single muscle fibres was based
upon previously published protocols (Collins, 2009; Pasut et al., 2013).
2.10Adenoviral Production
2.10.1Co-transfection of Ad293 cells for viral production
Ad293 cells were plated out onto a 25 cm3 flask and incubated overnight.
Cells were 60% confluent on the day of transfection. DNA plasmids were
transfected into Ad293 cells using the FuGene protocol (2.7.11). The two
DNA plasmids required for the co-transfection (pBHGlox and
pDC315_MEGF10 constructs) were mixed at a ratio of 1:2. The transfection
mix was added in a drop wise manner directly to the media of a T25 of
Ad293 cells and incubated at 37°C, 5% CO2 overnight. Cells were inspected
visually for GFP expression using a fluorescent microscope (Nikon) using
the 10x objective.
2.10.2Adenoviral amplification
Transfected Ad293 cells were grown to confluence with most of the cells
showing GFP expression. After 48 hrs cells were harvested using a cell
scraper and used to seed two 75 cm3 tissue culture flasks. The cells were
incubated at 37°C, 5% CO2 and inspected daily for viral production,
indicated by the infected cells becoming round and detaching from the
surface. After 10 days the cells showed at least 50% cytopathic effect and
were harvested using a cell scraper. Cells were pelleted by centrifugation at
2000 x g for 10 min before the supernatant was aspirated and the pellet
UHVXVSHQGHGLQȝO3%6DQGWUDQVIHUUHGWRDQ(SSHQGRUIWXEH
Virus was released from the cells using a freeze-thaw method. Ethanol was
added on top of dry ice and the cells frozen by floating the Eppendorf tube
on top of the ethanol for 5 min. Cells were thawed in a beaker of room
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temperature water and once defrosted the cells were mixed by vortex. The
process was repeated three times. The cells were centrifuged at 5000 xg for
10 min to pellet the cell debris, leaving the adenovirus in the supernatant. A
25 cm2IODVNRI$GFHOOVZHUHLQFXEDWHGZLWKȝOYLUXVȝOPHGLD
for 2 hr. 5ml of media was then added and the cells incubated for 3 days
until the viral infection caused the cells to round up and become detached
from the dish. The virus was harvested as described previously.
The virus was amplified three times in Ad293 Cells to increase the
adenoviral titre:
Amplification Flasks of Ad293 Cells Amount of Virus
1 1xT25 ϰϬϬʅů
2 2xT75 ϱϬʅůŽĨĂŵƉůŝĨŝĐĂƚŝŽŶϭƉĞƌĨůĂƐŬ
3 5xT75 ϮϬʅůŽĨĂŵƉůŝĨŝĐĂƚŝŽŶϮƉĞƌĨůĂƐŬ
After 50% of the cells had begun to show signs of infection, with the cells
becoming round and detatching from the dish, in the third amplification, the
cells were centrifuged and the pellet frozen at -80°C with the media from the
flask before purification of the adenovirus.
2.10.3Adenopack adenovirus purification
Adenovirus purification was performed using the Vivapure Adenopack 100
kit (Sartorius Stedim Biotech) following the manufacturer’s instructions.
Briefly, the infected cells and media were defrosted and the cells freeze-
thawed, as described previously. The cells were centrifuged at 3500 xg for
15 min to pellet the cell debris and the viral supernatant was transferred to a
PO)DOFRQWXEHRIWKDZHGPHGLDȝORI%HQ]RQDVH®QXFOHDVHȝOSHU
1 ml of culture) was added to the viral supernatant, mixed and incubated at
37°C for 30 min. For purification of the virus, a retort stand and clamp was
prepared in a tissue culture hood and all subsequent steps were performed
under sterile conditions. The provided tube set and 50 ml syringe were set
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up in the clamp with the feed tube in the viral supernatant. The supernatant
was drawn up into the syringe and the one-way valve used to ensure all air
was expelled from the syringe and tubing. A Minisart plus was attached to
the syringe assembly and the supernatant filtered into a fresh container,
leaving a small volume of supernatant to prevent air entering the Minisart.
Loading buffer at 1/9 volume of the total filtered supernatant was added and
the Minisart discarded. The Adenopack was prepared taking care to remove
all air to ensure efficient viral binding. A 10 ml syringe was filled with PBS,
connected to the Adenopack and 5 – 6 ml of PBS gently passed through.
The syringe plunger was pumped up and down a few times to remove air
from the Adenopack before the remaining PBS was passed, through leaving
1ml in the syringe to prevent air entering.
The feed tube from the 50 ml syringe and tube set was placed into the
prepared sample solution. The air was removed from the syringe and valve
and a wet-to-wet connection was made between the wetted Adenopack unit
and the tube outlet. The prepared sample was slowly passed through the
Adenopack unit at a rate of approximately 10 ml/min, determined by being
able to count single drops. To prevent air entering the system 1 - 2 ml of
sample was left in the syringe. The Adenopack was washed by slowly
passing through 100 ml of washing buffer using a higher flow-rate, leaving 1-
2 ml in the syringe to prevent air entering the system. To elute the virus, the
Adenopack was removed from the tube set and attached to a 10 ml syringe
filled with 5 ml elution buffer. The syringe was held over a sterile 15 ml tube
and 1 ml of elution buffer was very slowly passed through the Adenopack
over 1 - 2 min. The Adenopack was then incubated for 10 min at room
temperature before slowly passing the remaining elution buffer through at
approximately 1 ml/min.
2.10.4 Storage of adenovirus
The virus was concentrated and the buffer exchanged to storage buffer
(20 mM Tris/HCl, 25 mM NaCl, 2.5% glycerol (w/v), pH8). 1 ml of the purified
YLUXVLQVWRUDJHEXIIHUZDVGLVSHQVHGLQWR[ȝODQG[ȝODOLTXRWV
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2.10.5 Viral Titre Assay
The viral titre was calculated using the tissue culture infectious dose 50
(TCID50) method (AdEasyVector System, Qbiogen, Inc.). A 96 well plate
was prepared with 1x104 Ad293 cells per well incubated at 37°C, 5% CO2
overnight. The purified virus was serially diluted in media to give dilutions of
10-1 to 10-10 and one concentration was added to 10 wells per row of the 96
well plate, with the remaining two wells being left as a control without virus.
Cells were incubated for 10 days and the numbers of wells showing signs of
viral infection (cytopathic effect, CPE.) were counted. The ratio of the
number of wells showing cytopathic effect out of the 10 wells set up was
calculated for each viral dilution. The sum of the ratios was calculated and
denoted as ‘s’. The log10 of each viral dilution is denoted as ‘d’.
To calculate the viral titre:
T = 101+d(s-0.5)
T = 101+1(7.7-0.5) = 108.2IRUȝOGLOXWLRQ7KHUHIRUH7&,'50 is 109.2/ml
To calculate the PFU/ml: T = 1x10
9.2-0.7
= 1x10
8.5
PFU/ml = 3x10
8
PFU/ml
2.11Protein expression, purification and quantification
2.11.1 Production of stable cell lines expressing secreted protein
constructs
Stable cell lines expressing secreted constructs of MEGF10 were produced
for mammalian protein expression. pSecTag plasmid constructs were
transfected into HEK-293 cells by calcium chloride transfection (2.7.10).
Cells were harvested from 75 cm3 flasks 48 hrs post-transfection, counted by
haemocytometer and prepared at 1x105cells/ml. Two 100 mM diameter
tissue culture dishes (Corning) were seeded with 2x104 cells in 10 ml
selection media (DMEM supplemented with 10% FBS, 1% P/S and
 ȝJPO =HRFLQ  6HOHFWLRQ PHGLD ZDV FKDQJHG HYHU\  ±  GD\V IRU
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10 days, until cells not expressing the plasmid died and only single colonies
of cells expressing the Zeocin resistance in pSecTag2A vector survived.
After 10 days single colonies from each plate were picked using a blue
plastic pipette tip and used to seed duplicate wells in two 24 well plates.
Colonies were plated in non-selective media to enable to cells to recover
and grow. Plates were incubated at 37°C, 5% CO2 for 10 days changing the
media every 3 - 4 days. Media samples were taken from each well to be
analysed by dot blot to determine the clone with the highest expression level
of secreted protein.
2.11.1.1 Dot blot
A dot blot was performed as a relatively rapid diagnostic test to determine
the level of secreted protein expression into the media of HEK-293 cells. A
nitrocellulose membrane was cut to the required size and equilibrated in
PBS for 20 min prior to use. The dot blot apparatus was cleaned with 70%
ethanol and a piece of 3 mm Whatman chromatography paper placed in the
base of the apparatus. A piece of 3 mm Whatman chromatography paper
was pre-soaked in PBS and placed on the 96 well plate layout at the centre
of the dot blot apparatus (ScotLab) and the equilibrated nitrocellulose
membrane placed on top. The top portion of the dot blot apparatus was
placed on top and fixed in position by firmly tightening the screws. The lid
was sealed in place by turning on a vacuum pump. Samples were loaded
with the vacuum pump switched off to ensure even distribution onto the
PHPEUDQHEHQHDWKȝORIHDFKVDPSOHZDVORDGHGLQWRWKHUHVSHFWLYH
wells of the dot blot apparatus and the vacuum switched on to allow media
to be drawn onto the membrane. The membrane was removed from the
apparatus and transfer to a 50 ml falcon tube and blocked with 3% (w/v) milk
for 1 hr at room temperature for 1 hr. The membrane was then treated in the
same way as a western blot membrane for antibody incubations, washes
and development (2.12.5). Layout of the dot blot is shown in Figure 13 A.
and B.
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Figure 13. Dot blot apparatus.
A. Image of the dot blot apparatus (Scotlab), showing the connection to the vacuum
pump and 96 well plate layout. B. Diagram of the layout of the three pieces of the
dot blot apparatus, with 3 mm Whatman chromatography filter paper and
membrane.
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2.11.2Mammalian secreted protein expression in HEK-293 cells
For efficient expression and purification of secreted mammalian protein
constructs, HEK-293 stable cells lines were seeded onto five 75 cm3 flasks
FRDWHGZLWKȝJPOSRO\/ O\VLQH7RFRDW IODVNVZLWKSRO\/ O\VLQH IODVNV
ZHUHLQFXEDWHGZLWKPORIȝJPOSRO\/O\VLQHGLOXWHGLQG+20 for 20 min
at 37°C before it was removed and flasks allowed to dry overnight at 37°C.
Cells were grown to 80% confluence in normal growth media (2.7) and then
the medium was exchanged for OptiMEM low serum media (Gibco) to
reduce contaminants in the later purification stages. Cells were cultured in
OptiMEM for 3 days prior to harvesting the media and purifying the protein.
2.11.3 Protein purification using nickel affinity chromatography
The secreted protein constructs had a six histidine tag (6His) tag to enable
purification by nickel affinity chromatography. OptiMEM media was
harvested, centrifuged at 1000 x g for 5 min to pellet cells and incubated with
1 ml Complete His-Tag Purification Resin slurry (Roche) and Complete
EDTA-free protease inhibitor cocktail tablet (Roche) for 30 min on a roller.
Media was applied to the 5 ml column and the flow through collected. The
resin was washed with five times column volume wash buffer (300 mM
sodium chloride, 50 mM sodium phosphate). Protein was eluted with elution
buffer (300 mM sodium chloride, 50 mM sodium phosphate and 200 mM
imidazole).
2.11.4 Protein dialysis
Protein eluates in 300 mM sodium chloride, 50 mM sodium phosphate and
200 mM imidazole were pooled together and dialysed into 1 L PBS at 4°C
overnight, using a Gebaflex Maxi Dialysis Tube (MWCO = 3.5 kDa)
(Generon).
2.11.5 Freezing purified proteins
Purified proteins were stored in aliquots at -80°C.
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2.11.6Measuring protein concentration by spectrophotometry
The concentration of purified proteins was measured using a Cary® 50 Bio
UV-visible spectrophotometer [Varian]. 1 ml of buffer was used as a blank
before 1 ml of the sample was placed into a cuvette (Fisher) and the
absorbance measured at 280 nm.
The concentration was calculated based on the extinction coefficients
predicted for each construct assuming all pairs of Cys residues form
cysteine bonds by Protparam (Gasteiger et al., 2003).
2.12Protein isolation and separation
2.12.1 Preparation of whole cell extracts
Samples were prepared by scraping cells directly into 2x sample buffer prior
to boiling at 100°C for 10 min and freezing aliquots at -80°C.
Alternatively proteins were extracted and quantitated by BCA assay prior to
preparing samples for SDS-PAGE and western blot. All steps were
performed on ice. Immediately before use 1 ml lysis buffer (150 mM NaCl,
50 mM Tris (pH8), 1% Triton X-100, 1 mM EDTA (pH8)) was prepared with
10µl Halt Protease Inhibitor, single-use cocktail (Thermo Scientific). The
harvested cell pellet was washed in PBS and transferred to a 1.5 ml
centrifuge tube and the cells pelleted by centrifugation at 300 xg for 5 min at
4°C. The supernatant was removed and the pellet resuspended in 50 µl
lysis buffer with protease inhibitor. The cells were incubated on ice for
30 min and were mixed by vortex every 5 min. Cells were centrifuged at
17,000 xg for 20 min at 4°C. The supernatant was transferred to a fresh
1.5 ml centrifuge tube and the lysate stored at -20°C.
2.12.2Quantification of protein using the BCA assay
Protein concentration was calculated using the Pierce ® Micro BCA Protein
Assay Kit (Thermo Scientific) for microplate procedure. Briefly, a BSA
standard curve was prepared in Eppendorf tubes, changing tips and mixing
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thoroughly by vortex in between each dilution. (2 mg/ml BSA stock solution,
Pierce)
Tube Vol. of MilliQ (µl) Vol. and Source of BSA Final [BSA] (µg/ml)
A 1900 100 µl of stock solution 100
B 600 400 µl of A 40
C 667 330 µl of A 30
D 500 500 µl of B 20
E 500 500 µl of C 15
F 500 500 µl of D 10
G 500 500 µl of F 5
H 500 500 µl of G 2.5
I 500 - 0 (Blank)
Cell lysates were diluted 1:250 to bring the concentration values within the
range of the standard curve. Sufficient working reagent was prepared by
calculating the number of samples to be tested:
(number of standards + number of unknowns) x number of replicates x
volume of WR per sample = Total WR (ml)
The working reagent is composed of three reagents: Reagent A (MA),
Reagent B (MB), Reagent C (MC) at a ratio of 25 : 24 : 1.
150 µl of each sample and the standard curve was pipetted in triplicate into
the wells of a flat-bottomed, clear plastic 96 well plate (Nunc). The prepared
working reagent was transferred to a reservoir and 150 µl was added to
each well using multichannel pipette. The plate was gently mixed for 30 sec
before being incubated at 37°C for 2 hrs. The plate was removed from the
incubator and cooled to room temperature before reading. The absorbance
at 544 nm was measured using a Polstar Optima plate reader. The
concentration of the sample proteins was calculated based on the standard
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curve of the average, blank corrected measurements for each BSA
standard.
2.12.3 SDS-PAGE
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
was performed in order to separate protein samples according to their size.
Glass gel plates at the required spacer thickness (Table 10. B.) (BioRad)
were washed with detergent, cleaned with ethanol and dried prior to
assembling gel casings. Gel casings were placed in a casting stand and
checked for leaks with water. A separating gel was prepared and the
percentage acrylamide used was determined according to the size of
proteins to be resolved. Reagents were added in the order listed in Table
10., with the APS and TEMED being added simultaneously at the end
immediately before the gel was poured. A layer of 70% ethanol was added
on top to give the separating gel a level top and the gel was polymerized for
20 min at room temperature until fully set. Once the gel has set a 4%
stacking gel was prepared and poured on top of the separating gel (Table
11.). The comb (10 or 15 well) was inserted and the gel allowed to set for
20 min.
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Table 10. SDS-PAGE Separating Gel Composition.
The volume of reagents required to make 10 ml of 7.5 – 15% SDS-PAGE gels.
15% 12% 10% 7.5%
Distilled Water (ml) 2.35 3.35 4.02 4.85
1.5 M Tris-HCl pH8.8 (ml) 2.50 2.50 2.50 2.50
ϭϬй;ǁͬǀͿ^^ƐƚŽĐŬ;ʅůͿ 100.00 100.00 100.00 100.00
Acrylamide/Bis* (30% stock) (ml) 5.00 4.00 3.33 2.50
ϭϬйW^;ʅůͿ 50.00 50.00 50.00 50.00
dD;ʅůͿ 5.00 5.00 5.00 5.00
Total (ml) 10.00 10.00 10.00 10.00
(10% APS = 100 mg APS in 1 ml dH2O)
Calculated volumes (in ml) required per gel slab: Mini Protein II system.
Spacer Thickness (mm) Volume (ml)
0.50 2.80
0.75 4.20
1.00 5.60
1.50 8.40
Table 11. 4% Stacking Gel Composition
The volumes of each reagent needed to produce a 4%, 0.125M Tris, pH6.8 SDS-
PAGE stacking gel.
4%
Distilled Water (ml) 6.10
0.5M Tris-HCl, pH6.8 (ml) 2.50
ϭϬй;ǁͬǀͿ^^;ʅůͿ 100.00
Acrylamide/Bis* (30% stock) (ml) 1.30
ϭϬйW^;ʅůͿ 50 (0.05%)
dD;ʅůͿ 10 (0.1%)
Total Volume (ml) 10.00
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2.12.4Running SDS-PAGE gel
Gels were transferred to the gel tank (BioRad); 1X running buffer was
prepared from 10x stock (30 g/l TRIS base, 144 g/l Glycine, 10% SDS) by
diluting 100 ml into 1 L of dH2O and added to the centre of the apparatus. To
GHWHUPLQH WKHVL]HRISURWHLQVVHSDUDWHGE\6'63$*(ȝORI3DJH5XOHU
plus pre-stained protein ladder (Thermo Scientific) was loaded into the first
well. Protein samples were loaded in subsequent wells. Typically a gel was
run at a constant voltage of 100 V for 1 hr.
2.12.5Western Blot
In order to detect a protein of interest in a complex cell lysate separated on
an SDS-PAGE gel, proteins were transferred to a Hybond-ECL nitrocellulose
membrane (Amersham). 1 L of 1x transfer buffer was prepared (10x Pierce
Western Blot Transfer Buffer). The gel was removed from the running
apparatus and the stacking gel cut off. The transfer stack was prepared in
transfer buffer as depicted in Figure 14.
All the components were fully soaked in transfer buffer and the stack was
carefully smoothed to ensure that air bubbles were removed. A corner of the
nitrocellulose membrane and the corresponding corner of the gel were cut in
order to allow orientation of the membrane. The cassette was transferred to
the Bio-Rad transfer apparatus, the tank was filled with running buffer and
the transfer was run at 400 mA for 1 hr.
Once the transfer was complete, the stack was removed from the apparatus
and the membrane was checked to see if the coloured protein bands from
the re-stained ladder had properly transferred. The membrane was blocked
in 5% non-fat milk in PBS (AppliChem) for 1 hr at room temperature on a
roller. Primary antibody was prepared in 5 ml antibody buffer (2% milk in
PBS) and membrane was incubated with antibody overnight at 4°C. After
incubation overnight at 4°C, the membrane was washed 5 times over the
course of 1 hr with PBS + 0.05% Tween, with each wash being incubated at
room temperature. The secondary HRP conjugated antibody, was diluted
1:5000 in 5 ml antibody buffer (2% w/v milk protein dissolved in PBS).
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The membrane was incubated with the secondary antibody at room
temperature, on the roller for 1 hr. The membrane was then washed five
times with PBS + 0.05% Tween as before with a final 5 min wash with PBS
alone. The membrane was then gently blotted on filter paper and
transferred to a sheet of acetate. 2 ml of Super Signal West Pico
Chemiluminescent Substrate (ThermoFisher) was applied to the membrane
and incubated at room temperature for 10 min. The membrane was blotted
dry on filter paper and returned to the acetate and covered with a second
sheet of acetate and the casing sealed. The membrane was transferred to a
dark room and exposed to Lumi-Film Chemiluminescent Detection Film
(Roche) for between 1 sec and 25 min to obtain the correct exposure. The
film was then developed using an X-Ograph imaging system compact x4.
Membranes were stored at 4°C in PBS. To reprobe a membrane for a
different protein the membranes were stripped for 10 min in 5 ml Restore
West stripping buffer before washing three times with 10 ml PBS.
Membranes were then blocked with 5% (w/v) milk in PBS for 1 hr and
probed as described above.
Figure 14. The layout of a western blot sandwich.
The black band represents the side of the sandwich, which is present closest to the
anode. Green indicates the sponges and blue the filter papers at either side of the
sandwich.
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2.12.6Data anaylsis
Notation in figure legends presents the number of biological repeats (n=)
graphs show the mean average results and, where appropriate, error bars
depict either the standard error of the mean (S.E.M.) or standard deviation
(S.D.). To analyse statistical significance between conditions unpaired t-tests
were performed, using GraphPad Prism version 6 for Mac, GraphPad
Software, La Jolla California USA, www.graphpad.com. In figures the
condition marked # was used as the reference against which the other
conditions were compared. The level of statistical significance is indicated by
the number of asterisks displayed.
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3 Expression and localisation of endogenous MEGF10 in
muscle tissue.
3.1 Introduction
MEGF10 has been shown to be important for the normal function of satellite
cells within the skeletal muscle environment (Bröhl et al., 2012; Holterman et
al., 2007). Levels of MEGF10 are ~ 8 fold higher in C2C12 myoblasts than in
differentiated cells, as shown by qPCR, and ~100 fold in activated satellite
cells isolated from 8 week old mice (Holterman et al., 2007).
Overexpression of MEGF10 inhibited fusion (Holterman et al., 2007), this
effect is similar to that found for high levels of Notch signalling (Bröhl et al.,
2012), and MEGF10 has also been linked to Notch signalling (Holterman et
al., 2007). Conversely, a double knockout of both the downstream effector
of Notch signalling (Rbpj) and MyoD in mice increased levels of MEGF10
expression. In these double knockout animals, the satellite cells remain in
the interstitial space and do not migrate to their characteristic location
beneath the basal lamina of skeletal muscle fibres. This led to the
suggestion that Notch signalling is important for the formation of the basal
lamina around satellite cells, with MEGF10 playing a role in the adhesion of
the satellite cells to muscle fibres under the basal lamina (Bröhl et al., 2012).
In contrast, other research has linked increases in MEGF10 to increases in
myogenin, with changes in expression occurring in parallel, rather than
linked to changes in MyoD expression (Holterman et al., 2007).
Furthermore, this study showed that myogenin binds to the promoter region
of MEGF10 to induce its expression suggesting that the mechanisms by
which MEGF10 expression is regulated may be more complex than
previously described (Park et al., 2014). Outside of these mouse models of
MEGF10 function, a lack of MEGF10 was shown to result in the skeletal
myopathy EMARDD in humans, in which muscle fibres have a reduced fibre
diameter, and fewer nuclei per fibre, consistent with the expected effects on
satellite cell function (Logan et al., 2011).
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Given the rare nature of EMARDD and the invasive nature of the muscle
biopsy procedure (Logan et al., 2011), animal or in vitro studies are required
to study EMARDD. Previous papers studying MEGF10 and its orthologues
have used a number of different model systems including: Caenorhabitis
elegans (Lettre and Hengartner, 2006), Danio rerio (Boyden et al., 2012a),
Drosophila melanogaster (Draper et al., 2014; Tung et al., 2013) and Mus
musculus (Holterman et al., 2007). However, whilst these model systems
have their advantages in being simple to work with and to follow the
myogenic process they also have some drawbacks. For example, Draper is
the single orthologue of MEGF10, MEGF11 and MEGF12 in Drosophila,
making it difficult to tease out the specific functions of MEGF10. A mouse
knockout model for MEGF10 has been described (Kay et al., 2012), but this
only reported on effects in the retina with no description of any muscle
phenotype. MEGF10 knockdown was demonstrated in starburst amacrine
cells but not in other mouse tissues.
A number of different cultured mammalian cell lines have also been used to
study MEGF10, including HEK-293 cells stably expressing MEGF10_eGFP
(Suzuki and Nakayama, 2007a), HeLa cells (Hamon et al., 2006; Singh et
al., 2010) and C2C12 cells (Holterman et al., 2007; Mitsuhashi et al., 2013).
However, HeLa and HEK-293 cells are not derived from muscle, and the
cultured C2C12 myoblasts do not recreate the specific satellite cell niche in
vitro. C2C12 cells were derived as a diploid subclone from C2 myoblasts
(Blau et al., 1985). C2 myoblasts were derived from the C3H mouse 70 hr
after a leg muscle crush injury and were allowed to undergo a spontaneous
transformation while in culture, which led to their immortalization (Morgan et
al., 1992). These murine myoblasts can be induced to form myotubes that
express proteins typically present in in vivo muscle (Blau et al., 1985; Yaffe
and Saxel, 1977). C2C12 cells have been well studied, including a thorough
examination of protein expression, using LC-MS-based shotgun profiling
(mass spectrometry), over the course of differentiation (Kislinger et al.,
2005), in which ~1800 different proteins were investigated, and the results
broadly agreed with an earlier study that used gene profiling (Tomczak et al.,
2003). However, neither of these reports showed data on the expression of
MEGF10.
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However, C2C12 cells have the disadvantage that control over the switch
from proliferation to differentiation is not complete in this cell line, due to the
transformed nature of the cells. Commonly, differentiation is induced by
serum deprivation however, while this promotes differentiation, it does not
prevent undifferentiated cells in the culture from continuing to grow. These
cells can form new muscle when implanted into nude mice but do not form
mature pattern of differentiation in fibres, which may suggest their limited
myogenic potential (Morgan et al., 1992). Moreover, when these cells are
injected into mouse muscle in vivo, they form non-muscular tumours after a
couple of weeks (Morgan et al., 2002; Morgan et al., 1993; Wernig et al.,
1991).
The lack of control of differentiation and proliferation in C2C12 cells led to
the derivation of alternative myoblast cell culture systems. Our laboratory
commonly uses myoblast cultures derived from isolated skeletal muscle
tissue from the Immortomouse H-2Kb-tsA58, which have several advantages
over C2 cells (Jat et al., 1991; Morgan et al., 1994). These cells possess a
temperature sensitive mutant T-antigen gene (tsA58), derived from the SV40
virus, that maintains the cells in a proliferative state. This gene is under the
regulation of the Ȗinterferon sensitive H-2Kb promoter. Cells grown in the
presence of Ȗinterferon at 33°C switch on tsA58 gene expression which
promotes cell proliferation, with the T-antigen remaining stable at 33°C.
Withdrawal of Ȗinterferon prevents further tsA58 gene transcription, while
incubating the cells at 37 - 39°C degrades any remaining T-antigen,
providing a mechanism to stop myoblast proliferation, while allowing
differentiation (Morgan et al., 1994). Several clonal cell lines have been
derived from this mouse model, including C1F (Morgan et al., 1994; Peltzer
et al., 2008), which is a highly fusigenic clone. These cells provide a good
alternative in vitro culture model to those of C2C12 cells, with a more
controllable switch between proliferation and fusion. Furthermore, the C1F
cell line is simple to culture and appears to retain some stem cell-like
properties through the cells ability to differentiate after serial passage
(Morgan et al., 1994). Implantation of these cells into mice leads to the
formation of normal muscle but non-muscular tumours are not subsequently
formed as seen in C2C12 cells (Morgan et al., 1994; Morgan et al., 2002).
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C1F cells, and other clones derived from this mouse model, are capable of
undergoing differentiation into fibres with a more mature phenotype than
described for other myoblast lines such as C2C12 cells and primary satellite
cell cultures (LaFramboise et al., 2003; Morgan et al., 2002). These
characteristics of C1F cells make them a good model to investigate MEGF10
in an in vitro cultured myoblast system.
Whilst C2C12 and C1F myoblasts are simple to culture, this approach does
not fully recreate the satellite cell niche. To investigate MEGF10 expression
in activated satellite cells within the stem cells niche, a number of
approaches can be used. One is to isolate single muscle fibres, and the
culture of these fibres outside of the skeletal muscle environment causes
satellite cells to become activated and proliferate beneath the basal lamina
(Pasut et al., 2012). This approach has often been used to investigate
satellite cell biology (Beauchamp et al., 2000; Cornelison and Wold, 1997;
Zammit et al., 2006) and was used to investigate MEGF10 expression and
localisation in quiescent and activated satellite cells (Holterman et al., 2007).
Therefore, I have also used this model to perform a more in depth
characterisation of the expression and localisation of MEGF10.
Finally, satellite cells can also be activated in vivo using a number of
different strategies. A number of techniques, which provoke major muscle
damage and subsequent regeneration, involve the injection of muscle with
toxins such as cobra cardiotoxin (ctx); chemicals such as barium chloride
and physical damage such as freeze injury. Each of these techniques have
been compared and whilst each technique induces muscle regeneration the
time course of the regenerative process can vary quite significantly between
the different methods used (Hardy et al., 2016). Ctx treatment has already
been used to show by qPCR that MEGF10 expression increases markedly 3
days after injury, as the muscle is regenerating (Holterman et al., 2007).
Each of these models cause severe damage to the muscle and large
reduction in stem cell number beyond what would be expected within the
physiological range of muscle damage. Therefore, I have used a more
physiological model of muscle damage, in which the EDL muscle is
overloaded by removing the tibialis anterior (TA) muscle. This treatment both
increases the sarcomere length of the EDL muscle and causes a mild
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hypertrophy (Egginton et al., 2011; Egginton et al., 1998). Studies have
shown that satellite cells are important in hypertrophic muscle regeneration
and therefore we would expect to be able to observe activated satellite cells
in vivo through this approach (Liu et al., 2015b; Rosenblatt et al., 1994).
I have therefore used these three approaches: an in vitro muscle cell culture
model, an isolated fibre culture model, and an in vivo model to investigate
the expression pattern of MEGF10 to determine its spatial and temporal
localisation over the course of myogenesis. I first characterised three
commercially available antibodies used within the literature to determine
their specificity for MEGF10 and suitability for western blotting and
immunofluorescence. To enable me to do this, I used eGFP_MEGF10
(described in Chapter 4), and the purified ECD from MEGF10, expressed
using HEK-293 cells (Chapter 5). I then used the best antibody to
investigate expression of MEGF10 in relation to other satellite cell markers in
all three model systems. In addition, I use RNAseq to investigate the
expression of MEGF10 and other muscle specific proteins in the cultured cell
model during differentiation.
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3.2 Methods
3.2.1 RNAseq
In order to determine the relative expression levels of RNA in myoblast cells
at different stages of differentiation the TruSeq stranded mRNA sample
preparation, low sample (LS) protocol (Illumina) was followed (an overview
of the process is depicted in Figure 14.). Thanks to Clare Logan and
Gabrielle Wheway, LIMM for their help in setting up the RNA seq experiment
and processing the data. Sequencing was performed at at the Next
Generation Sequencing Facility, LIMM.
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Figure 15. Overview of the TruSeq stranded mRNA protocol.
A flow diagram depicting the key stages in RNA sequencing, including the isolation
and fragmentation of mRNA, the synthesis of cDNA, adaptor ligation and PCR
amplification to form a validated library (Diagram adapted from the TruSeq manual).
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3.2.1.1 Handling and isolating total RNA from mammalian cells
To determine the levels of MEGF10 expression, RNA was isolated from C1F
cells at different stages of differentiation. Three 25 cm2 flasks were seeded
with 2x105 C1F cells and cultured to proliferate for 24 hrs as undifferentiated
myoblasts (UD) or cultured to proliferate before being switched to
differentiation conditions and differentiated for one or seven days, to produce
early fusing myoblasts (D1) and fully differentiated myotubes (D7)
respectively. The cells were harvested from each flask by cell scraper into 5
ml fresh growth media and pelleted by centrifugation at 1000 xg for 5 min at
4°C, washed in 1 ml DPBS and transferred to a 1.5 ml centrifuge tube. Cells
were pelleted by centrifugation at 13,000 xg for 5 min at 4°C and stored at -
80°C.
To make RNA, C1F cells pellets were thawed and total RNA was extracted
using the GenElute Mammalian Total RNA Miniprep Kit (Sigma) following
WKHPDQXIDFWXUHUV¶SURWRFRO%ULHIO\HDFKSHOOHWZDVUHVXVSHQGHGLQȝO
O\VLV VROXWLRQSUHSDUHGZLWK IUHVKȕPHUFDSWRHWKDQRODQGPL[HG WKRURXJKO\
by vortex. To remove cellular debris and shear any DNA the lysate was
filtered using a GenElute Filtration Column at 16,200 xgIRUPLQȝORI
70% ethanol was added to the filtered lysate and thoroughly mixed by
vortex.
To bind the RNA to a column the lysate was loaded onto a GenElute binding
column by centrifuging at 16,200 xg for 15 sec. The flow-through was
GLVFDUGHG FROXPQZDVKHGZLWK ȝOZDVK VROXWLRQ  DQG FHQWULIXJHG DW
16,200 xg for 15 sec. All subsequent centrifugation steps were at 16,200 xg.
The binding column was transferred to a fresh 2 ml collection tube and
ZDVKHG WZLFH ZLWK  ȝO ZDVK VROXWLRQ   7KH FROXPQ ZDV GULHG E\
centrifuging for 2 min.
7KH 51$ ZDV HOXWHG IURP WKH FROXPQ ZLWK  ȝO HOXWLRQ VROXWLRQ E\
centrifuging for 1 min. The RNA was stored on ice and the concentration
measured using the Nanodrop. Absorbance was measured at 260 nm and
concentration calculated using the Beer-Lambert law, which predicts a linear
change in absorbance with concentration, where an A260 reading of 1.0 is
equivalent to ~40 µg/ml of single-stranded RNA. The ratio of absorbance
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readings at 260 nm and 280 nm was used to assess the purity of the RNA
with a ratio between 1.8 and 2.1 indicating ‘pure’ RNA. The level of
contaminants that absorb at 230 nm such as EDTA or carbohydrates were
checked by measuring the 260/30 nm ratio where a ratio of 2.0 - 2.2
indicates pure RNA. RNA was stored at -80°C until ready to perform
RNAseq.
3.2.1.2 Quantification of RNA using the Agilent 2100 bioanalyser
To check the quality and quantity of RNA samples, the RNA 6000 Nano Kit
(Agilent) was used following the manufacturers’ instructions. Briefly, an
$JLOHQW51$1DQRJHOPDWUL[ZDVSUHSDUHGE\DGGLQJȝORI51$G\H
FRQFHQWUDWH WRDȝODOLTXRWRIVWHULOH ILOWHUHGJHO 7KHJHOZDVPL[HGE\
vortex and centrifuged at room temperature, at 13,000 xg for 10 min. An
RNA nanochip (Figure 16. B.) was placed on the chip priming station and
ȝORIJHOG\HPL[ZDVDGGHGWRWKHERWWRPRIZHOOµ*¶)LJXUH&7KH
plunger on the chip priming station was positioned to 1ml and the chip
priming station clicked shut. The chip was pressurised by pressing the
plunger down until it is held by the clip (Figure 16. C.2). After exactly 30 sec
the plunger was released, and after a further 30 sec was slowly pulled back
WR WKHPOSRVLWLRQ 7KHFKLSSULPLQJVWDWLRQZDVRSHQHGDQGȝORIJHO
dye mix was added to two wells above the well marked ‘G’ (Figure 16. C.3).
7KH51$1DQRPDUNHUZDVORDGHGRQWRWKHFKLSE\SLSHWWLQJWKHȝO
into the ladder well and each of the 12 sample wells (Figure 16. C. 4). The
RNA ladder was thawed, heated to 70°C for 2 min to minimise secondary
VWUXFWXUHDQGȝODGGHGWRWKHODGGHUZHOORQWKHFKLS)LJXUH&ȝO
of each sample was added to the sample wells (Figure 16. C. 6). The chip
was mixed at 2400 rpm or 1 min on an IKA vortexer. The chip was run in an
Agilent 2100 Bioanalyzer, using the 2100 expert software (Figure 16. A.).
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Figure 16. Agilent 2100 bioanalyzer equipment.
A. An example of the equipment used to measure RNA concentration (adapted
from http://www.thelabworldgroup.com/agilent-g2938b-bioanalyzer). B. The RNA
nano chip (Agilent), used to measure the concentration of RNA. C. The steps of
priming, and loading the chip ready for analysis (Adapted from Agilent RNA 6000
Nano Kit protocol).
3.2.1.3 Purification and fragmentation of mRNA
7R LVRODWH WKHP51$DQG IUDJPHQW WKH51$ IRU VHTXHQFLQJ  ȝO LVRODWHG
WRWDO 51$ ZDV GLOXWHG LQWR  ȝO QXFOHDVHIUHH ZDWHU WR JLYH D PLQLPXP
FRQFHQWUDWLRQRIQJ51$LQȝO7KH51$ZDVWUDQVIHUUHGWRDZHOO
3&5SODWHDQGȝORI51$SXULILFDWLRQEHDGVZHUHDGGHGWRHDFKZHOODQG
mixed to enable binding of the polyA RNA to the oligo dT magnetic beads.
The PCR plate was sealed and the RNA denatured by incubating at 65°C for
5 min, then cooled to 4°C before incubating on the bench for 5 min to enable
RNA binding to the beads. The plate was placed on a magnetic stand for 5
min at room temperature to pull the beads out of solution and the
supernatant discarded. The plate was removed from the magnetic stand
DQGWKHEHDGVZHUHZDVKHGZLWKȝORIEHDGZDVKLQJEXIIHU WRUHPRYH
any unbound RNA. The plate was returned to the magnetic stand for 5 min
and the supernatant, containing ribosomal and other non-messenger RNA,
was carefully removed. The plate was removed from the magnetic stand
DQGȝORIHOXWLRQEXIIHUZDVDGGHGWRHDFKZHOODQGPL[HGWRUHVXVSHQG
the beads. The plate was sealed and incubated in a thermal cycler at 80°C
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for 2 min, then cooled to 25°C to release the mRNA and any contaminating
rRNA from the beads.
:RUNLQJRQWKHEHQFKȝORIEHDGELQGLQJEXIIHUZDVDGGHGWRHDFKZHOO
and mixed to allow mRNA to rebind to the beads. The plate was incubated
at room temperature for 5 min and then transferred to the magnetic stand for
a further 5 min. The supernatant was removed, the plate removed from the
VWDQGDQG WKHEHDGVZDVKHGZLWK ȝO EHDGZDVKLQJEXIIHU  7KHSODWH
was returned to the magnetic stand for 5 min and the supernatant,
containing rRNA and additional contaminants, was removed. The plate was
UHPRYHG IURP WKHPDJQHWLF VWDQGDQGȝO IUDJPHQW SULPH ILQLVKPL[
which contains random hexamers for reverse transcription priming, was
added to each well and beads resuspended by mixing. The plate was
sealed and incubated in a thermal cycler at 94°C for 8 min, cooled to 4°C
and briefly spun down to elute, fragment and prime the RNA.
3.2.1.4 First strand cDNA synthesis
The plate seal was removed and plate transferred to the magnetic plate
VWDQG IRUPLQ  ȝO RI WKHVXSHUQDWDQWZDV WUDQVIHUUHG WRD IUHVK3&5
plate and SuperScript II was diluted into first strand synthesis act D mix tube
DWDUDWLRRIDQGȝODGGHGWRHDFKZHOODQGPL[HG7KH3&5SODWHZDV
sealed and incubated in a thermo cycler at 25°C for 10 min, 42°C for 15 min,
70°C for 15 min before cooling to 4°C.
3.2.1.5 Second strand cDNA synthesis
7KHSODWHVHDOZDVUHPRYHGDQGȝOUHVXVSHQVLRQEXIIHUDQGȝOVHFRQG
strand marking master mix was added to each well and mixed. The plate
was sealed and incubated in a thermal cycler at 16°C for 1 hr. After bringing
WKHSODWH WR URRPWHPSHUDWXUHȝORIZHOOPL[HG$03XUH;3EHDGVZDV
added to each well and mixed. The plate was incubated at room
temperature for 15 min, transferred to a magnetic stand and incubated for 5
PLQWRVHSDUDWHWKHEHDGVIURPWKHVXSHUQDWDQWȝORIWKHVXSHUQDWDQW
ZDVUHPRYHGDQGGLVFDUGHGIURPHDFKZHOODQGȝOIUHVKO\SUHSDUHG
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ethanol was added without disturbing the beads. The plate was incubated
for 30 sec before removing the supernatant from each well. The 80%
ethanol wash was repeated twice. The plate was dried at room temperature
IRU  PLQ EHIRUH UHPRYLQJ IURP WKH PDJQHWLF VWDQG   ȝO RI
resuspension buffer was added to each well and beads thoroughly
resuspended by mixing. The plate was incubated at room temperature for 2
PLQ EHIRUH WUDQVIHUULQJ WR WKH PDJQHWLF VWDQG IRU  PLQ   ȝO RI WKH
supernatant was transferred to the wells of a fresh 96 well PCR plate.
3.2.1.6 Adenylation of 3’ ends
In order to prevent blunt fragments ligating to one another during the adaptor
ligation reaction, a single ‘A’ nucleotide was added to the 3’ end, which is
recognised by a ‘T’ nucleotide at the ‘ end of the adaptor and allows ligation.
7RHDFKZHOOȝORIUHVXVSHQVLRQEXIIHUDQGȝORI$7DLOLQJPL[ZDV
added and mixed thoroughly. The plate was sealed and incubated in a
thermal cycler at 37°C for 30 min, 70°C for 5 min and then cooled to 4°C.
3.2.1.7 Ligation of adaptors
Indices were selected for each sample to give a unique 6 nucleotides at the
end and allow identification of sample specific sequences.
Sample RNA Adapter Index Sequence
Undifferentiated 19 GTGAAA(C)
Day 1 Differentiation 2 CGATGT(A)
Day 7 Differentiation 4 TGACCA(A)
7KHSODWHVHDOZDV UHPRYHGDQGȝO UHVXVSHQVLRQEXIIHUȝO OLJDWLRQ
PL[DQGȝO51$DGDSWHULQGH[ZDVDGGHGWRHDFKZHOODQGPL[HG3ODWH
was sealed, centrifuged at 280 xg for 1 min and incubated in a thermal
F\FOHUDW&IRUPLQ7KHSODWHVHDOZDVUHPRYHGDQGȝOVWRSOLJDWLRQ
buffer was added to each well and mixed. AMPure XP beads were
WKRURXJKO\ UHVXVSHQGHG E\ YRUWH[ DQG  ȝO DGGHG WR HDFK ZHOO DQG
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incubated at room temperature for 15 min. The PCR plate was transferred to
WKH PDJQHWLF VWDQG IRU  PLQ XQWLO WKH OLTXLG LV FOHDU DQG  ȝO RI WKH
supernatant was removed, taking care not to disturb the beads. The beads
ZHUHZDVKHGWZLFHZLWKȝOIUHVKO\SUHSDUHGHWKDQRODVEHIRUH
Samples were air-dried at room temperature for 15 min before removing
IURPWKHPDJQHWLFVWDQG%HDGVZHUHUHVXVSHQGHGLQȝOUHVXVSHQVLRQ
buffer, thoroughly mixed and incubated at room temperature for 2 min. The
SODWHZDVUHWXUQHGWRWKHPDJQHWLFVWDQGIRUPLQDQGȝORIVXSHUQDWDQW
transferred to fresh tube on a 96-well PCR plate for a second clean up step.
$03XUH;3EHDGVZHUHIXOO\UHVXVSHQGHGDQGȝODGGHGWRHDFKVDPSOH
and mixed. The plate was incubated at room temperature for 15 min before
WUDQVIHUULQJ WR WKHPDJQHWLFVWDQGIRUPLQ ȝORI WKHVXSHUQDWDQWZDV
removed from each well and the beads washed twice with 80% ethanol as
described previously. The plate was air-dried for 15 min before removing
IURPWKHPDJQHWLFVWDQGDQGȝORI UHVXVSHQVLRQEXIIHUDGGHGWRHDFK
well. The plate was incubated at room temperature for 2 min before being
WUDQVIHUUHG WR WKHPDJQHWLFVWDQG IRUPLQ ȝORI WKHVXSHUQDWDQWZDV
transferred to a fresh well of a 96 well PCR plate.
3.2.1.8 DNA fragment enrichment
DNA fragments with adapter molecules at both ends were selectively
enriched by PCR to amplify the amount of DNA in the library. To set up the
3&5UHDFWLRQȝORI3&5SULPHUFRFNWDLODQGȝO3&5PDVWHUPL[ZHUH
DGGHGWRWKHȝORIVDPSOHLQHDFKWXEHDQGPL[HG7KHSODWHZDVVHDOHG
transferred to a thermal cycler and the PCR programme run as 15 cycles of
98°C for 10 sec, 60°C for 30 sec, 72°C for 30 sec and 72°C for 5 min. The
VHDOZDVUHPRYHGIURPWKHSODWHDQGȝOUHVXVSHQGHG$03XUH;3EHDGV
were added to clean up the PCR product. The plate was incubated at room
temperature for 15 min before being transferred to the magnetic stand for
PLQȝORIWKHVXSHUQDWDQWZHUHUHPRYHGDQGEHDGVZDVKHGWZLFHDV
EHIRUHZLWKHWKDQRO%HDGVZHUHUHVXVSHQGHGLQȝOUHVXVSHQVLRQ
buffer and incubated at room temperature for 2 min. Plate was transferred
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WRWKHPDJQHWLFVWDQGIRUPLQEHIRUHWUDQVIHUULQJȝORIVXSHUQDWDQWWRD
fresh well on a 96 well PCR plate.
3.2.1.9 Library validation
The quality and quantity of the cDNA libraries were validated using the high
sensitivity D100 screen tape assay. An 8 x strip of optical tubes (Agilent)
ZDVSUHSDUHGE\DGGLQJȝOKLJKVHQVLWLYLW\'VDPSOHEXIIHU WRHDFK
WXEH 7R WKH ILUVW WXEHȝORI ODGGHUZDVDGGHGDQGȝORIHDFKVDPSOH
added to the remaining tubes. Tubes were mixed by vortex at 2000 rpm for
1 min using the IKA vortexer. Samples were briefly spun to move liquid to
the bottom of the tube and transferred to the TapeStation. The Agilent 2200
TapeStation software was loaded, sample details entered and programme
run to determine the concentration and purity of the cDNA.
3.2.1.10 RNAseq pooling
The peak molarity measured on the TapeStation was used to pool the RNA
samples for sequencing. The samples were pooled together each at a final
FRQFHQWUDWLRQ RI  Q0 LQ  ȝO DQG VHQW IRU VHTXHQFLQJ DW WKH 1H[W
Generation Sequencing Facility, LIMM using the Illumina Hiseq 2500
sequencer.
3.2.1.11 Analysis of RNAseq data
The fastq.gz files generated from the RNA sequencing were analysed using
UNIX commands in Terminal (Mac). The analysis protocol used was based
upon the Nature Protocols method (Trapnell 2012). Briefly, TopHat2 was
used to analyse the data by mapping the reads to the Mus musculus
genome. The Bowtie command was used to align the short sequencing
reads against the genome. The identified, aligned RNAseq transcripts were
assembled and abundance estimated using the Cufflinks command. The
programme Cuffcompare was used to compare transcripts from each C1F
sample to known transcripts in a reference transcriptome. The Cuffmerge
command was used to merge the transcripts from each sample to enable
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further analysis into differential expression. The Cuffdiff command was then
used to find significant changes in transcript expression, splicing, and
promoter usage between the C1F samples. Results were copied and
opened using Microsoft Excel.
3.2.2 Colocalisation calculation
To determine the efficacy of each of the commercially available antibodies
tested (Table 12.) to recognise exogenously expressed MEGF10, in a
quantitative manner, the colocalisation between expressed MEGF10_GFP
protein and anti-MEGF10 antibodies in cultured myoblasts was determined.
C1F cells were infected with 100 MOI MEGF10_GFP adenovirus, incubated
for 24 hrs prior to fixing and staining the cells for MEGF10 (Millipore, Santa
Cruz or Sigma Prestige). Colocalisation was calculated, following the
protocol described in http://imagej.net/Coloc_2, using the Coloc2 plugin in
Fiji, using 100 iterations of the Costes statistical significance test. The
colocalisation is quantified using Pearson’s R-value where a value of 0
indicates no colocalisation and a value of 1.0 shows perfect colocalisation
(Dunn et al., 2011).
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3.2.3 Muscle hyperplasia model
Thanks to Professor Stuart Egginton and Roger Kissane for their help in
performing the mouse surgery under project licence number PPL 70/8674.
3.2.3.1 Hyperplasia model surgery
In order to determine if changes in MEGF10 expression occur in
regenerating muscle an in vivo mouse muscle hyperplasia model was set up
(Egginton et al., 2011; Egginton et al., 1998). In this, the tibialis anterior (TA)
was removed from the right leg of a C57BL/6 mouse to increase the load on
the underlying extensor digitorum longus (EDL) muscle causing muscle
hyperplasia. Changes in satellite cells and MEGF10 expression were
examined in the hyperplasia and the contralateral EDL.
Twelve 6 week old male C57BL/6 mice were divided into six cages with two
mice per cage. Two mice were retained as controls and did not undergo
surgery. Mice were anaesthetised with 5% isoflurane in 2 L/min oxygen
prior to shaving the right leg and injecting the mice in the scruff of the neck
with analgesic and anti-infective Enrofloxacin (Baytril® 2.5%). The
subsequent steps of the operation were performed with the mouse
anaesthetised with 2.5% isoflurane in 2 L/min oxygen. The skin on the
shaved right leg was cleaned by wiping with chlorhexadine to remove any
surface bacteria. All work was performed using sterile instruments under a
dissection microscope. A single incision was made to expose the TA
muscle. Tweezers were used to identify and lift up the superficial distal TA
tendon. The TA tendon was cut and TA muscle dissected out with a scalpel
leaving the EDL muscle below. The TA muscle was briefly returned to the
wound to release cytokines that aid clotting and reduce bleeding but was
removed fully before closing the wound. The wound was sealed by suturing
with Mersilk 4 - 0 silk braided sutures and sterile saline used to remove any
blood to reduce irritation. The mouse were allowed to recover in a chamber
heated to 35°C, because of their small size, before returning to their cage.
Mice were kept in a clean air filtered room with regular food and water ad
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libitum over the course of 14 days (Egginton et al., 2011; Egginton et al.,
1998).
3.2.3.2 Sample isolation and storage
Changes in muscle were measured in control mice, 1, 3, 6, 10 and 14 days
post-surgery. At each time point two mice were euthanized by cervical
dislocation and weighed prior to dissecting the damaged and contralateral
EDL muscles. The dissected muscle was weighed prior to sample
preparation. The damaged muscle and contralateral muscle from one
mouse were snap frozen in liquid nitrogen for protein extraction and stored
at -80°C. The muscles from the second mouse were isolated and
transferred to medium 199 (Gibco) prior to digestion in 2 mg/ml collagenase
for single fibre isolation (2.9).
3.2.3.3 Protein sample isolation
RIPA buffer (150mM NaCl, 1% IGEPAL® CA-630, 0.5% sodium
deoxycholate, 0.1% SDS, 50mM Tris pH8) was prepared and cooled on wet
ice. Muscle was ground to a fine powder by pestle and mortar under liquid
nitrogen and transferred to a 1.5ml Eppendorf tube. The muscle was
resuspended in 200 µl lysis buffer (RIPA buffer supplemented with 1% Triton
X-100, 1% glycerol and Halt Protease Inhibitor Cocktail (Roche)). Samples
were incubated on ice for 30 min, mixing by vortex every 5 min. Samples
were centrifuged at max. speed (13,600 x g) for 30 min at 4°C. The
supernatant was transferred to a fresh 1.5 ml Eppendorf tube and 4 Ɋl used
for BCA Assay (2.12.2).
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3.3 Results
3.3.1 Antibody selection for fluorescence microscopy and western
blotting applications
To test three different commercially available antibodies against MEGF10
(Table 12.) for their ability to recognise MEGF10 by immunostaining, C1F
myoblasts expressing a MEGF10_eGFP adenoviral construct were stained
with each antibody. MEGF10_eGFP was localised to the Golgi, intracellular
vesicles, and to the plasma membrane (Figure 17. A. and inserts). The
colocalisation between expressed MEGF10_GFP and anti-MEGF10
antibodies was quantitated using ImageJ (Figure 17. B). Co-staining with
both the Millipore and Sigma Prestige antibodies showed good co-
localisation with a mean Pearson’s R value 0.91 and 0.93 respectively, in
which the majority of the staining observed for the antibody matched that
see for MEGF10_eGFP. In contrast, the antibody from Santa Cruz showed
significantly lower co-localisation (Pearson’s R value 0.83) compared to the
Millipore (p=0.0026) and Sigma Prestige (p=<0.0001) antibodies, suggesting
that this antibody does not specifically recognise MEGF10. There is no
significant difference between the colocalisation of the Millipore and Sigma
Prestige antibodies with the expressed MEGF10_eGFP (p= 0.1884) (Figure
17. B.).
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Table 12. Commercially available anti-MEGF10 antibodies tested.
Details of the three commercially available antibodies tested for their efficacy at
recognising MEGF10 by immunocytochemistry and western blot. The source and
species of each antibody, the region of MEGF10 that the antibody was raised
against, and an example of a publication that has previously used each antibody is
provided.
Company Recognition site Species Reference
Millipore
Cytoplasmic domain of
mouse MEGF10 Rabbit (Kay et al., 2012)
Santa Cruz
Cytoplasmic domain of
human MEGF10 Goat (Bröhl et al., 2012)
Sigma
Prestige
EGF domains 5 - 8 of
human MEGF10
Rabbit (Chung et al., 2013)
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Figure 17. Localisation of MEGF10_GFP and anti-MEGF10 antibodies in
myoblasts.
A. Immunocytochemistry showing antibody staining against MEGF10 in red,
MEGF10_GFP in green and the nuclei, stained with DAPI, in blue. Arrows in inset
show colocalisation. B. MEGF10_GFP and anti-MEGF10 antibody colocalisation
quantitated by the Pearson’s R value. Colocalisation is significantly lower when
staining with the Santa Cruz antibody, ** p = 0.0026 and **** p = <0.0001. There is
no significant difference between the Millipore and Sigma Prestige antibodies
(p = 0.1884). (Mean values +/- S.D.).
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To test the abilities of each antibody to recognise MEGF10 by western
blotting, cell extracts from C1F cells, transfected with the adenoviral
construct expressing full length MEGF10_eGFP (Chapter 4.), together with
the expressed and purified ECD of MEGF10 (Chapter 5.), were used. Only
the Sigma Prestige antibody (raised to the ECD of MEGF10) recognised
MEGF10 on western blots. This antibody was expected to recognise both
MEGF10_eGFP and the purified ECD. However, while it recognised the
purified ECD of MEGF10 (Figure 18.), it did not recognise MEGF10_eGFP
expressed in C1F cells, possibly because the protein levels were too low for
detection. A further blot, using Ad293 cells expressing MEGF10_eGFP, did
show a band of the correct size using the Sigma Prestige antibody
(Figure 18. A.). The size of the detected band for the purified ECD is higher
than expected (120 kDa), but this is due to extensive post-translational
modification of this protein.
Neither the Millipore antibody nor the Santa Cruz antibody recognised the
purified ECD of MEGF10, which was expected since both antibodies were
raised against the cytoplasmic domain of MEGF10, which is absent from the
purified peptide. However, neither antibodies showed a band of the
expected size for MEGF10_eGFP in cell extracts, and the Millipore antibody
additionally showed a band of an incorrect size (~60 kDa) (Figure 18. A.).
MEGF10_GFP in the cell extracts was recognised by an anti-GFP antibody.
A dilution series of the purified ECD of MEGF10 showed the Sigma Prestige
antibody could be used to detect concentrations as low as ~ 25 ng of protein
(Figure 18. B.), and thus expression levels of the MEGF10_eGFP in cell
extracts must be below this detection limit for the anti-MEGF10 antibodies.
I chose to use only the Sigma Prestige antibody in future experiments, since
it was the only antibody tested that recognised MEGF10 in both
immunostaining and western blot applications, even though it was unable to
recognise low concentrations of MEGF10_GFP.
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Figure 18. Anti-MEGF10 recognition of MEGF10 by western blot.
A. SDS-PAGE gel showing the cell extract for C1F cells expressing MEGF10_GFP
(Expected size ~145 kDa) and the purified ECD protein (expected size 120kDa).
Western blots probed with anti-MEGF10 antibodies from Santa Cruz, Millipore and
Sigma Prestige (indicated by arrow). All blots include GAPDH as a positive control
(indicated by arrow head). B. A western blot testing the sensitivity of the anti-
MEGF10 antibody (Sigma Prestige) in recognising purified ECD protein (5 min
exposure).
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3.3.2 Endogenous expression of MEGF10 in C1F cells is below the
detection limit by immunofluorescence and western blot
Immunostaining of C1F cells using the Sigma Prestige antibody did not
convincingly show that C1F cells expressed significant levels of endogenous
MEGF10 (Figure 19. A.) either in myoblasts or in differentiated cells.
Staining patterns were not significantly different from those seen for negative
controls, which used secondary antibody only (Figure 19. B.). Actin staining
shows that the cells start to differentiate into myotubes by day 3, with
multiple myotubes observed at days 5 and 7 (Figure 19.). The majority of
fusion into myotubes occurs between days 1 and 3. If MEGF10 expression
levels decrease upon differentiation (by ~6 fold) as reported (Holterman et
al., 2007), this should have been evident in the staining shown.
Western blotting of C1F cells at different stages of differentiation also did not
show a band for MEGF10 (Figure 20.), although bands were detected in the
positive control. Therefore, if the C1F cells do express MEGF10 it is at such
low levels that it is below our detection limit for both western blotting and
immunostaining.
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Figure 19. Endogenous expression of MEGF10 in C1F cells and non-
specific secondary antibody staining.
Immunostaining of undifferentiated (UD) to day seven differentiated (D7) C1F cells
(Actin is stained with fluorescent phalloidin in red and the nuclei, stained with DAPI,
are shown in blue in the merged image. A. Anti-MEGF10 (Sigma Prestige) staining
is shown in green. B. Secondary anti-rabbit (Rbt488) only staining is shown in
green.
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Figure 20. Endogenous expression of MEGF10 in C1F cells and anti-
MEGF10 antibody test.
A. SDS-PAGE gel showing the lysates of mouse myoblasts (C1F) differentiated
over 7 days. MEGF10_GFP overexpressed in C1F cells (Expected size 145 kDa)
and eMEGF10 purified protein (Expected size 120 kDa) were used as positive
controls. B. Western blot probed with anti-MEGF10 (Sigma Prestige) and GAPDH
(Expected size 37 kDa) as a loading control.
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3.3.3 Low level expression of MEGF10 in C1F cells is confirmed by
RNAseq
As I was unable to detect expression of MEGF10 by immunostaining or
western blotting, I next used RNAseq to characterise the expression of
MEGF10. Whilst qPCR could have been used to study changes in MEGF10
and related protein expression, this had already been performed by
Holterman et al, and it was hoped that by performing the more laborious
RNAseq method information on the expression of MEGF10 and a wide
range of potentially related proteins could be explored in differentiating
myoblasts as well as giving information on the distribution of MEGF10
isotypes. These experiments confirmed that endogenous MEGF10
expression levels were low and that they did not change significantly during
C1F myoblast differentiation. A small reduction in MEGF10 expression was
observed during differentiation, but this change was not significant. In
contrast, levels of ACTA1 (skeletal muscle specific actin) increased after
seven days of differentiation as expected. Pax7, a TF found in quiescent
satellite cells, was present at low levels in undifferentiated and differentiated
cells as expected. Levels of MyoD, a myoblast determination protein that is
upregulated during differentiation, was markedly increased at day 7 of
differentiation was not expected, however this may reflect previously high
levels of MyoD, which are still decreasing at day 7 and would have dropped
further over subsequent days. Unfortunately, these timepoints do not cover
each stage of myogenesis. Similarly, levels of myogenin, a second muscle
specific TF upregulated during differentiation, had also markedly increased
by day seven (Figure 21. A. and B.). Thus, the C1F cells do show the
expected changes in muscle-specific markers. Taken together, these data
suggest that MEGF10 levels are extremely low in cultured myoblasts,
limiting their usefulness in studying endogenous MEGF10.
MEGF10 is predicted to be present in two isoforms, the predominant full
length construct and a second truncated isoform (UniProtKB). RNAseq
analysis identified the presence of the two isoforms of MEGF10, however
the second isoform was at a very low level. There is no change in the
relative proportions of the two isoforms over the course of myoblast
differentiation. Further repeats of the RNAseq along with alternative analysis
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techniques may give a better insight into the possible changes in isoform
expression.
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Figure 21. Changes in RNA expression levels in differentiating C1F
cells.
A. Undifferentiated, day 0, early differentiating, day 1, and fully differentiated, day 7,
C1F cells were analysed for mRNA expression levels by RNAseq. Pax7, MyoD and
myogenin are expressed in quiescent, activated and differentiated cells
respectively. Acta1, the gene encoding skeletal muscle actin was included as an
additional positive control for differentiated myotubes. The graph shows the
fragments per kilobase million (FPKM), estimating transcript abundance, as a
percentage of the value for undifferentiated C1F cells. B. The fold change in FPKM
between undifferentiated and day 1 (red) and day 7 (green) cells. (FPKM values,
n=1).
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3.3.4 Endogenous expression of MEGF10 in isolated single fibres
Since the expression of endogenous MEGF10 in cultured myoblasts is very
low, I next looked at MEGF10 expression in satellite cells in situ on isolated
muscle fibres, cultured for up to 5 days in vitro. Under these conditions, the
quiescent satellite cells should become activated, allowing the determination
of changes in MEGF10 expression during activation of these primary cells in
their niche environment beneath the basal lamina. To enable identification of
satellite cells, co-staining was performed for CD34, a positive marker
expressed in the membrane of the majority of satellite cells (Beauchamp et
al., 2000). Low magnification images show the low numbers of satellite cells
per fibre, with a mean average of 2.65 satellite cells per fibre in day 0 fibres
with the most satellite cells seen in fibres 4 days post-isolation which had a
mean average of 9.4 satellite cells per fibre (Figure 22.). Furthermore, the
difficulty in identifying which satellite cells were positive for CD34 and the TF
being tested, that were also stained positively for MEGF10 gave
inconclusive results (Figure 22.). Thus, further analysis of co-staining was
performed using higher magnification images (Figures 23. and 24.).
A comparison of the MEGF10 staining pattern for satellite cells on cultured
fibres at high magnification (Figures 23. and 24.) shows that quiescent
satellite cells (day 0) did not express MEGF10. However, MEGF10 staining
was observed at day 1, in some Pax7+/CD34+ satellite cells (Figure 23.), and
in day 2, for some MyoD+/CD34+ satellite cells. In day 1 and 2 cells,
MEGF10 was co-localised with CD34 at the plasma membrane (Figures 23.
and 24.). At day 3 or 4, staining was more variable. Some MyoD+/CD34+
satellite cells did not show positive staining (Figure 23.) but others did
(Figure 24.). At day 4, some myogenin+/CD34+ cells could also be found
that show positive staining for MEGF10. Note that at days 3 and 4, satellite
cells have already undergone cell division, and the examples show two
adjacent satellite cells. By day 5, myogenin+/CD34+ cells may show some
MEGF10 staining as shown in this example of a cluster of satellite cells,
however it is more likely that the limited staining remaining is simply
autofluorescence. Therefore there appears to be a peak of MEGF10
expression 2 - 3 days post-isolation as the satellite cells become activated,
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and increased MEGF10 expression was associated with both Pax7+ and
MyoD+ cells, but less so with myogenin+ cells.
Quantification of these data (Figure 25.) showed that while CD34+ cells
could be found at each time point, not all of these cells were additionally
MEGF10 positive. Three days post-isolation, when satellite cells were most
abundant, only ~50% of the CD34+ cells were also positive for MEGF10.
Overall, it is not clear that the single fibre culture model provides a clear
picture of how MEGF10 expression is upregulated. Levels of CD34 decrease
after 4 days.
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Figure 22. Immunostaining of fibres isolated from murine
gastrocnemius muscle.
Gastrocnemius fibres cultured over 5 days (D0 – D5) and stained for MEGF10 in
far-red, CD34 in green, each TF, Pax7, MyoD, Myogenin in red and the nuclei
stained with DAPI in blue. Examples of possible MEGF10/CD34/TF+ cells are
shown with an arrow and TF/CD34+ cells by an arrow head.
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Figure 23. Time course of MEGF10 expression in isolated single fibres.
Gastrocnemius fibres cultured were cultured over 5 days (D0 – D5) and
stained for MEGF10 (red), CD34 (green) and each TF either Pax7 (for day 0,
1), MyoD (for day 2, 3) or Myogenin (for day 4, 5) as satellite cell markers
(blue).
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Figure 24. Satellite cells co-stained for MyoD, CD34 and MEGF10.
Isolated single myofibres fixed immediately (D0) and 3 days (D3) post-isolation
were stained for nuclear TF MyoD shown in blue, CD34 shown in green and
MEGF10 shown in red. Cells were imaged on the LSM880 confocal.
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Figure 25. Satellite cell populations counted on single fibres isolated
from murine gastrocnemius muscle.
Single fibres isolated from the gastrocnemius stained for MEGF10, CD34 and TFs
(TF) Pax7, MyoD, myogenin that, act as markers of satellite activation. Satellite
cells were counted on five fibres and expression of each marker used to classify
satellite cells into distinct populations. (Mean values +/- S.E.M. with a minimum of
five fibres analysed for each repeat; n=3).
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3.3.5 Muscle hyperplasia model
To try to develop a better model for investigating MEGF10 expression in
response to satellite cell activation, I used a hyperplasia model, in which a
load applied to the EDL muscle is expected to stimulate satellite cells in vivo.
Loading the EDL muscle increased its mass by ~ 20%, six days post-
surgery, compared to the control muscles (Figure 26.), a value similar to the
~15% change described earlier for this type of model (Egginton et al., 2011).
This increase in muscle mass was maintained over the remaining ten days
(Figure 26.). The initial increase in EDL muscle mass observed one day
post-surgery is due to oedema rather than an increase in muscle mass
(Egginton et al., 2011). However, the statistical significance of the increase
seen between control and loaded muscle could not be determined due to the
low sample size.
We expected that this level of hyperplasia might activate satellite cells.
Quantifying the numbers of CD34+ satellite cells present on the fibres
(Figure 27. A.) did appear to show an increase in satellite cell number in the
hyperplasia muscles compared to control muscles with time, however the
difference between the control and hyperplasia muscle were not significant
(Figure 27. B.). Positive MyoD expression was used as an indicator of
CD34+ satellite cell activation and the number of satellite cells counted
(Figure 27. C.).
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Figure 26. EDL muscle mass changes in hyperplasia model.
The EDL muscle mass is shown as a proportion of the total body mass of the
mouse. Control EDL muscle was compared to hyperplasia EDL muscle post-
surgery over the course of two weeks. (Mean values with 2 muscles analysed for
each repeat; n=1).
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Figure 27. Satellite cell populations on isolated EDL muscle fibres.
Isolated EDL muscle fibres stained for satellite cell markers Pax7, MyoD and
myogenin were imaged and counted. Satellite cells were identified by CD34+
staining. A. The average number of CD34 positive cells counted per fibre. B. shows
the number of Pax7+ cells per fibre (** p = <0.008), and C. the number of MyoD+
cells per fibre (** p = 0.0018). (Mean values +/- S.D. with a minimum of five fibres
analysed for each repeat; n=3. # indicates the condition used as a comparison for t-
test statistical analysis and asterisks indicate statistically significant changes.)
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3.3.6 Immunostaining of isolated single fibres from EDL muscle
Analysis of satellite cells on loaded hyperplasia muscle fibres, showed an
increase in activated satellite cell number shown by CD34+/MyoD+ staining
in the loaded muscles compared to unloaded muscles with time (Figure 27.).
Staining for MyoD and Pax7 (Figures 28 – 30.) showed that levels of
MyoD+ satellite cells increased with time in the loaded muscles, but not in
the unloaded controls (Figure 27. C). Pax7 levels varied with time, but did
not markedly differ between loaded muscles and controls (Figure 27 B.).
Co-staining fibres for Pax7, CD34 and MEGF10 showed that while that
Pax7+/CD34+ satellite cells could be found throughout the fibres (from day 1
to day 14) in loaded muscles, none of these cells expressed MEGF10
(Figures. 28., 29. and 30.). Staining for MyoD, CD34 and MEGF10,
additionally showed that MyoD+/CD34+ cells did not express MEGF10. I
also stained for myogenin, but was unable to find any myogenin+/ CD34+
cells at any of the time points, suggesting that while satellite cells become
activated, as indicated by expression of MyoD, they have not gone on to
express myogenin by day 14. Staining of control fibres showed that the
majority of the satellite cells were primarily Pax7 positive and therefore
quiescent (Figure 28. A. and 29. A.).
However, while analysing the fibre images, I noticed that there were cells
that had stained positively for MEGF10, which were CD34-/Pax7-. These
cells were adjacent to CD34+ cells. On re-evaluating this in the loaded
sample, I found many more examples of this type of cell (Pax7-/CD34-
/MEGF10+) on hyperplasia muscle fibres (Figure 31.). It is unclear what the
identity of these cells is, but unlike the more conventional CD34+/Pax7+
satellite cells, which do not express MEGF10, these cells do show very clear
MEGF10 positive staining.
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Figure 28. Low magnification images of Isolated fibres from control and
hyperplasia EDL muscle.
Single fibres isolated over 14 days post-surgery (D0 – D14) from control A. and
hyperplasia muscle B. Fibres were stained for TFs Pax7, MyoD or Myogenin in red,
CD34 in green, MEGF10 in red and nuclei stained with DAPI in blue. Examples of
possible MEGF10/CD34/TF+ cells are shown with an arrow and TF/CD34+ cells are
shown by an arrow head.
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Figure 29. Satellite cells from control and hyperplasia EDL fibres.
Satellite cells on fibres from control A. and hyperplasia B. EDL muscle isolated over
14 days post-surgery and stained for MEGF10 in red, CD34 in green and Pax7 in
blue.
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Figure 30. Staining of satellite cells on isolated fibres from hyperplasic
EDL muscle.
Satellite cells imaged on isolated single fibres from hyperplasia EDL muscle over 14
days post-surgery. Cells were stained for MEGF10 in red, CD34 in green and MyoD
in blue.
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Figure 31. Localisation of MEGF10+/CD34- cells adjacent to CD34+ cells
on hyperplasia EDL muscle fibres.
Satellite cells on isolated EDL fibres stained for MEGF10 in red, CD34 in green,
and nuclei stained with DAPI in blue. Merged images also show TF (Pax7/MyoD)
staining in red. Arrows indicate MEGF10 expression in neighbouring CD34 negative
cells.
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3.3.7 Western Blot of EDL muscle samples.
I also performed western blotting to assess any changes in expression level
for MEGF10 as a result of hyperplasia. An equal amount of protein was
loaded into each well of the gel as confirmed by SDS-PAGE (Figure 32. A.)
and GAPDH staining (Figure 32. C.). The blots showed a band for MEGF10
at the expected size (122 kDa) but an additional high molecular weight band
(>250 kDa) of unknown size and identity was also present. It is unclear what
this band is, but it may result from oligomerisation of MEGF10, possibly
through its multiple cysteine residues (Figure 32. B.). Overall levels of
MEGF10 (122 kDa band) were very low at the start of the experiment, but
increased steadily over the next 14 days. However, there was no striking
difference between expression levels in the loaded muscle and unloaded
controls. A similar pattern was seen for the high molecular weight band,
suggesting it may indeed be derived from MEGF10. However neither band
showed a clear increase in MEGF10 in hyperplasic samples compared to
controls, and in fact levels of MEGF10 were perhaps even lower in the
hyperplasic samples. Overall, these results do not indicate that there is a
clear effect of hyperplasia on MEGF10 expression (Figure 32.).
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Figure 32. EDL Muscle Western Blot.
A. 6'63$*( JHO RI  ȝJ&RQWURO & DQG+\SHUSODVLD + ('/ ZKROHPXVFOH
samples taken over 14 days (D1 – D14). B. Western blot probed with anti-MEGF10
(Sigma Prestige), (expected 120 kDa), 25 min exposure. C. Western blot probed
with anti-GAPDH (expected 37 kDa), 1 min exposure.
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3.4 Discussion
These data show that cultured myoblasts and quiescent satellite cells either
do not express MEGF10 or express very low levels of the protein. Activated
MyoD+/CD34+satellite cells imaged in situ on isolated muscle fibres appear
to express MEGF10, which colocalises with CD34 in the membrane of
satellite cells. In contrast, MyoD+/CD34+ cells in the hyperplasia model do
not express MEGF10. However, MyoD-/CD34- cells adjacent to
MyoD+/CD34+ cells were found to express MEGF10. These data show that
MEGF10 is not consistently associated with satellite cells as previously
assumed, but that MEGF10 appears to be associated with other cells of
unknown origin, that are not typical satellite cells but are associated with
muscle fibres.
The finding that there is very little or no expression of MEGF10 in cultured
myoblasts is in contrast to earlier findings (Holterman et al., 2007; Seale et
al., 2004). In the first study (Seale et al., 2004), MEGF10 expression was
analysed by northern blotting and found to be expressed at relatively high
levels in proliferating cells, and then down regulated upon differentiation. In
the second study (Holterman et al., 2007), MEGF10 expression was
analysed by qPCR and again found to decrease during differentiation, while
in MyoD-/- myoblasts, levels of MEGF10 did not change. Knockdown of
MEGF10 expression by ~50% in the primary cultured cells also decreased
levels of Pax7, MyoD and myogenin while increasing expression of skeletal
muscle myosin heavy chain, which was provided as evidence of premature
differentiation. In contrast, overexpression of MEGF10 inhibited fusion.
However, given the very low levels of MEGF10 in cultured myoblasts that we
observed, it is unclear how it plays such a key role in myoblast fusion as
described.
This data failed to show a clear link between MyoD or myogenin expression
and any changes in MEGF10 expression. In earlier studies, MEGF10
expression was associated with a loss of MyoD, when a high level of
MEGF10 expression seen in proliferating wildtype and MyoD-/- primary
myoblast cultures (Seale et al., 2004). Furthermore, an increase in MEGF10
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mRNA levels was recently associated with an increase in myogenin
expression in C2C12 cells (Park et al., 2014). However, our RNAseq data
for cultured myoblasts did not show any marked change in MEGF10
expression levels when either MyoD or Myogenin levels increased. In
addition, we found evidence that MEGF10 expression increased rather than
decreased, when MyoD started to be expressed in the in vitro fibre model,
while it was not associated with an increase in myogenin expression. There
is also no or very little MEGF10 expressed in quiescent satellite cells,
therefore it is unlikely to be required for maintaining stem cell quiescence as
suggested earlier (Brohl et al., 2012). However, that study used the Santa-
Cruz antibody to MEGF10 to identify MEGF10 staining in satellite cells in
embryonic muscle, and our tests on this antibody failed to show that it
recognised MEGF10.
Strikingly CD34+/MyoD+ or CD34+/Pax7+ cells in all the models we tested
had relatively low levels of MEGF10 expression. However, in hyperplasic
muscle, cells adjacent to CD34+/Pax7+ or CD34+/MyoD+ satellite cells were
positive for MEGF10. It is unclear what the identity of these cells are.
Approximately 20% of satellite cells are CD34- and thus it is possible that
these cells fall in this population. These CD34- cells are still capable of
mediating muscle regeneration (Beauchamp et al., 2000), since once
isolated they have been shown to be myogenic both in vivo and in vitro.
(Pisani et al., 2010). In addition, the presence of this side population of cells
has been linked to skeletal muscle response to acute injury (Ieronimakis et
al., 2010). However, these MEGF10+/CD34- cells were also negative for
Pax7 and MyoD, which suggests that they are not myogenic cells at all, as
they would be expected to stain for muscle TFs. It is possible that they are
some other cell type such as pericytes, which have been shown to play a
role in myogenesis. To characterise these cells further, future experiments
may look at individual cell populations such as pericytes, PICS and FAPS
separated by FACS cell sorting for MEGF10 expression.
In conclusion, despite testing three different model systems for MEGF10
expression, we were unable to conclusively find satellite cells that stain for
MEGF10 at a defined time point, and always associated with a specific
muscle TF such as MyoD or myogenin. However, we did find MEGF10 cells
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that were not positively stained for muscle TFs or other markers. The identity
of those cells is unclear.
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4 Effect of Overexpression of Wildtype and Mutant MEGF10
on Cellular Function.
4.1 Introduction
Previously, MEGF10 has been overexpressed in C2C12 cells by retroviral
infection (Holterman et al., 2007). That study showed that over-expression of
MEGF10 increased cell proliferation 24 - 72 hrs post-infection and inhibited
myoblast fusion five days post-differentiation. Over-expression of MEGF10
also maintained myoblasts in a quiescent state and down regulated the
expression of the key myogenic proteins MyoD and Pax7 (Holterman et al.,
2007). Cells overexpressing MEGF10 also failed to increase expression
levels of skeletal myosin heavy chain and myogenin, when induced to
differentiate. In those experiments, the MEGF10 was tagged with an HA
epitope, which allowed the localisation of the expressed MEGF10 to be
visualised in fixed C2C12 cells using an anti-HA antibody. This showed that
the HA-tagged MEGF10 was found mainly in the cytoplasm with some
localisation to the plasma membrane. However, no high magnification
images were shown to clearly see the protein localisation.
As overexpression of MEGF10 appears to have distinct effects on
proliferation and differentiation on myoblasts, this could be a useful system
in which to compare the effects of wildtype and mutant isoforms of MEGF10.
Mutant isoforms may not be able to elicit the same response as the wildtype
protein when overexpressed, and may have less effect on proliferation or
differentiation. In addition, expression of a GFP-tagged MEGF10 would allow
direct visualisation of MEGF10 in live cells. Therefore, I generated
expression constructs for wildtype and mutant MEGF10 with a C-terminal
GFP tag. An additional 6His tag was also included (A diagram of wildtype
and mutant constructs is presented in Figure 33).
I used an adenoviral system to express MEGF10_eGFP in cultured C1F
myoblasts (protocol described in 2.10). Infection with the adenovirus typically
involves attachment of the virus to receptors such as coxsackie- and
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adenovirus receptor (CAR) as well as interactions with sialic acid. After
attachment to the cell the virus is internalised by interaction with receptors
including integrins, which, initiate the process of viral entry in clathrin-coated
vesicles and transported to endosomes. Upon acidification the virus leaves
the endosome, enters the cytoplasm and is transported to the nucleus for
replication (Rux and Burnett, 2004; Zhang and Bergelson, 2005). It has
previously been shown that commonly used C2C12 myoblasts lack the
coxsackie receptor, which reduces the efficacy of viral uptake. This means
that a high MOI is required for effective adenoviral transduction and gene
expression in the C2C12 cells (Nalbantoglu et al., 1999; Tanaka et al.,
2011). However, the RNAseq data for undifferentiated C1F cells, (Chapter
3.) shows the presence of a low level of RNA (FPKM = 4.06) for the CXADR
gene, which encodes CAR, and thus adenoviral infection was expected to
work for the C1F cells, although a high MOI may still be needed.
Four different MEGF10_eGFP constructs were made: wildtype, and the
three mutants: C774R, W520X and R71W. C774R is in the 16th EGF-like
(EGF-laminin) domain. This mutation to arginine will disrupt one of the di-
sulphide bonds between pairs of cysteines in this domain, and may affect
the overall folding and stability of the protein. Mutation R71W that replaces
an amphipathic arginine with a hydrophobic tryptophan in the EMI domain.
The difference in chemical structure and size of tryptophan may have a large
effect on protein stability and the ability to form interactions. Replacement of
the arginine, which are typically found at protein binding sites, such as in
SH2 domains, may further disrupt protein interactions with the ECD.
Mutation W520X is a substitution of a tryptophan residue for the termination
codon, and thus would be expected to produce a shorter non-functional
protein unless there is ‘read-through’ of the termination codon. Despite being
rare in mammalian genes, an increasing number of genes have been
identified as having stop codon read-through (Loughran et al., 2014). Each
mutant construct is depicted in Figure 33.
All 4 MEGF10_GFP constructs were expressed in C1F cells, and the effects
on myoblast differentiation and cell motility was measured by
immunostaining of fixed cells during differentiation, and by differential
interference contrast (DIC) imaging of live C1F myoblasts respectively. It
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was expected that wildtype MEGF10_eGFP would inhibit myoblast fusion as
previously reported (Holterman et al., 2007), whereas mutant isoforms may
have different effects. Live cell imaging of MEGF10_GFP expressed in Cos-
7 cells was also performed to determine the localisation of MEGF10 within
cultured cells and the addition of TRITC labelled dextran was used to
explore the possibility of endocytic cycling of MEGF10 as previously
predicted (Barry and Camargo, 2013; Singh et al., 2010; Suzuki and
Nakayama, 2007a).
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Figure 33. MEGF10 adenoviral constructs.
A diagram showing full length MEGF10 and mutant adenoviral constructs designed
with C-terminal GFP and 6 His tags. Full-length wildtype MEGF10 and full length
MEGF10 with pathogenic mutations (indicated by x) for exogenous expression in
myoblast cells are shown. The mutations are: c.2320T>C p.C774R, c.1559G>A
p.W520X and c.211C>T p.R71W.
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4.2 Methods
4.2.1 Cloning
To express MEGF10 as an adenoviral construct, full length MEGF10 was
cloned into the pDC315 vector with C-terminal 6His and enhanced green
fluorescent protein (eGFP) tags in a two-step process. Firstly, full length
MEGF10 cDNA was PCR amplified from the pBluescript II SK+_MEGF10
plasmid using InFusion primers which added an NheI site to the N-terminus
followed by a Kozak sequence and initiation codon
(pDC315_MEGF10_FWD). The reverse primer corresponded to the C-
terminus of MEGF10 removing the stop codon (NS), and adding a SalI
restriction site (pDC315_MEGF10_NS_REV) (Figure 34. A.). Using InFusion
cloning, MEGF10_NS was cloned into the AdMax system shuttle vector
pDC315 (Figure 34. B.). The second step of cloning was to add a C-terminal
6His and eGFP, separated from MEGF10 by a flexible linker composed of
three glycine residues. Full length eGFP was PCR amplified from the
pEGFP-N1 vector using InFusion primers; the forward primer was designed
to add the last 15 bp of the MEGF10 construct and the 3 glycine linker to the
N-terminus of eGFP to allow InFusion cloning into the pDC315_MEGF10
vector at the SalI site. The reverse primer was designed to incorporate a
6His-tag, stop codon, SalI site and bases of pDC315 vector to the C-
terminus of eGFP to enable InFusion cloning into the SalI site
(eGFP_6His_REV) (Figure 34. C.). Colonies from cloning steps were
analysed by colony PCR (Figure 34. D.) and restriction digests
(Figure 34. E.) (InFusion cloning primers are listed in Table 13.). Positive
clones were Sanger sequenced to confirm clones were in-frame and no
additional mutations had been introduced into the vectors (Sequencing
primers are listed in Table 3.). The full pDC315_MEGF10_GFP_6His vector
map shows the final construct (Figure 34. F).
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Figure 34. Cloning of MEGF10_GFP into adenoviral vector pDC315.
A. A 0.7% agarose gel of full length MEGF10 PCR product (Expected size: 3423
bp). B. Sal I restriction enzyme digest of pDC315_MEGF10 colonies 1 - 4
(Expected size: 8.3 Kb (vector 3.9 Kb + insert 3.4 Kb). C. eGFP PCR product
amplified from the GFP_N1 plasmid (Expected size: 750 bp). D. A colony PCR of
the EGF domain of pDC315_MEGF10_6His_GFP colonies 1 - 7 and lane 8 is the
pDC315_MEGF10 vector without GFP/6His Tag (Expected size: 750 bp). E.
HindIII/SalI restriction digest confirming the presence of the MEGF10_GFP insert in
Control pDC315_MEGF10 and colonies 1 and 6 pDC315_MEGF10_GFP(Two
bands with a size of ~ 5 Kb and 3 Kb were expected). F. pDC315_MEGF10_GFP
vector map.
- 136 -
4.2.2 MEGF10 adenovirus in vitro mutagenesis
Mutagenesis primers were designed according to the parameters described
in (Table 14.). Briefly, mutations c.2320T>C, c.1559G>A and c.211C>T (for
the mutations: C774R, W520X and R71W respectively) were introduced into
pDC315_MEGF10_GFP construct using the QuikChange XL Mutagenesis
Kit (Agilent Technologies). Each point mutation was placed in the centre of
the primers. Clones were sequenced using the sequencing primers listed in
(Table 3.) to ensure that the mutagenesis had been successful and that de
novo mutations had not been introduced.
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Table 13. InFusion cloning primers
Primer Name Primer sequence (5’to 3’) Tm (°C)
pDC315_MEGF10_FWD aattcaagctgctagcgccaccatggttatttctttgaactcatgc 83.12
pDC315_MEGF10_NS_REV gttgctcgaagtcgacttcactgctgctgctgctgttgct 85.80
GGG_eGFP_FWD agcagcagcagtgaaggaggcggtgtgagcaagggcgaggag 90.89
eGFP_6His_REV gttgctcgaagtcgactcagtgatggtgatggtgatgcttgtacagctcgtccatgcc 91.50
Table 14. Mutagenesis primers
Single nucleotides targeted for in vitro mutagenesis base pairs are highlighted in bold.
Primer Name Primer sequence (5’ to 3’) Length Tm (°C)
c.2320T>C forward cacatttctgggcagcgtacttgccgcactg 31 80.51
c.2320T>C reverse cagtgcggcaagtacgctgcccagaaatgtg 31 80.51
c.1559G>A forward cgtgtgcacctggatagcgcggggagaaatg 31 81.73
c.1559G>A reverse catttctccccgcgctatccaggtgcacacg 31 81.73
c.211C>T forward tggtttaaatgcacgtggcacagagtcagc 30 76.50
c.211C>T reverse gctgactctgtgccacgtgcatttaaacca 30 76.50
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4.2.3 MEGF10 adenovirus titre
Adenoviral constructs were prepared as described in 2.10 and the viral titre
was calculated, as described in 2.10.5, to ensure that cells were infected
with the same MOI of virus in subsequent experiments. Each viral construct
showed good GFP expression in cultured cells, including mutant W520X
which was not expected to produce the GFP protein due to the premature
stop codon introduced by the mutation. This suggests that there may be
read-through through the premature stop codon enabling continued
expression of the protein.
Virus Construct Viral Titre (PFU/ml)
eGFP 6.3x108
MEGF10 3x108
C774R 6.3x108
W520X 7.9x108
R71W 1.6x109
4.2.4 Fusion Index Calculation
To determine the effect of MEGF10 constructs on myoblast differentiation
the fusion index was calculated. Briefly, C1F cells were seeded onto 13 mm
diameter coverslips, coated with 0.1% gelatin and differentiated for seven
days. Cells were fixed with pre-warmed 4% PFA prior to permeabilisation
with 0.1% Triton X-100 in PBS. The nuclei were stained with DAPI, actin
stained with fluorescently labelled phalloidin and myotubes indicated by
staining for skeletal myosin using the A4.1025 antibody (Cho et al., 1994;
Maggs et al., 2000).
The fusion index is the percentage of cells in skeletal myosin positive
myotubes as a percentage of the total number of cells. The total cell number
is determined by counting the number of DAPI stained nuclei. Only skeletal
myosin positive myotubes with three or more nuclei were classed as
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myotubes. For each condition, five fields of view were imaged and cells
counted from three biological replicates.
4.2.5 Cell Motility Assay
To determine the effect of MEGF10 over-expression on cell motility, cells
were imaged overnight by differential interference contrast (DIC)
microscopy. Briefly, a 96 well plate with a borosilicate glass bottom (Iwaki)
ZDVVHHGHGZLWKȝORI&)FHOOVSUHSDUHGDW[5 cells/ml. Cells were
LQFXEDWHGZLWKȝO RI FXOWXUHPHGLDDW&DQG&22. 100 MOI of
HDFKDGHQRYLUDO FRQVWUXFWZDVDGGHG WRHDFKZHOO LQȝO FXOWXUHPHGLD
and the plate incubated overnight. The cells were filmed over 14 hrs,
capturing images at 10 min intervals using a 10x lens (512 x 512 total pixel
size, 2 x 2 binning). Imaging was performed on a DeltaVision deconvolution
system with a motorised stage and incubator. For each condition, five fields
of view were imaged and cells tracked from three biological replicates. Cell
motility was analysed using ImageJ software (MTrackJ plugin), tracking 10
cells per field of view.
4.2.6 Live cell imaging of MEGF10_GFP in cultured cells
The fibroblast-like cell line, Cos-7, derived from African green monkey
kidney was used for live cell imaging experiments. Cos-7 cells were cultured
in DMEM supplemented with 10% FBS and 1% P/S, and cultured 2 - 3 times
a week as described for other cell lines (2.7). For live cell imaging, Cos-7
cells were plated onto glass-bottomed dishes (Ibidi) at 1x105 cells/ml. Cos-7
cells were infected with 100 MOI MEGF10_GFP adenovirus and incubated
at 37°C for 24 hr prior to imaging. For live cell imaging, the culture media
was supplemented with 50 mM HEPES. For the dextran endocytosis assay
75,7&BGH[WUDQZDV SUHSDUHG DW PJPO LQ VHUXPIUHHPHGLD DQG  ȝO
was added to 2 ml media in each dish. The cells were incubated with
dextran at 37°C, 5% CO2 for 20 min. Excess dextran was washed out with
PBS prior to imaging. Cells were imaged on the LSM 880 confocal
microscope (Zeiss) using the 63x objective and the chamber heated to 37°C.
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Cells expressing MEGF10_GFP were imaged as a time series, with 665
cycles at a time interval of 500 ms. Cells expressing MEGF10_GFP and
with TRITC_dextran uptake were imaged for 200 time points taken every
500 ms.
4.3 Results
4.3.1 The optimal MOI for the MEGF10_eGFP adenoviral infection of
C1F cells was 100
The MOI required to infect C1F myoblasts was determined by incubating the
cells with a range of viral MOIs (50 to 500 MOI). The MOI (multiplicity of
infection) is defined as the ratio of viral particles to cells, where a 50 MOI is
50 viral particles per cell). An MOI of 100 was optimal for the efficient
infection of the cells without causing the aggregation of the protein. High
MOIs (250 - 500 MOI) resulted in high levels of fluorescence close to the
nucleus, which may have been MEGF10_eGFP that was trapped in the
Golgi, rather than being transported to the membrane. The lower MOI of 50
resulted in low levels of expression that were difficult to image successfully.
A 100 MOI infection produced sufficient MEGF10 expression that was
distributed throughout the cell and correctly targeted to the plasma
membrane (Figure 35.). An MOI of 100 was therefore used for subsequent
experiments.
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Figure 35. C1F adenoviral MOI infection.
Representative images of C1F cells infected with 50 - 500 MOI MEGF10_GFP
adenovirus. Cells were fixed 24 hr post infection and stained for actin with phalloidin
(red), the nuclei stained with DAPI (blue) and the MEGF10 adenovirus tagged with
GFP (green). Cells were imaged using the same microscope settings.
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4.3.2 Mutant MEGF10_eGFP constructs showed a markedly different
localisation compared to wildtype in C1F myoblasts
In C1F myoblasts, MEGF10_eGFP was localised to the membrane and
throughout the cytoplasm, where it was mostly found in vesicles, and to a
perinuclear region that was most likely the Golgi (Figure. 36.). As MEGF10
has to be transported to the membrane, and is most likely endocytosed once
at the membrane, the vesicles are likely to be either secretory vesicles or
endosomes. Live cell imaging showed that many of these vesicles were
highly motile (Figure. 37. A). The addition of texas-red dextran to the cells,
which is taken up into endosomes via endocytosis additionally showed that
many of the MEGF10_GFP positive cells also stained positively for texas-red
dextran (Figure. 37. B).
In contrast to wildtype MEGF10_eGFP, all 3 mutant MEGF10_eGFP
isoforms tested do not localize to the membrane but form aggregates.
(Figure. 36.). In each case, the majority of these aggregates were found
close to the nucleus. The mutant C774R forms an almost continuous ring
around the nucleus, whilst aggregates of mutants W520X and R71W are
smaller.
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Figure 36. Localisation of MEGF10 and Mutant Adenovirus in C1F cells.
Immunofluorescence staining of C1F cells infected with MEGF10 and the three
mutant adenoviral constructs. Cells were stained for actin, with phalloidin, in red,
the nucleus with DAPI in blue, and GFP tagged MEGF10 in green. Inset shows
zoomed in region of the cell. Arrows indicate clumps of GFP; arrowheads indicate
GFP in the membrane).
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Figure 37. MEGF10_GFP is localised in vesicles and endosomes.
A. Images Cos-7 cells overexpressing MEGF10_GFP and imaged over time,
showing the dynamic movement of MEGF10 within vesicles (GFP fluorescence in a
predicted vesicle is tracked, as shown by arrows). B. Cos-7 cells infected with
MEGF10_GFP partially colocalised with dextran, suggesting an endosomal
localisation (indicated with arrows). Not all MEGF10_GFP is colocalised with
dextran (shown with arrow heads).
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4.3.3 Expression levels of wildtype and mutant MEGF10 constructs in
cultured cells were similar.
To confirm that the differences in localisation observed for the wildtype and
mutant constructs were not due to higher levels of expression of the mutant
MEGF10 constructs, expression was assessed by western blot. Cells were
infected with 100 MOI of each viral construct and the protein extracted and
prepared for western blotting as described (2.12). An adenoviral construct
that only expressed eGFP, and the purified ECD of MEGF10 (Chapter 5)
were used as positive controls on the blot. An equal amount of whole cell
O\VDWHȝJZDVORDGHGSHUZHOORID6'6B3$*(JHODQGDZHVWHUQ
blot performed. The blot was probed for MEGF10 (Sigma Prestige) and
GFP (CUSABIO). The results showed that an MOI of 100 produced a
similar level of protein expression in cultured cells for both the wildtype and
mutant constructs. It also demonstrates that there must be read-through of
the termination codon in the W520X mutant, as otherwise a full-length
protein that is recognised by the anti-MEGF10 antibody would not be
produced (Figure 38).
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Figure 38. Expression levels of MEGF10 constructs in cultured cells.
A western blot showing the even expression of MEGF10_GFP adenoviral
constructs in cultured cells. A GFP only adenoviral construct (27 kDa) and purified
MEGF10 ECD (~130 kDa) were used as positive controls. The membrane was
probed with anti-MEGF10 (Sigma Prestige) and anti-GFP (CUSABIO) antibodies.
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4.3.4 Expression of MEGF10 affects myoblast fusion.
Over-expression of wildtype and each of the 3 mutant MEGF10_GFP
isoforms in C1F cells inhibited myoblast fusion (Figure 39. A. and B.).
Uninfected C1F cells fused into multinucleated myotubes with high efficiency
(fusion index of ~80%, Figure 39. B.). Infection of C1F cells using adenovirus
that only expressed GFP significantly reduced fusion to 64% (p = 0.0039),
suggesting that viral infection alone may reduce fusion. However, the fusion
index was much more markedly reduced after infection with the wildtype
MEGF10_eGFP adenovirus (7.5%) and each of the mutants (C774R (9.9%),
W520X (2.3%) and R71W (8.9%) (p = < 0.0001)) (Figure 39. B.).
To determine if the decrease in fusion was linked to a decrease in cell
number caused by overexpression of MEGF10_eGFP, cell counts were
performed at day 7 of differentiation. For wildtype and each of the mutant
isoforms of MEGF10_eGFP, cell number was significantly reduced at day 7
of differentiation (Figure 39. C.). This effect is unlikely to be due solely to
infection with the adenovirus, as expression of GFP alone using an
adenoviral construct did not affect cell number (Figure 39. C.). This suggests
that expression of both wildtype and mutant isoforms of MEGF10_eGFP
affect either cell viability or division.
To test if the reduction in fusion arising from expression of wildtype or
mutant MEGF10_eGFP isoforms was due to a reduction in C1F cell motility,
live cell imaging of myoblasts was performed. Expression of GFP alone had
a small effect on motility compared to control, uninfected cells
(Figure 39. D. and E.). However expression of MEGF10_eGFP significantly
reduced cell motility compared to the GFP control. Expression of each of the
MEGF10_eGFP mutant isoforms resulted in a further significant reduction in
cell motility, that was lower than that observed for cells expressing wildtype
MEGF10_eGFP (Figure 39 D. and E.). This suggests that expressing
MEGF10_eGFP does affect cell motility, which may contribute to a reduction
in fusion.
To check if the effects on fusion were likely due to expression of MEGF10
during the early stages of myoblast fusion, expression levels of
MEGF10_eGFP were measured over the course of differentiation by
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analysing the number of cells positive for eGFP. This showed that levels of
MEGF10_eGFP were highest at days 0 and 1 after initiation of
differentiation, (1 – 2 days post-infection with adenovirus), before decreasing
at day 3 of differentiation. A small subset of cells were still positive for eGFP
at day 7 of differentiation (Figure 40. A. and B.). C1F cells would have
undergone approximately 2 rounds of division after infection, before
becoming confluent and entering the differentiation pathway suggesting that
the level of MEGF10_GFP may have been diluted slightly through cell
division. Therefore, levels of MEGF10_eGFP were highest during the early
stages of myoblast fusion.
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Figure 39. C1F cells seven days after differentiation.
A. Adenoviral infected C1F cells after seven days of differentiation with
nuclei stained in blue and skeletal myosin in red. B. The fusion index of
infected C1F cells after seven days of differentiation. (**** p < 0.0001, ** p =
0.0039). C. Total number of cells counted after seven days of differentiation.
(**** p < 0.0001, control: p = 0.5343). D. The motility of C1F myoblasts
infected with each construct measured over 14 hr. E. Sample fields of view
showing the tracks recorded using ImageJ. (Mean values +/- S.E.M. with 10
cells tracked in a minimum of five fields of view for each repeat; n=3. #
indicates the condition used as a comparison for t-test statistical analysis
and asterisks indicate statistically significant changes.)
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Figure 40. Viral expression in C1F cells during differentiation
A. Immunofluorescence staining of C1F cells infected with adenoviral constructs
tagged with GFP in green, and stained for skeletal myosin in red and the nuclei
stained with DAPI in blue. B. A quantification of adenoviral expression in C1F cells
over seven days of differentiation. The graph depicts the percentage of the total
number of cells showing positive GFP expression. (Mean values +/- S.E.M. with a
minimum of five fields of view analysed for each repeat; n=3).
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4.4 Discussion
These data show that wildtype MEGF10_eGFP localised to vesicular
structures in the cytoplasm and to the plasma membrane, whilst each of the
mutant constructs formed aggregates close to the nucleus and poorly
localised to vesicles and the plasma membrane. Despite this difference in
localisation, expression of both the wildtype MEGF10_eGFP and the mutant
constructs significantly inhibited myoblast fusion. This was accompanied by
a significant reduction in cell motility, as well as a reduced cell number by
day 7 of differentiation. The mutant isoforms of MEGF10_eGFP behaved
similarly to wildtype in their effects on fusion and cell number, but showed a
much higher effect on cell motility compared to the wildtype.
The localisation of wild-type MEGF10_eGFP throughout the cytoplasm and
at the plasma membrane is consistent with the localisation reported for the
HA-tagged MEGF10 construct reported previously (Holterman et al., 2007).
As MEGF10 is a membrane protein, its localisation to the plasma membrane
and intracellular vesicles is consistent with what has been previously
reported for proteins with similar structure (Yamamoto et al., 2010). Live cell
imaging and the use of Texas-red dextran confirmed that MEGF10_eGFP
was likely to be in vesicles, and that some of these were likely to be in the
endocytic pathway (Barysch et al., 2010).
Localisation of MEGF10 at the plasma membrane and in intracellular
vesicles could mean that MEGF10 activation can occur in both places. It is
still unclear how MEGF10 is activated, as a MEGF10 binding partner has not
yet been clearly demonstrated. The MEGF10 extracellular binding partner is
unknown; although it has been suggested to interact with Notch (Bröhl et al.,
2012; Holterman et al., 2007), it is not known if MEGF10 can be cleaved in a
similar manner to Notch, or if this is important for its activation. The
intracellular domain of MEGF10 interacts with and contains well known
motifs for binding to other proteins (1.3) and is suggested to bind to AP50
enabling clathrin mediated endocytosis (Singh et al., 2010; Suzuki and
Nakayama, 2007b).
Notch, another TM protein with multiple EGF domains, is normally activated
when plasma membrane bound Notch binds to a ligand, such as Delta or
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Serrate (reviewed in (Kopan and Ilagan, 2009)) on an adjacent cell.
Subsequent cleavage steps of Notch result in the release of its intracellular
domain, which translocates to the nucleus. Once in the nucleus it interacts
with Suppressor of Hairless and Mastermind to form a transcriptional
regulatory complex. However, Notch is also present in endocytic vesicles,
where the cytoplasmic domain remains available on the surface of the
vesicle for binding to other proteins such as Deltex, a cytoplasmic ring finger
protein. Binding of Deltex promotes trafficking of Notch to the lysosome,
where the intracellular domain can then be released by a similar mechanism
of cleavage to that of the plasma membrane bound Notch (Baron, 2012; Hori
et al., 2011; Wilkin et al., 2008). Mutations that prevent Notch from being
transferred from the endosome limiting membrane into the internal
endosomal compartment, result in high levels of mis-activation of Notch
(reviewed in (Fortini and Bilder, 2009)). This raises the possibility that
MEGF10 may also be able to be activated or participate in downstream
signalling pathways both at the plasma membrane and in vesicles and it is
possible that the mislocalised MEGF10 mutant isoforms, even though
apparently aggregated, could interfere with this process.
The mutant MEGF10_eGFP isoforms appear to aggregate close to the
nucleus, suggesting that each of the mutations causes misfolding in the
otherwise rigid ECD, and that this inhibits effective transport to the cell
membrane. EGF-like domains in the ECD of MEGF10 are predicted to be
heavily post-translated (1.3.3) and therefore the mutations present here may
also disrupt sites of post-translational modification, which may have a
significant role in protein function. The impact of these pathogenic mutations
on the post-translational modification of the ECD will be further explored
through protein expression in the following chapter.
It is interesting that each mutation causes the resulting protein to aggregate,
as one mutation is in the EMI domain (R71W), one is in an EGF-laminin
domain (C774R), and the third mutation (W520X) introduces a termination
codon, although a full length protein is still apparently produced. This
suggests that small changes throughout the ECD of MEGF10 can have
significant effects on protein localisation and function. Other recessive
pathogenic conditions, such as cystic fibrosis caused by missense mutations
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in the protein responsible for regulating epithelial surface fluid secretion in
the GI and respiratory tracts, Cystic Fibrosis TM Conductance Regulator
(CFTR) (Cutting, 2015),also result in aggregated protein causing the disease
phenotype (Belcher 2010). This and other diseases caused by the misfolding
and localisation of protein may give an insight into possible disease
mechanisms of MEGF10 (Reviewed by Valastyan and Lindquist, 2014).
Overexpression of both wildtype and mutant MEGF10 constructs, through
the expression of MEGF10_eGFP, significantly inhibited myoblast fusion,
confirming previous results (Holterman et al., 2007). However, in our
experiments, MEGF10 overexpression did not increase cell number as
previously reported (Holterman et al., 2007), but by day 7 of differentiation,
cell number was significantly reduced. This reduction in cell number may
help to explain the reduction in fusion, as a lower number of cells would
reduce the number of cell-cell interactions necessary for myoblast fusion and
therefore inhibit myofibre formation. The reduction in fusion could also be
linked to the reduction in cell motility, as cells need to migrate towards each
other in order to fuse. If MEGF10 increases cell adhesion as reported
(Holterman et al., 2007; Suzuki and Nakayama, 2007a), this could explain
the reduction in cell motility observed. Thus, high levels of MEGF10 reduce
motility and inhibit cell proliferation.
Unexpectedly, the effects of mutant MEGF10 isoforms were similar to those
of the wildtype isoform in each of the experiments performed. The mutants
also significantly reduced fusion, and cell number. However, they each had a
larger effect on cell motility compared to wildtype MEGF10. This may
suggest that the mutations in the ECD may not have a large influence on
function, but that the presence of the intracellular domain of MEGF10 may
be important for regulating myoblast fusion, and that the presence of
intracellular MEGF10 as well as MEGF10 in the plasma membrane may be
important for its function.
This study therefore has confirmed and addressed some of the previously
published data on the over expression of MEGF10 and extended the work to
explore the effect of pathogenic mutations on cellular function. However, it
has not been able to demonstrate clearly why mutations in MEGF10 might
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cause disease. If these proteins are also aggregated in vivo, it is possible
that the resulting lack of localisation to the plasma membrane is the
underlying cause of the disease. Without identifying the binding partners for
MEGF10 and the downstream signalling pathways resulting from its
activation, it is difficult to specifically determine the effects of the MEGF10
mutations.
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5 Characterisation of the Extracellular Domain of MEGF10.
5.1 Introduction
The extracellular region of MEGF10 contains an N-terminal EMI domain and
17 EGF-like domains. The EMI domain was first described in proteins in the
EMILIN family of glycoproteins and is associated with protein multimer
formation (Doliana et al., 2000). Typically, EMI domains have seven cysteine
residues, differing from other cysteine-rich domains, which have 6 or 8
cysteine residues. However, the EMI domain of MEGF10, whilst having the
conserved consensus sequence at the C-terminus (WRCCPG(Y/F)xGxxC),
only has six cysteine residues, with the second cysteine missing, as has also
been described for the EMI domain in MMRN1 (multimerin) (Colombatti et
al., 2012; Doliana et al., 2000). EMILIN proteins are associated with cell
adhesion, migration and proliferation (Spessotto et al., 2003). MEGF10 in
mammals was identified as the potential orthologue of the C.elegans CED-1
protein through the EMI domain and this protein has similar predicted
functions to other EMILIN proteins, such as cell adhesion and cell
proliferation (Callebaut et al., 2003; Holterman et al., 2007; Suzuki and
Nakayama, 2007b). The EMI domain is predicted to interact with the
membrane phospholipid PS which is exposed on the surface of apoptotic
cells as a signal marking the cell for phagocytosis via TTR-52 (Tung et al.,
2013). EGF-like domains in stabilin-2 have also been shown to directly
recognise PS (Park et al., 2008). EGF-like domains are well-characterized
protein domains present in a number of membrane proteins including Notch
and Delta (Rao et al., 1995). There are a number of different classes of EGF
domain, with differing PTMs and predicted functions (Wouters et al., 2005).
MEGF10 contains two different forms of EGF-like domains: twelve EGF-like
domains composed of seven conserved cysteine rich residues
(Figure 41. A.), and five laminin-type EGF-domains that contain eight
conserved cysteine residues capable of forming four disulphide bonds
(Figure 41. B. and C.). Crystal structures of the EGF-like domains of Notch
bound to Ca2+ show the importance of Ca2+ in stabilising and giving rigidity to
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the rod-shape in the repeating structure of the ECD. Glycosylation of these
domains has been shown to be important in regulating Notch signalling
(Chillakuri et al., 2012). The structure and function of EGF-like domains has
been described (Appella et al., 1988), and subsequent studies have
suggested that EGF domains may have a role in mediating intercellular
signalling and act in receptor-ligand interactions (Sorkin, 2001; Wouters et
al., 2005).
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A. EGF-like domains
EGF1 HCADKCVHG-----RCIAPN-TCQCEPGWGGTNCS------------
EGF3 DCHQRCQCQNG--ATCDHVTGECRCPPGYTGAFCE------------
EGF4 QCEQRCPCQNG--GVCHHVTGECSCPSGWMGTVCG------------
EGF6 LCAETCQCVNG--GKCYHVSGACLCEAGFAGERCE------------
EGF8 ACQQICSCQNG--ADCDSVTGKCTCAPGFKGIDCS------------
EGF9 NCSSRCGCKND--AVCSPVDGSCTCKAGWHGVDCS------------
EGF10 GCNLTCQCLNG--GACNTLDGTCTCAPGWRGEKCE------------
EGF12 NCSLPCYCKNG--ASCSPDDGICECAPGFRGTTCQ------------
EGF13 RCSQTCPQCVHSSGPCHHITGLCDCLPGFTGALCN------------
EGF14 NCAGICTCTNN--GTCNPIDRSCQCYPGWIGSDCS------------
EGF15 NCIHTCNCHNG--AFCSAYDGECKCTPGWTGLYCT------------
EGF17 GCRQICDCLNN--STCDHITGTCYCSPGWKGARCD------------
B. EGF-laminin domains
EGF2 -----CQCKNG--ALCNPITGACHCAAGFRGWRCEDRCEQGTYGNDC
EGF5 -----CQCHNG--GTCDAATGQCHCSPGYTGERCQDECPVGTYGVLC
EGF7 -----CPCHLENTHSCHPMSGECACKPGWSGLYCNETCSPGFYGEAC
EGF11 -----CDCSHA--DGCHPTTGHCRCLPGWSGVHCDSVCAEGRWGPNC
EGF16 -----CQCQNG--ADCDHISGQCTCRTGFMGRHCEQKCPSGTYGYGC
C. Cysteine-cysteine interactions
+--------------+
+-|-------+ | +--------+ +--------+
| | | | | | | |
XCXCXXXXXXXCXXXXXXCXCXXXXXGXXCXXXCXXGAAGXXC
Figure 41. Alignment of EGF domains in MEGF10 and cysteine
interactions.
A. The EGF-like and B. EGF-laminin domains in MEGF10 were aligned and the
conserved cysteine residues highlighted in green. Multiple protein sequence
alignment was performed using Clustal W (CLUSTAL 2.1) (Larkin et al., 2007;
Thompson et al., 1994) C. The typical interactions between conserved cysteine
residues in EGF-laminin domains are shown, the underlined portion is similar to
EGF-like domains. Conserved glycine (G) and aromatic (A) residues to identify
EGF-like domains are shown in the sequence
(http://www.ebi.ac.uk/interpro/entry/IPR002049).
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The post-translational modification of proteins with multiple EGF domains,
such as Notch, have been shown to play an important role in intercellular
signalling (Luther and Haltiwanger, 2009b). The sequence of MEGF10 is
predicted to have multiple N-linked glycosylation sites (Figure 42.) (Gupta
and Brunak, 2002). N-linked glycosylation of EGF domains has been shown
to affect ligand recognition and binding in proteins (Wobus et al., 2004).
EGF-like domains are further predicted to be modified by more unusual
PTMs including O-fucosylation and interactions with sialic acid, which can
affect intercellular signalling (Kao et al., 1999; Luther and Haltiwanger,
2009b).
MEGF10 has been suggested to play an important role in cell adhesion
(Suzuki and Nakayama, 2007a). If this is the case, expressed and purified
ECD would be expected to promote adhesion of myoblasts to a non-
adhesive surface. Mutations in the ECD might exert their effects by affecting
the structure of this domain, which could reduce any adhesive properties of
the ECD. Removal of the EMI domain from an expressed ECD construct
might also affect adhesion. Therefore, the objective of this chapter was to
express and purify the ECD of MEGF10, analyse its potential to promote cell
adhesion, and test the effects of mutants on this behaviour. This approach
also allows further characterisation of the ECD, including an analysis of post-
translational modification, and lipid binding behaviour
To express the ECD of MEGF10, I used a mammalian cell system. This
approach has already proved beneficial in the expression of secreted protein
products and identification of protein interactions (Dalton and Barton, 2014;
Sakamoto et al., 2002). The expression vector I used allows the ECD to be
secreted. This expression method should additionally generate protein that
is fully post-translationally modified and correctly folded, which is likely to be
important for its function. HEK-293 cells were selected as the mammalian
expression cell line because they are simple to culture, amenable to
transfection and stable cell lines can be readily made (Thomas and Smart,
2005). E.coli cannot promote PTMs, and typically lack the necessary
chaperone proteins required for correct folding of many membrane proteins.
Other eukaryotic expression systems such yeast and insect cells may also
not enable full glycosylation of the protein (Yin et al., 2007).
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Thus, the results in this chapter describe the production of various MEGF10
ECD constructs (Figure 43.) using mammalian cell expression, an analysis
of their PTMs, an analysis of their lipid binding ability and tests of these
constructs in their ability to promote adhesion, cell motility and differentiation
for mouse myoblasts.
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Figure 42. Predicted N-linked glycosylation of MEGF10.
The amino acid sequence of MEGF10 was analysed for predicted sites of N-
glycosylation using the NetNGlyc 1.0 Server. Potential sites of N-
glycosylation are highlighted in red. Mutations introduced to the ECD
construct are positioned as follows R71W W520X C774R. Tyrosine Y1030 is
highlighted in green Y.
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Figure 43. MEGF10 extracellular domain protein constructs.
Protein constructs for secreted mammalian expression of wild-type extracellular
domain (ECD), epidermal growth factor (EGF)-like domains, and EMI domain
proteins. The pathogenic mutations c.2320T>C p.C774R and c.1559G>A p.W520X.
of the ECD investigated in this study are indicated by a cross (X).
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5.2 Methods
5.2.1 Cloning the extracellular domain of MEGF10 into pSecTag2A.
The ECD of MEGF10 was cloned into the pSecTag2 vector by InFusion
cloning (2.6.10). Mutagenesis was performed as described for the adenoviral
constructs (2.6.12 and 4.2.2). Clones that had successfully undergone
mutagenesis without introducing novel mutations were identified by Sanger
sequencing.
MEGF10 ECD was cloned into the pSecTag2A vector (Invitrogen, Carlsbad,
CA, U.S.A.) for the secreted expression of the protein in mammalian cells
using the primers described in Table 15. A. and confirmed by Sanger
sequencing using the primers listed in Table 3. The mammalian expression
vector pSecTag2A has previously been used for the expression of cysteine-
rich proteins similar to MEGF10 and therefore a possibly good system to use
(Carlson et al., 2003). pSecTag2a contains an N-terminal secretion signal
IURP ,Jț IRU HIILFLHQW SURWHLQ VHFUHWLRQ LQ WKH PHGLXP D cytomegalovirus
(CMV) promoter for high-level expression and C-terminal 6His and c-myc
tags for nickel column purification and antibody detection, respectively. The
vector also contains a Zeocin resistance gene for the selection of stable
mammalian cell lines expressing each protein construct. Features are
presented in each vector map designed using SnapGene software (GSL
Biotech) (Figure 44.).
The pSecTag2A vector was linearised by restriction digestion with HindIII
and NotI and purified by gel extraction (2.6.7). The ECD, EGF and EMI
inserts were PCR amplified using the primers listed in Table 15. prior to
InFusion cloning (2.6.10) (Figure 44.). Four positive colonies were selected
for each construct were picked and the clone used in subsequent
experiments is shown in Figure 43. Successful cloning was confirmed by
restriction digest: the digestion of ECD and EGF vectors produce three
bands due to an internal HindIII site in the MEGF10 ECD (Figure 44.).
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Table 15. Cloning primers for ECD.
Primers used to clone the ECD, EGF and EMI domains into pSecTag2A. The base
pairs in red indicate the sequence overlapping the vector for InFusion cloning.
Cloning Primer Sequence Tm (°C)
pSecTag2A_ECD_Fwd
GCGCCGTACGAAGCTTGCTGAATC
TTGAAGACCCTAATGTG
pSecTag2A_ECD_Rev
CCTCCTCGAGCGGCCGCCTGGTAG
GAATCAGCAGGGAG
pSec_EGF_Fwd GCGCCGTACGAAGCTTGCACTGTGCTGATAAATGT 67
pSec_EMI_Rev CCTCCTCGAGCGGCCGCGGGGACACACATTTCCCC 74
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Figure 44. Cloning the ECD, EGF and EMI constructs into pSecTag2A. 
ECD. ECD PCR product (Expected size: 2490 bp). HindIII/NotI digest of ECD 
colony 2 (Expected sizes: 5159, 1145 and 1345 bp). EGF. EGF PCR product 
(expected size: 2244 bp). HindIII/NotI digest of EGF colony 3 (Expected sizes: 
5059bp, 1346 and 905 bp).  EMI. EMI PCR product (expected size: 246 bp). 
SacII/SpeI digest of colony 2 (Expected sizes: 4349 and 999 bp). 
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5.2.2 Production of stable cell lines expressing secreted protein
constructs
To express the ECD of MEGF10 in mammalian cells each pSecTag2A
construct was transfected into HEK-293 cells and single clone colonies were
selected with Zeocin to produce stable cell lines. High expressing clones
for each construct were chosen in order to produce consistent levels of
protein expression from a clonal cell pool.
The concentration of Zeocin required to effectively select HEK-293 cells
expressing the pSecTag2A construct was determined by incubating
XQWUDQVIHFWHG+(.FHOOVZLWK DQGȝJPO=HRFLQ
IRUILYHGD\V$FRQFHQWUDWLRQRIȝJPOKDGWKHJUHDWHVWF\WRSDWKLFHIIHFW
in the majority of cells after five days (Figure 45.). This is in line with the
concentration recommended by the manufacturer (Invitrogen) and that used
in other experiments (Freeze et al., 2006; Mullershausen et al., 2004).
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Figure 45. Zeocin Selection of HEK-293 cells.
A%ULJKWILHOGLPDJHVRI+(.FHOOVLQFXEDWHGZLWK±ȝJPO=HRFLQDQG
imaged for five days. Black arrows indicate Zeocin sensitive cells identified by the
formation of long appendages formed from the breakdown of the plasma
membrane. Open arrowheads show cell disintegration and cell particle release. B.
The average number of cells counted per field of view after five days incubation
with Zeocin. Control shows the average number of cells 24 hr after plating before
Zeocin addition. (Mean values +/- S.E.M. with a minimum of five fields of view
analysed for each repeat; n=3).
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5.2.2.1 Production of stable cell lines expressing secreted protein
constructs
Stable cell lines expressing secreted constructs of MEGF10 were produced
for mammalian protein expression as follows. pSecTag plasmid constructs
were transfected into HEK-293 cells by calcium chloride transfection
(2.7.10). Cells were harvested from 75 cm3 flask 48 hrs post-transfection,
counted using a haemocytometer and diluted to 1x105 cells/ml. Two 100
mm diameter tissue culture dishes (Corning) were seeded with 2x104 cells in
10 ml selection media (DMEM supplemented with 10% FBS, 1% P/S and
ȝJPO=HRFLQ 6HOHFWLRQPHGLDZDVFKDQJHGHYHU\GD\V IRU
days, until cells not expressing the plasmid died and single colonies of cells
expressing the Zeocin resistance in the pSecTag2A vector survived. After 10
days, single colonies from each plate were picked using a pipette tip and
used to seed duplicate wells in two 24 well plates. Colonies were plated in
non-selective media to enable cells to recover and grow. Plates were
incubated at 37°C, 5% CO2 for 10 days changing the media every 3 - 4 days.
Media samples were taken from each well to be analysed by dot blot to
determine the clone with the highest expression level of secreted protein.
5.2.2.2 Dot blot
A dot blot was performed as a relatively rapid diagnostic test to determine
the level of secreted protein expression into the media of the selected
HEK-293 cell lines. For the ECD, EGF and mutant constructs nitrocellulose
membrane was cut to the required size and equilibrated in PBS for 20 min
SULRUWRXVH'XHWRWKHVPDOOVL]HRIWKH(0,GRPDLQDȝPSRUH39')
membrane was activated with methanol for 30 sec, washed in water for
5 min and equilibrated in PBS prior to blotting, to ensure the protein was
efficiently captured. The dot blot apparatus was cleaned with 70% ethanol
and a piece of 3 mm Whatman chromatography paper placed in the base of
the apparatus. A piece of 3 mm Whatman chromatography paper was pre-
soaked in PBS and placed on the 96 well plate layout at the centre of the dot
blot apparatus and the equilibrated membrane placed on top. The top
portion of the dot blot apparatus was placed on top and fixed in position by
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firmly tightening the screws. The lid was sealed in place by turning on a
vacuum pump. Samples were loaded with the vacuum pump switched off to
HQVXUHHYHQGLVWULEXWLRQRQWRWKHPHPEUDQHEHQHDWKȝORIHDFKVDPSOH
was loaded into the respective wells of the dot blot apparatus and the
vacuum switched on to allow media to be drawn onto the membrane. The
membrane was removed from the apparatus and transferred to a 50 ml
falcon tube and blocked with 3% (w/v) milk for 1 hr at room temperature for 1
hr. The membrane was then treated in the same way as a western blot
membrane for antibody incubations, washes and development (2.12.4).
5.2.3 Mammalian secreted protein expression in HEK-293 cells
For efficient expression and purification of secreted mammalian protein
constructs, HEK-293 stable expressing cells lines were seeded onto five 75
cm2 IODVNV FRDWHGZLWK  ȝJPO SRO\/ O\VLQH  7R FRDW IODVNVZLWK SRO\/
O\VLQHIODVNVZHUHLQFXEDWHGZLWKPOȝJPOSRO\/O\VLQHGLOXWHGLQG+20
for 20 min at 37°C before it was removed and flasks allowed to dry overnight
at 37°C. Cells were grown to 80% confluence in growth media (Table 7.)
before the media was exchanged for OptiMEM low serum media (Gibco) to
reduce contaminants in the later purification stages. Cells were cultured in
OptiMEM for 3 days prior to harvesting the media and purifying the protein.
5.2.4 Protein purification using nickel affinity chromatography
The secreted protein constructs had a 6xHis tag to enable purification by
nickel affinity chromatography. OptiMEM media was harvested, centrifuged
at 1000 x g for 5 min to pellet cells and the supernatant transferred to a fresh
tube and one Complete EDTA-free protease inhibitor cocktail tablet (Roche)
added per 50 ml of media. The media was incubated with 1 ml Complete
His-Tag Purification Resin slurry (Roche) for 30 min on a roller. The slurry
was applied to the 5 ml column and the flow through collected. The resin
was washed with five times column volume wash buffer (300 mM NaCl,
50 mM NaH2PO4, pH 8). The protein was eluted in a total of 2 ml elution
buffer (300 mM NaCl, 50 mM NaH2PO4 and 200 mM imidazole, pH 8). The
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protein was eluted by incubating the slurry with elution buffer three times,
0.5 ml for 5 min, 0.5 ml for 10 min and 1 ml for 5 min.
5.2.5 Protein dialysis
Protein eluates in elution buffer were pooled together and dialysed into 1l
PBS at 4°C overnight, using a Gebaflex Maxi Dialysis Tube (MWCO =
N'D*HQHURQ3XULILHGSURWHLQVZHUHVWRUHGLQȝODOLTXRWVDW&
DWDW\SLFDOFRQFHQWUDWLRQRIDERXWQJȝO
5.2.6 Measuring protein concentration by spectrophotometry
The concentration of purified proteins was measured using a Cary® 50 Bio
UV-visible spectrophotometer [Varian]. 1 ml of buffer was used as a blank
before 1 ml of the sample was placed into a cuvette (Fisher) and the
absorbance at 280 nm measured.
The concentration was calculated based on the extinction coefficients
predicted for each construct assuming all pairs of Cys residues form
cysteines (are not reduced) by Protparam (Gasteiger et al., 2003). Protein
concentrations for each of the constructs prepared are shown in Table 16.
Table 16. Typical concentrations of expressed MEGF10 proteins.
The protein concentration of each expressed protein construct was measured by
spectrophotometry.
Construct 3URWHLQ&RQFHQWUDWLRQQJȝO
ECD 60 - 100
EGF 150 - 200
C774R 29
W520X 15
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5.2.7 Mass Spectrometry
Purified proteins were submitted as SDS-PAGE gel bands for protein
LGHQWLILFDWLRQ E\ PDVV VSHFWURPHWU\ %ULHIO\  ȝO RI SXULILHG SURWHLQ ZDV
loaded per well and an SDS-PAGE gel run (2.12.3). Protein was stained with
Instant Blue Coomassie stain (Expedeon) and the gel band cut out with a
clean scalpel. The gel band was stored in 30% ethanol and submitted to
James Ault at the University of Leeds Mass Spectrometry Facility for protein
identification by tandem mass spectrometry.
5.2.8 Lectin Blots
Lectins were used to determine the nature of the glycosylation on the ECD
of MEGF10. The Biotinylated Lectin Kit I (Vector Laboratories) was used and
the protocol based on those described by (Freeze, 2001). 500 ng of purified
MEGF10 proteins were separated by SDS-PAGE and transferred to a
nitrocellulose membrane by western blot or blotted directly onto
nitrocellulose by dot blot. Ovalbumin was included as a positive control.
The membrane was incubated with 2% (w/v) fish skin gelatin in Tris-Tween-
Buffer-Saline (TTBS) composed of 50 mM Tris HCl pH 7.5, 150 mM NaCl,
0.1% (w/v) Tween as blocking buffer, for 30 min on a roller at room
temperature. Gelatin was used instead of BSA since BSA can contain
carbohydrates which may interfere with lectin binding (Freeze, 2001). The
membrane was washed three times with TTBS for 15 min per wash before
incubating the membrane with each biotinylated lectin (Table 17.) diluted to
ȝJPO LQ77%6 IRU KU DW URRP WHPSHUDWXUH RQD UROOHU 7KHPHPEUDQH
was washed three times with TTBS for 10 min per wash and incubated with
anti-biotin antibody conjugated with HRP (Invitrogen) diluted 1:2000 in
TTBS. The membrane was washed three times with TTBS for 10 min per
wash, followed by a final wash with TBS only for 10 min. The membrane was
incubated with ECL reagent and exposed to film as described for western
blots (2.12.4).
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5.2.9 Protein lipid overlay assay.
Protein interactions with phosphoinositides are important for the localisation
of proteins within the cell for their correct function (Hurley and Meyer, 2001;
Sato et al., 2001). To determine if MEGF10 contains phosphoinositide
recognition sequences and to analyse the lipid-binding specificity of the ECD
of MEGF10 a protein lipid overlay assay was performed. The protein-lipid
overlay assay (Dowler et al., 2000; Dowler et al., 2002) was performed using
PIP strips (Molecular Probes) composed of 15 different phospholipids and a
blank sample. Each PIP strip membrane was blocked for 1 hr at room
temperature with blocking buffer (TTBS (10 mM Tris-HCl, pH 8.0, 150 mM
NaCl, 0.1% (v/v) Tween) supplemented with 3% fatty acid–free BSA). The
PHPEUDQH ZDV LQFXEDWHG ZLWK SXULILHG SURWHLQ GLOXWHG WR  ȝJPO LQ
blocking buffer overnight at 4°C. The membrane was washed with TTBS
three times for 10 min. The membrane was incubated with anti-MEGF10
primary antibody diluted 1:1000 into TTBS for 1 hr at room temperature.
The membrane was washed as before prior to being incubated with anti-
rabbit-HRP secondary diluted 1:5000 in TTBS. The membrane was washed
again with TTBS before being incubated with ECL and exposed to film as
described for western blots (2.12.4).
5.2.10Cell attachment assay.
To determine the ability of the ECD and the truncated and mutated proteins
to mediate C1F myoblast attachment to a surface a cell attachment assay
was performed. Briefly, the wells of a non-adhesive 24 well plate (Greiner),
ZHUHFRDWHGZLWKȝJSURWHLQGLOXWHG LQȝO3%6 IRUPLQDW&
Harvested myoblast cells were prepared at 1x104 cells/ml in growth media
DQGȝODGGHGWRHDFKZHOO&HOOVZHUHLQFXEDWHGDW&&22 for
PLQ EHIRUH DGGLQJ  ȝO RI IUHVKPHGLD $IWHU  KU LQFXEDWLRQ FHOOV
were imaged on a Cytomate instrument, taking 5 different fields of view and
counting the number of nuclei from each field. The experiment was repeated
three times.
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5.2.11Cell Motility Assay
To determine the effect of an ECD surface coating on cell motility, cells were
imaged overnight by DIC microscopy. Briefly, a 96 well plate with
ERURVLOLFDWH JODVV ERWWRP ,ZDNL ZDV FRDWHG ZLWK  ȝJ RI SXULILHG
MEGF10 proteins for 20 min at 37°C. The coating was aspirated and wells
VHHGHGZLWKȝO&)FHOOVSUHSDUHGDW[5 cells/ml. Cells were incubated
ZLWK  ȝO RI FXOWXUHPHGLD DW & &22 for 24 hrs. The cells were
filmed overnight and motility analysed as described in (4.2.5).
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5.3 Results
5.3.1 Expression of MEGF10 in HEK-293 cell clones
The level of MEGF10 expression in HEK-293 cells was measured in media
samples taken from 48 HEK-293 clones (2 x 24 well plates), 24 hrs after
changing the media, by dot blot. This shows if the protein is expressed and
secreted into the medium. All of the constructs (ECD, EGF, EMI and mutants
C774R and W520X) were successfully expressed, except mutant R71W that
was not expressed at all (Figure 46. A. and D.).
Four clonal cell lines expressed high levels of the ECD. One of these clones
(marked with an asterisk) was selected, and used in all future experiments
(Figure 46. A.). A much higher number of clones that expressed the EGF
construct were obtained. One clone was selected and taken forward for
future experiments (Figure 46. B.). Whilst the selected ECD clone does not
appear to be the highest expressing clone on the dot blot, it grew better and
gave a good level of expression in subsequent experiments. Only one clone
was obtained that expressed the EMI domain, suggesting that this protein
construct may not be well expressed or secreted into the media
(Figure 46. C.). Only a few positive clones were obtained for the C774R and
W520X mutant constructs, and one of each was selected for future
experiments. No positively expressing clones were obtained for the R71W
mutant, suggesting that it was either not expressed or secreted into the
media in this system and therefore this mutant could not be tested in
subsequent experiments (Figure 46. D.).
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Figure 46. Dot Blots of protein expression
Dot blots probed with anti-cmyc for each protein construct; ECD (A), EGF (B), EMI
(C), and Mutants C774R, W520X and R71W (D) showing positive HEK-293 clones.
An asterisk marks those used in subsequent experiments. Positive controls, purified
c-myc tagged protein, are ringed.
- 175-
5.3.2 Time course of MEGF10 expression.
In order to determine the optimal time point to harvest secreted protein from
the media, a time course of expression was set up using the ECD clone. A
dot blot of media samples taken over the course of 8 days showed that the
expression levels were highest at days 1 - 3 following a change of medium
(Figure 48. A.).
To ensure that the protein was not significantly degraded over time and to be
certain of the optimal time for protein expression, a western blot was then
performed for samples taken from day 1 to day 3 of expression. The western
blot confirmed that expression levels were highest at day three and the
protein did not show any significant signs of degradation (Figure 48. B.)
The molecular weight of the expressed protein was approximately 130 kDa
(Figure 48), which is about 40 kDa larger than the predicted molecular
weight from Protparam (Gasteiger et al., 2003) of 91 kDa. This suggested
that the secreted protein was extensively post-translationally modified as
expected for secreted proteins of this kind (Chillakuri et al., 2012). To
confirm this, the protein was purified from the media via its His tag and
subjected to western blot and mass spectrometry.
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Figure 47. Time course of MEGF10 ECD expression
A. Media samples taken from the ECD clone C6-2, taken at 24 hr intervals, show
that 72 hr after a media change is optimal for protein expression and secretion
levels. B. Optimal expression after 72 hrs was confirmed by western blot against
the c-myc tag.
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5.3.3 Purification of MEGF10 protein constructs
Each protein construct was purified by nickel affinity chromatography against
the His tag. Samples taken from each stage of the purification process were
run on an SDS-PAGE gel and the protein identity was confirmed by western
blot and mass spectrometry (Figure 48.). The eluted ECD was relatively
pure with few contaminating proteins. The molecular weight of the ECD is
predicted by Protparam (Gasteiger et al., 2003) to be 91 kDa, however the
purified protein is running at a higher molecular weight, approximately
130 kDa, suggesting the protein may be heavily post-translationally
modified.
The EGF protein was predicted to have a molecular weight of 81 kDa,
however the purified protein is approximately 130 kDa, although it appears
to run at a slightly lower Mw than the full ECD. The mutant construct,
C774R, only has a single point mutations and therefore is predicted to have
the same molecular weight as the ECD protein (91 kDa). The purified mutant
protein constructs also run at a higher molecular weight suggesting that the
mutations do not markedly disrupt the sites of post-translational modification.
The purification of the two mutant constructs produced a low protein yield
(Table 16.).
The molecular weight of the EMI domain was predicted by Protparam
(Gasteiger et al., 2003) to be 12 kDa, but its apparent molecular weight on
the gel appears to be ~16 kDa. The eluted sample containing purified EMI
domain also contains many other bands with higher molecular weights
(Figure 48.). Attempts to further purify the protein and remove the higher
molecular weight contaminants were not successful. To further purify the
protein, ion exchange chromatography was performed on an Äkta FPLC
system and using a spin column with low molecular weight cut off (MWCO =
50k) to separate the small EMI domain from the larger molecular weight
contaminants. However, neither technique was successful in purifying the
EMI domain. Since the concentration of protein expressed was relatively
low, the amount of protein recovered after a second round of purification was
either too low to detect (not visible with silver stain) or the EMI protein was
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lost in the process, possibly through aggregation. Since pure protein was
not obtained, the EMI domain was not used in subsequent experiments.
The identity of each of the protein constructs was confirmed by mass
spectrometry. This approach also detected a number of PTMs, primarily
carbamidomethylation of the multiple cysteine residues present in each EGF
domain. The large number of cysteine residues and heavy glycosylation
disrupted efficient protein digestion required for mass spectrometry and
therefore reduced the number of peptides recorded (Figure 48.).
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Figure 48. Purification of MEGF10 Protein Constructs
Purification of the ECD, EGF, EMI domains and mutations of the ECD C774R,
W520X. SDS-PAGE gels show purified protein and any contaminating protein.
Identity of protein was confirmed by western blot against the c-myc tag, and mass
spectrometry. Mass spectrometry also showed potential PTMs identified for each
construct. (Arrows indicate each purified MEGF10 protein construct).
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5.3.4 Lectin Blots
To determine the nature of the PTMs on the ECD of MEGF10, a lectin blot
was performed. Each lectin specifically recognises different forms of sugars
attached to the protein. Each of the purified proteins were loaded onto a gel
together with a sample of ovalbumin as a positive control. The ECD, EGF
and C774R proteins were loaded at a relatively similar concentrations, while
the mutant W520X was found to be at a slightly lower concentration, likely
due to the low levels of the purified protein obtained for this mutant (Figure
49. A).
Lectin blots showed that both the ECD and the EGF domain are heavily
post-translationally modified with mannose, glucose, N-acetylgalactosamine,
IXFRVH JDODFWRVH ȕ 1DFHW\OJOXFRVDPLQH DQG VLDOLF DFLG VKRZQ E\
positive interactions with each of the relevant lectins (Figure 49. B.,
Table 17.). However, good results were not obtained for the mutant
proteins, and for W520X, this may be due to its low concentration.
Therefore, I also performed a dot plot to allow sufficient protein to be loaded
and probed with each lectin.
Dot blots with the various lectins showed that the mutant MEGF10 proteins
are both recognised by PNA and ConA, indicating that they may have N-
DFHW\OJDODFWRVDPLQHJDODFWRVHȕPDQQRVHDQGĮJOXFRVHPRGLILFDWLRQV
However, SBA recognised N-acetylgalactosamine on mutant C774R but not
on mutant W520X and WGA recognised N-acetylglucosamine or sialic acid
on mutant W520X but not on mutant C774R. This suggests that the
mutations may have subtle effects on the post-translational modification of
the proteins (Figure 49. C., Table 17.).
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Figure 49. Lectin blots of MEGF10 proteins.
A. 6'63$*( JHO RI SXULILHG 0(*) SURWHLQV  ȝJ ORDGHG SHU ZHOO DQG D
western blot of the proteins probed with anti-cmyc. B. SDS-PAGE and lectin blots of
lectin interactions with the ECD and EGF proteins. C. Dot blots showing lectin
binding to each MEGF10 construct, with ovalbumin as a positive control and PBS
as a negative control. (Exposure for 1 sec).
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Table 17. Summary of lectin interactions with purified MEGF10
proteins.
Lectins were prepared as stock solutions at 2 mg/ml and stored at 4°C. Ovalbumin
(Ov) was used as a positive control, recognised by ConA.
Lectin Ov ECD EGF C774R W520X Specificity
Soybean Agglutinin
(SBA)
俵 俵 俵 GalNAc
Peanut Agglutinin (PNA) 俵 俵 俵 俵 'ĂůEĐ͕'ĂůɴϭͲϯ
Concanavilin A (ConA) 俵 俵 俵 俵 俵 ɲDĂŶ͕ɲ'ůĐ
Wheat Germ Agglutinin
(WGA)
俵 俵 俵
ɴͲ'ůĐEĐ͕^ŝĂůŝĐ
Acid
Ulex europeaus
agglutinin 1 (UEA1)
俵 俵 nd nd Fucose
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5.3.5 Protein-lipid overlay assay
I next performed a protein-lipid overlay assay to determine if the expressed
proteins bound to phospholipids, and if so, to which ones. The data
(Figure 50.) suggests that both the ECD and EGF purified proteins interact
strongly with several phosphatidylinositol phosphate (PI, or PtdIns) species.
These include PtdIns3P, PtdIns4P, PtdInI5P, PtdIns(3,5)P2 and
PtdIns(4,5)P2. The ECD additionally appears to interact with PtdIns(3,4)P2,
but this interaction is not seen with the EGF construct. This suggests that the
EMI domain (lacking the EGF peptide) may be important for facilitating this
interaction. Furthermore, removal of the EMI domain in the EGF protein
appears to have enabled the interaction with phosphatidic acid (PA), a major
component of the cell membrane. Both the ECD and EGF proteins interact
with PS, which suggests that the EMI domain is not specifically required for
this interaction. An overview of these protein lipid interactions is presented in
Table 18.
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Figure 50. Protein lipid overlay assay.
The binding of the purified ECD and EGF proteins to a range of phospholipids was
probed with anti-MEGF10 (Sigma Prestige). Positive interactions are seen between
both proteins and a number of phospholipids. (Abbreviations listed in Table 18. with
localisation and functions of each phospholipid). (PI: PtdIns).
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Table 18. Phospholipid interactions with ECD and EGF proteins.
Phospholipid ECD EGF Localisation / Function
Lysophosphatidic acid (LPA) Plasma membrane, present in all examined
tissues as minor membrane components and
extracellular signalling (Sheng et al., 2015).
Lysophosphatidylcholine
(LPC)
Biological membranes. (Tawk et al., 2010)
Phosphatidylinositol (PI) Plasma membrane, abundant in the brain but
present in all cell and tissue types.
Phosphatidylinositol 3-
phosphate (PI3P) 5.3.5.1.1.1.1 俵 5.3.5.1.1.1.2 俵
Early endosome (Tawk et al., 2010)
Phosphatidylinositol 4-
phosphate (PI4P) 5.3.5.1.1.1.3 俵 5.3.5.1.1.1.4 俵
Golgi apparatus (Tawk et al., 2010)
Phosphatidylinositol 5-
phosphate (PI5P) 5.3.5.1.1.1.5 俵 5.3.5.1.1.1.6 俵
Plasma Membrane (Tawk et al., 2010)
Phosphatidylethanolamine
(PE)
Present in most biological membranes, second
most abundant in mammalian membranes. Role
in regulating autophagy and longevity
(Rockenfeller et al., 2015).
Phosphatidylcholine (PC) Present in a high proportion of the outer leaflet of
the plasma membrane. phosphatidylcholine is
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also the principal phospholipid circulating in
plasma, where it is an integral component of the
lipoproteins.
Sphingosine 1-phosphate
(SIP)
Present in circulating plasma and the plasma
membrane. Roles in vascular development,
immune cell function, and inflammation. (Lipid
library).
Phosphatidylinositol (3,4)-
bisphosphate (PI(3,4)P2) 5.3.5.1.1.1.7 俵
Binds pleckstrin homology (PH)-domains and it
also has an important role in podosome formation
near focal adhesions.
Phosphatidylinositol (3,5)-
bisphosphate (PI(3,5)P2) 5.3.5.1.1.1.8 俵 5.3.5.1.1.1.9 俵
Late endocytic organelles (Tawk et al., 2010)
Phosphatidylinositol (4,5)-
bisphosphate (PI(4,5)P2) 5.3.5.1.1.1.10 俵 5.3.5.1.1.1.11 俵
Present in the plasma membrane (Tawk et al.,
2010) with a role in nnucleation of endocytic
clathrin-coated pits (Posor et al., 2013)
Phosphatidylinositol (3,4,5)-
trisphosphate (PI(3,4,5)P3)
Present in the plasma membrane. A potent
membrane-bound signaling molecule that
regulates a number of cellular functions including
cell survival, proliferation, and cytoskeletal
rearrangement (Ooms et al., 2009; Riehle et al.,
2013)
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Phosphatidic acid (PA)
5.3.5.1.1.1.12 俵
Present in the plasma membrane and plays a key
role in modulating membrane curvature.
(Kooijman et al., 2003)
Phosphatidylserine (PS)
5.3.5.1.1.1.13 俵
5.3.5.1.1.1.14 俵
Inner leaflet of the plasma membrane and in
endocytic membranes but is exposed on the
outer leaflet of the plasma membrane in apoptotic
cells. PS is required for the targeting and function
of several intracellular signaling proteins(Leventis
and Grinstein, 2010; Vance and Tasseva, 2013).
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5.3.6 Cell attachment assay
MEGF10 has been suggested to play a role in mediating cell attachment
(Suzuki and Nakayama, 2007a). Having confirmed that the expressed and
purified MEGF10 domains were post-translationally modified, I then went on
to test if these domains promoted myoblast attachment onto non-adhesive
surfaces. Each of the expressed and purified domains promoted cell
attachment compared to uncoated surfaces (Figure 51.). Removing the EMI
domain from the ECD (EGF construct) reduced attachment compared to the
full length ECD suggesting that the EMI domain contributes to cell adhesion.
Both mutant MEGF10 proteins, C774R and W520X were also able to
promote cell attachment, suggesting that these mutations do not disrupt
cellular interactions with MEGF10 (Figure 51.).
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Figure 51. Myoblast attachment to MEGF10
The number of cells attaching to a non-adhesive surface coated with purified
MEGF10 proteins. (* = p 0.0277, *** = p 0.0002, **** = p < 0.0001). Gelatin
compared to mutants C774R and W520X showed no significant difference.
(Mean values +/- S.E.M. with a minimum of five fields of view analysed for
each repeat; n=3. # indicates the condition used as a comparison for t-test
statistical analysis and asterisks indicate statistically significant changes.).
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5.3.7 Coated Coverslip Fusion Index Assay
Overexpression of MEGF10 constructs in C1F myoblasts caused a
significant inhibition of myoblast fusion during differentiation. Therefore, I
also wanted to test if adding exogenous purified MEGF10 domains would
also have an effect on fusion and differentiation. Glass coverslips were
coated with these domains, and C1F myoblasts allowed to attached and
differentiate.
Surfaces coated with the ECD protein significantly inhibited C1F myoblast
fusion. In contrast, neither the EGF constructs nor the mutant ECD domains
significantly reduced fusion, and the mutant W520X increased it. Cells fused
equally well on uncoated surfaces as they did on gelatin-coated surfaces.
(The fusion index was calculated as described 4.2.4) from cells stained for
striated muscle myosin and nuclei (Figure 52. A.) and quantified (Figure 52.
B.). These results suggest that the EMI domain may play an important role in
regulating myoblast fusion during differentiation (Figure 52. B.) in the
wildtype construct, but not in the mutants.
As fusion can be affected by cell density, the total number of cells (as
indicated by DAPI stained nuclei) after differentiation were also counted
(Figure 52. C.). The cell density was reduced for ECD, but this reduction was
not significant. However a slightly lower cell density could have partly
contributed to the reduction in fusion observed. However, while cell density
was significantly lower for the mutant EGF domain, C774R, this reduced
density was not linked to a lower fusion index.
Finally, changes to cell motility might also contribute to a reduction in fusion,
as the myoblasts need to migrate towards each other in order to fuse. Test
of cell motility on the different surfaces showed that C1F myoblast motility is
not significantly affected by the presence of any of the ECD/EGF protein
constructs compared to the 0.1% gelatin control (Figure 52. D.). Therefore,
any change to fusion cannot be explained by a reduction in cell motility.
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Figure 52. C1F cell activity on coated coverslips
A. C1F myoblasts differentiated on coated coverslips for seven days, stained for
nuclei (blue) and skeletal myosin (red). B. The fusion index calculated for C1F
myoblasts differentiated on coated coverslips. Five fields of view were imaged to
calculate the fusion index. Fusion indices were compared to that obtained for
gelatin (#). (* = p 0.0156, **** = p< 0.0001). [Gelatin vs. no coat p= 0.2524 – not
significant] C. The total number of cells counted per field of view. [** = p 0.0037] D.
The motility of C1F myoblasts measured over 14 hrs. 5 fields of view were imaged
with 10 cells tracked per field. Sample fields of view showing the tracks recorded
using ImageJ. (Mean values +/- S.E.M (n=3)).
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5.4 Discussion
In this study stable mammalian cell lines were produced that express the
ECD of MEGF10. Expression of the secreted protein constructs was optimal
after three days incubation. Purified ECD, EGF and mutant constructs ran at
a higher molecular weight than predicted on SDS-PAGE gels, consistent
with post-translationally modifications of these constructs. The identity of the
protein constructs was confirmed by mass spectrometry, which showed that
these constructs were likely to have carbamidomethylation, and deamidation
(Figure 48.). The lectin blots further indicated that a broad range of sugars
are present on both ECD and EGF constructs, and that the two mutations
(C774R and W520X) may subtly affect these post-translational modification.
Removal of the EMI domain in the EGF construct does not seem to remove
any specific PTMs. Lipid blots appear to show that the EMI domain may be
important for the interaction with PtdIns(3,4)P2 (Table 18.).
A number of different PTMs were observed for the MEGF10 ECD and EGF
constructs. Mass spectrometry indicated that both carbamidomethylation
and deamidation are present. Carbamidomethylation (CAM), is the alkylation
of the free cysteine thiol group by iodioacetamide (IAM) and is commonly
performed on cysteine residues during preparation of protein for mass spec
analysis to produce cysteine residues of a known, predictable mass.
Therefore the CAM modification identified by mass spectrometry is likely an
artefact due to this process, and the large number of cysteine residues
present in the ECD (Gundry et al., 2009; Meng et al., 2011). Deamidation is
the removal of an amide group, and is a critical PTM involved in ageing and
a number of conditions such as coeliac disease and neurodegenerative
diseases (Li et al., 2010; Robinson and Robinson, 2001). Deamidation is
dependent on the structure of the protein. In vivo deamidation of proteins
has previously been suggested to act as a regulator of the molecular timing
of biological events, in particular in protein turnover and development
(Robinson, 2002). CAM is therefore most likely an artefact of mass
spectrometry but deamidation of the ECD and EGF domains may play a role
in myogenic development in MEGF10.
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A large number of further PTMs in the MEGF10 ECD and EGF constructs
were discovered from the lectin blots. Comparisons with the mutant ECD
constructs showed that the C774R mutant was not recognised by wheat
JHUPDJJOXWLQLQVXJJHVWLQJLWPD\ODFNPRGLILFDWLRQE\ȕ*OF1$FDQGVLDOLF
acid. Sialic acid is part of a family of sugars composed of a 9 carbon
backbone. In vertebrates the most common member of the family is N-
acetylneuraminic acid is typically found at the ends of glycan branches of
glycoproteins, where it increases biological diversity in PTM proteins, plays a
role in maintaining the stability and turnover of glycoproteins as well as being
involved in cellular functions such as intercellular interactions and signalling.
In skeletal muscle, sialic acid has been identified as a marker of aging
(Hanisch et al., 2013). Sialic acid is synthesised by GNE, mutations in which
lead to a rare recessive myopathy characterised by distal muscle weakness
and atrophy (Nishino et al., 2015).
Modification of serine and threonine residues of nucleocytoplasmic proteins
ZLWK WKH PRQRVDFFKDULGH ȕ*OF1$F LV ZHOO GHVFULEHG O-linked N-
acetylglucosamine (O-GlcNAc) is a PTM of serine and threonine residues of
cytoplasmic and nuclear proteins. This modification has been shown to
influence a range of cellular and physiological process including signal
transduction, the regulation of gene expression and protein degradation, as
well as neurodegenerative disease Therefore the lack of these modifications
in the C774R mutant may disrupt the ability of MEGF10 the mediate
signalling.
Conversely, mutant W520X was not recognised by soybean agglutinin and
therefore may not have sialic acid or GalNAc modifications. The enzyme
UHVSRQVLEOH IRU IRUPLQJ ȕ*DO1$F OLQNDJHV F\WRWR[LF 7 FHOO &7 *DO1$F
transferase, influences myofibre growth, laminin expression and the
neuromuscular structure in skeletal muscle (Xia et al., 2002). Therefore,
mutations in the ECD of MEGF10 may affect the post-translational
modification of the protein and thus influence its function.
In addition the ECD and EGF domains interact with a wide range of lipids.
Their interaction with PS agrees with previous work showing that proteins
containing EMI and EGF-like domains interact with PS (Park et al., 2008;
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Tung et al., 2013). Intriguingly, PS is normally found on the inner leaflet of
the plasma membrane, and only becomes exposed during apoptosis, or
during myoblast fusion (Hochreiter-Hufford et al., 2013). This interaction
with PS is consistent with the proposed role of MEGF10 in engulfing
apoptotic cells, particularly its role in neuronal corpse clearance in concert
with JEDI-1 and may also be important in fusion of myoblasts. The
membrane receptor BAI1 is expressed in myotubes and recognises PS
exposed on apoptotic cells. This interaction has been shown to mediate
enhanced myoblast fusion independently of any fusion or engulfment of the
apoptotic cell. This mechanism of PS recognition mediating cell fusion has
been described in other tissues, including the fusion of trophoblast cells
during development of the placenta. Therefore this mechanism could also be
conserved in myoblast fusion (Yu and Baylies, 2013; Gauster et al., 2009)
EGF and ECD domains were also found to interact with PtdIns3P and
PtdIns4P phospholipids. These lipids are associated with the early
endosome and Golgi apparatus respectively (Roth, 2004; Tawk et al., 2010).
As shown in Chapter 4 MEGF10_GFP localizes in vesicles and colocalises
with labeled dextran internalized by endocytosis, suggesting localiation of
MEGF10 within endosomes. Thus, this interaction may be important in both
the secretion and internalisation of MEGF10 in cells.
The demonstration that exogenous MEGF10 ECD/EGF helps to promote
myoblast attachment is consistent with a number of other previous studies
that show the EGF domains of other proteins mediate cell attachment,
(Kansas et al., 1994; Stacey et al., 2003).
The presence of the EMI domain in the wildtype EGF construct inhibited
myoblast fusion. This suggests that the EMI domain is important in
regulating fusion. The EMI domain enables multimerisation of the ECD of
other proteins (Doliana et al., 2000). Loss of this domain may inhibit
interactions between MEGF10 and itself, or other interacting proteins on the
same cell or on adjacent cells, which may contribute to decreased fusion.
Conversely, the mutant ECD proteins, which still have the EMI domain, do
not affect myoblast fusion, and it is unclear why this is the case.
- 195 -
Overexpression of MEGF10_eGFP significantly reduced myoblast cell
number over the course of differentiation (Chapter 4.), while addition of ECD
protein constructs used here had little effect, except for the mutant C774R.
Moreover, overexpression of MEGF10_eGFP and mutant isoforms in
cultured myoblasts significantly inhibited myoblast motility, addition of the
ECD protein constructs to myoblast cells does not. This may suggest the
importance of the intracellular domain of MEGF10 in regulating cell activity.
The intracellular domain may be crucial in enabling downstream signalling
and mediating changes in fusion and cell motility. However, the correct
localisation of the full length protein within the membrane may be important
for mediating protein interactions, and this may not occur when the ECD is
presented externally to the cells.
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6 Discussion.
6.1 Robust reagents and model systems are necessary for
the study of MEGF10.
One of the main findings of this research is the importance of using properly
validated reagents and model systems when studying MEGF10. The
contradictions and complexity of data reported in the literature concerning
MEGF10 (reviewed in Chapter 1.) may arise from the intricate and dynamic
nature of the skeletal muscle environment during development and
regeneration. However, many of the inconsistencies may also be due to the
choices of reagents and model systems that had not been fully validated for
their efficacy or relevance in studying this protein.
In this study, I tested 3 commercially available antibodies, previously used in
MEGF10 studies reported in the literature, to validate their ability to
recognise MEGF10 in immunofluorescence and western blot. Of these three
antibodies, only the Sigma Prestige antibody, which recognises the ECD of
MEGF10, showed good recognition in both immunocytochemistry and to
some extent western blot. I subsequently used this antibody in future
experiments. The two other commercially available antibodies, both of which
recognise the intracellular domain of MEGF10, from Millipore (Kay et al.,
2012) and Santa Cruz (Bröhl et al., 2012) do not recognise expressed
MEGF10 in our assays. This could be because protein interactions with the
intracellular domain of MEGF10 (Figure 8.) may inhibit antibody binding. The
inability of these commercially available antibodies to recognise the
intracellular domain of MEGF10 may also suggest that the non-commercial
antibody raised against the intracellular domain of MEGF10 used by
(Holterman et al., 2007) may also not be effective at recognising MEGF10
and may therefore also explain some of the conflicting data presented in that
study.
In contrast to the previously reported findings (Holterman et al., 2007) I
found that endogenous expression levels of MEGF10 are low in cultured
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myoblasts and myotubes by western blot and immunofluorescence, and
RNAseq confirmed this. In satellite cells associated with isolated fibres,
levels of MEGF10 are low in quiescent satellite cells, and appear to increase
between 24 and 72 hrs post-isolation. Since the fibre isolation model has its
limitations, in that it removes the cells (and fibres) from the native muscle
environment, and therefore possible less physiological, I also investigated
MEGF10 expression in an in vivo model system of mild hyperplasia. Again, I
found that MEGF10 levels increased in response to physiological levels of
fibre damage and was either non-existent or expressed at very low levels in
quiescent satellite cells.
Importantly, MEGF10 does not appear to be expressed in the typical CD34+,
Pax7+/MyoD+ satellite cells, but in neighbouring cells that are CD34+/Pax7-
/MyoD-. These cells could represent another subgroup of satellite cells within
the heterogeneous population of cells, arising from asymmetric cell division
(Kuang et al., 2007). Alternatively, they could be myofibre associated cells
such as pericytes or interstitial cells (Figure 9.). Further experiments to
isolate this population of cells by FACS (Liu et al., 2015a) and to perform
single cell sequencing to better characterise this population of cells would
give a new insight into the role of MEGF10 (Gawad et al., 2016; Li et al.,
2012; Dueck et al., 2015). Further staining of hyperplasia model fibres may
give an indication into whether this model leads to the formation of new
fibres. Pax7 and Pax3 play different roles in adult regenerative myogenesis
and therefore determining the expression of these TFs in relation to
MEGF10 expression may give an insight into this role (Kuang et al., 2007).
6.2 MEGF10 reduces myoblast fusion and motility.
This study has confirmed the work of Holterman et al. by showing that
overexpression of MEGF10 inhibits myoblast fusion in cultured myoblasts.
However, in this study, overexpression of MEGF10 did not increase cell
proliferation as described previously in C2C12 cells (Holterman et al., 2007).
However, the use of C1F cells to study myoblast proliferation may not have
been a good model, since cell proliferation is controlled by temperature and
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WKH SUHVHQFH RI Ȗ,)1 0RUJDQ  WKHUHIRUH IXWXUH H[SHULPHQWV PD\
need to be performed in primary myoblasts. In this study, overexpression of
MEGF10 in C1F cells actually reduced cell number, in a manner that was
independent of adenoviral infection. The overexpression of full length
MEGF10 also reduced myoblast motility. Furthermore coating surfaces with
the ECD of wildtype MEGF10 increased cell attachment, inhibited myoblast
fusion and reduced the total number of cells after 7 days differentiation,
further suggesting a role for MEGF10 in cell attachment and a role in
regulating differentiation.
6.3 The extracellular domain of MEGF10 is post-
translationally modified and interacts with membrane
lipids.
Analysis of the purified ECD of MEGF10 showed the high level of PTMs of
this protein, as expected for an ECD (Bard and Chia, 2016). It has been
suggested that MEGF10 may interact with PS through its EMI domain to
enable recognition of apoptotic cells (Chung et al., 2013; Scheib et al., 2012;
Tung et al., 2013). However this study shows that MEGF10 may interact with
PS but also recognises other lipids (including PtdIns(4)P, PtdIns(4,5)P2 and
Phosphatidic Acid) in agreement with a recent study (Iram et al., 2016).
Interestingly I also found that constructs lacking the EMI domain recognised
phosphatidic acid, whilst the full-length protein did not. MEGF10 has already
been associated with TTR-52, which interacts with phosphatidic acid (Kang
et al., 2012). Phosphatidic acid is a fusogenic lipid proposed to play a role in
muscle protein accumulation (Mobley et al., 2015; Zhang et al., 2008).
Removal of the EMI domain may uncover a binding site for phosphatidic acid
that is blocked by the EMI domain in the full-length ECD. It is possible that
when the EMI domain interacts with its binding partners, this would also
expose the phosphatidic binding domain, which could be important for the
function of MEGF10.
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6.4 Mutagenesis of MEGF10
As part of this study, I have also tried to uncover why point mutations in the
ECD of MEGF10 lead to skeletal muscle disease. Expressed mutant GFP-
tagged adenoviral constructs showed a different pattern of localisation
compared to the wildtype protein. In particular, the mutants did not localise
to the membrane but formed aggregates surrounding the nucleus. Further
staining is required to confirm whether these mutant proteins are misfolded
or incorrectly processed and therefore are not transported to the membrane
but retained within the ER. Contrary to expectation, the three mutations
investigated produced very similar effects in myoblast cells compared to the
wildtype protein. Each of the GFP-tagged mutants significantly inhibited
myoblast fusion, reduced cell number after 7 days of differentiation, and
severely reduced myoblast motility as found for WT GFP-tagged constructs.
In addition, purified mutant MEGF10 ECD constructs coated onto cell culture
surfaces enabled cell attachment in a similar manner to the wildtype ECD.
However, unlike the ECD, the two mutant ECDs tested did not affect
myoblast fusion or motility and had a mixed effect on the total cell number.
Similarly, results were obtained for the EGF domain. The differential effect
seen between overexpression of full length MEGF10 and the external
presence of the ECD of MEGF10 (coated onto coverslips) may indicate that
the intracellular domain of MEGF10 is crucial for mediating some of the
functions of MEGF10.
Whilst this study has provided some new insights into MEGF10 there are a
number of questions remaining for future study.
6.5 Are mouse models the most helpful for the study of
human skeletal myopathies?
MEGF10 has been studied using a knock out mouse model, where
dysregulation of retinal neuron spacing was described (Kay et al., 2012).
However the mouse phenotype did not describe any myopathic symptoms.
Since mouse models of MEGF10 deletion do not appear to produce an
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obvious skeletal muscle phenotype determining the differences between
human and mouse MEGF10 to better understand the range of phenotypes
observed may enable more reliable and disease relevant model systems to
be developed. Indeed it may be that mutations in MEGF10 which produce
EMARDD in humans are embryonic lethal in mice and therefore these
phenotypes are not described. A MEGF10 lacZ reporter tagged knockout
mouse has been listed by the International Mouse Phenotyping Consortium,
and although no phenotype has yet been described for this mouse, it may be
useful in future studies to visualise localisation and changes in expression of
MEGF10 over the course of development or differentiation. Mouse models of
human disease have both their benefits and limitations, however more
recent initiatives to characterise the function in all mouse genes and
describing phenotypes through mutagenesis will likely give more accurate
models of human disease in mice (Justice and Dhillon, 2016; Rosenthal and
Brown, 2007).
6.6 How important might the post-translational modification
of MEGF10 be for its function within skeletal muscle?
Properly folded proteins are transported form the ER to the Golgi before
being transported to the cell surface. Mis-folded and poorly assembled
proteins are retained in the rough ER before degradation in proteasomes
(Hebert and Molinari, 2007). The post-translational modification of EGF-like
domain containing proteins plays an essential role in mediating protein
interactions and function, as described in Chapter 1. These protein domains
are also subject to unusual forms of post-translational modification, including
O-linked fucosylation. Modification of Notch has been well described as
influencing signalling at the membrane as well as protein folding and
trafficking to the membrane (Acar et al., 2008; Kritikou, 2008). Due to the
similar structure of MEGF10 and Notch, it may be that MEGF10 is regulated
in a similar manner. Further studies, perhaps using cell lines which limit
branching of sugar residues may give insight into MEGF10’s ability to
perform its function in the absence of complete post-translational
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modification. CFTR (Cystic Fibrosis TM conductance Regulator), which is
mutated in cystic fibrosis, is another good example of a membrane protein
where post-translational modification regulates protein synthesis, trafficking
and membrane stability (reviewed (Amaral and Farinha, 2013). Therefore,
further study into the effect of post-translational modification of MEGF10
may be crucial in determining the mechanisms by which it is regulated,
transported and functions within the membrane.
6.7 How might the structure of MEGF10 influence its
function?
Proteins with multiple EGF-like domains have been described as being
relatively rigid within the membrane, such as Notch and MEGF9. Electron
microscopy of MEGF9 has shown Rod-like particles (Brandt-Bohne et al.,
2007), however MEGF9 has fewer EGF-like domains than MEGF10
(Chapter 1 Figure 3.) and therefore future experiments to investigate the
structure of the ECD of MEGF10 by negative stain or rotary shadowing
electron microscopy may be valuable in understanding MEGF10 function.
Furthermore, visualising how the EMARDD mutations may affect the
structure of the ECD may also give an insight into how these mutations
affect MEGF10 structure and function.
6.8 Is MEGF10 regulated in a similar manner to Notch?
Notch and MEGF10 have been compared due to their similarity in structure
and relationship during myoblast differentiation, where MEGF10 has been
shown to activate Notch signalling and thereby suppress myoblast
differentiation and fusion (Holterman et al., 2007). Notch has recently been
shown to be cycled from the membrane and stored in vesicles with the
intracellular domain exposed to the cytoplasm and still able to mediate
downstream signalling. Two pathways have been suggested to mediate this
internalisation of Notch, mediated either by Deltex or Suppressor of Deltex
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(Shimizu et al., 2014). MEGF10 is also found in intracellular vesicles and
therefore further experiments may be needed to determine if MEGF10 is
regulated by a similar mechanism.
Like Notch, MEGF10 has been described as regulating myogenic
progression. The relationship between Notch and DLL1 has been shown to
regulate asymmetric stem cell division enabling renewal of the stem cell
niche in neuronal stem cells (Kawaguchi et al., 2013) as well as muscle cell
self-renewal (Sun et al., 2008). Indeed RT-PCR has shown that MEGF10 is
upregulated in response to DLL1-dependent induction (Bröhl et al., 2012).
Therefore further exploring the relationship between MEGF10 and Notch
and its other interacting partners may give insights into the mechanisms by
which MEGF10 acts.
6.9 How can the differences in the effect of MEGF10 on
neuronal and skeletal muscle be explained?
The published literature about MEGF10 gives either a description of the
roles of MEGF10 in neuronal/ brain tissue or within skeletal muscle.
Reconciling the description of neurological dysfunction in mice with
mutations in MEGF10 but with no description of a skeletal muscle disease
and EMARDD patients with severe muscle myopathy but no neurological
symptoms gives a confusing picture for the role of MEGF10 in disease.
One explanation for the different disease phenotypes observed may be due
to differential expression of MEGF10 isoforms in different tissues. Two
isoforms of human MEGF10 have currently been described. The second
isoform lacks several 3’ exons and has an alternative C-terminal sequence.
However, there is no clear data about the differential expression of these
isoforms and therefore further studies into these isoforms may be helpful in
determining their function.
Furthermore, cells that form the head and skeletal muscle have different
developmental origins (Shi and Garry, 2006) and this may give rise to
different populations of satellite cells with differential expression of MEGF10.
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Characterising the, as yet, unidentified MEGF10 positive cells may give
insight into their lineage from development which may help to explain the
differences in expression in the brain and skeletal muscle.
6.10Limitations of this study.
A limitation of this study, like that of previously published papers, is that part
of this study has focused on the overexpression of MEGF10 to determine
function This is due to the low endogenous expression of MEGF10 in
cultured myoblasts. However, this method does not give a physiologically
relevant insight into MEGF10 function and potential interactions.
This study has also focussed on the ECD of MEGF10, but further study into
the intracellular domain of MEGF10 is also needed to better understand the
downstream signalling pathways involved in myogenesis and muscle
regeneration.
Satellite cells only account for 2 - 5% of nuclei beneath the basal lamina in
adult muscle. Therefore studying these cells within the complex skeletal
muscle environment requires a relatively large amount of material to collect
sufficient satellite cells to study (Bischoff and Heintz, 1994).
6.11How might this study impact upon research into skeletal
muscle myopathies and dystrophies?
MEGF10 was highlighted as a protein of interest through its association with
skeletal muscle myopathy EMARDD. Whilst this study may not directly have
given any further insights into the effect of disease mutants on MEGF10
function, the identification of MEGF10 positive cells, which do not appear to
be typical satellite cells, may give an insight into the disease. Further
experiments to characterise this population of MEGF10 positive cells may
lead to the identification of novel targets that could be exploited in the wider
field of regenerative medicine. Whilst EMARDD is a very rare recessive
condition, understanding the function of MEGF10 through its dysfunction in
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patients may add to the current body of knowledge about muscle
development, regeneration and disease. This could impact on research into
and potential treatment for muscle weakness in an aging population, sports
injuries and more common muscular dystrophies and myopathies.
This study has looked at mutations linked to EMARDD (W520X, C774R) and
the associated myopathy with minicores disease (R71W). The R71W
mutation in the EMI domain of MEGF10 disrupted expression of the protein,
suggesting the importance of the EMI domain in the correct folding,
processing and localisation of the whole protein. Mutations in the EGF
domains of MEGF10 which cause EMARDD did not disrupt protein
expression. The two mutations associated with EMARDD disrupted the
localisation of the MEGF10 protein suggesting that the protein may not be
able to perform its predicted role in cellular signalling. These two different
mutations led to similar levels of inhibition of myoblast fusion and reduction
in cell motility when exogenously expressed, which may give insight into the
mechanism by which skeletal muscle is poorly formed within EMARDD
patients. The mutations used in this study give an insight into both the
mutations which induce a premature stop codon and the pC774R point
mutation which changes a cysteine residue in an EGF domain, however in
this study the effect of these different mutations did not appear to produce
changes in the cellular response. Therefore further study in either primary
human cells or knockout mouse models may be beneficial in exploring the
spectrum of disease phenotypes described for each mutation.
EMARDD appears to fit within a spectrum of disease with variation in the
onset of the disease and therefore being able to determine the prognostic
factors which regulate the stage of disease onset (infantile or adult) may
help to better understand the role of MEGF10 and potentially ways to treat or
delay the onset of myopathic disease (Liewluck et al., 2016; Logan et al.,
2011). Furthermore, understanding the factors, by which MEGF10 mutations
cause either the formation of minicores or a more severe phenotype may
give further insight into the complex class of minicore diseases (Boyden et
al., 2012b).
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6.12Final Conclusions
This study into MEGF10 has given some new insights into MEGF10, in
particular in its response to skeletal muscle hyperplasia. However, there are
still a number of questions remaining for future study, some of which have
been discussed here. MEGF10 is expressed within the complex environment
of skeletal muscle and is likely to interact with a rage of different proteins
and signalling molecules via its intracellular and ECDs. How it responds to
changes in its environment under conditions of development, stress and
injury remain to be fully explored.
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